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7Chapter 1. Introduction, aim and outline
8THE TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS IN THE PRE-BIOLOGIC ERA
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic diseases, 
characterised by the presence of arthritis starting before the age of 16, persisting for over 
six weeks. According to the classification of the International League of Associations 
for Rheumatology (ILAR), seven different categories of JIA are defined based on clinical 
and laboratory findings and are described in table 1, together with their distribution 
(percentages are taken from several studies).1 2 
Table 1 Description and incidence of JIA categories
JIA category Characteristics % of total JIA
Systemic JIA Arthritis and daily fever ≥ 3 days, accompanied by at least 
one of the following: evanescent (non-fixed) erythematous 
rash, generalised lymph node enlargement, hepatomegaly/
splenomegaly, serositis
4-17
Oligoarticular JIA:
  Persistent form
  Extended form
Arthritis in 1-4 joints during the first 6 months of the disease
Arthritis in 1-4 joints throughout the disease course
Arthritis in > 4 joints after the first 6 months of the disease
27-60
Polyarticular JIA RF + Arthritis in > 4 joints during the first 6 months of the 
disease, two or more positive tests for rheumatoid factor at 
least 3 months apart
2-7
Polyarticular JIA RF - Arthritis in > 4 joints during the first 6 months of the 
disease, negative tests for rheumatoid factor
11-30
Psoriatic JIA Arthritis and psoriasis, or arthritis and at least two of the 
following: dactylitis, nail pitting or onycholysis, psoriasis in a 
first degree relative
2-11
Enthesitis related  
arthritis
Arthritis and enthesitis, or arthritis or enthesitis with at 
least two of the following: sacroiliac joint tenderness or 
inflammatory lumbosacral pain, HLA-B27 antigen positive, 
onset in a boy >6 years old, acute anterior uveitis, HLA-B27 
associated disease* in first degree relative
1-11
Undifferentiated JIA Arthritis that does not fulfil criteria in one of the categories 
or meets criteria for more than one category
11-21
 
*Ankylosing spondylitis, enthesitis related arthritis, sacroiliitis with inflammatory bowel disease, Reiter’s syndrome,  
or acute uveitis
JIA=juvenile idiopathic arthritis, RF=rheumatoid factor
9Just as the disease, the prognosis is very heterogeneous. Some of the categories 
(predominantly the oligoarticular persistent form) have a very favourable prognosis. 
However the arthritis frequently continues into adulthood, particularly in the polyarticular 
categories.3 The persistent disease activity, together with the extra-articular 
manifestations of the disease can lead to chronic functional disability, social and 
psychological impairments and a decrease of quality of life.4-6 
No cure is available for JIA. Its treatment is therefore aimed at relieving the symptoms and 
if possible suppressing the disease activity, thereby preventing growth impairments, long 
term disability and a reduced quality of life. Especially for JIA patients with polyarticular 
or systemic forms of JIA, these goals were hard to reach. However, in the last three 
decades, the treatment of JIA has greatly progressed.
The first description of JIA appeared in medical literature in 1864.7 Initially the disease 
was predominantly treated with basic supportive measures such as rest, physical therapy, 
support in the form of splints and relief in the form of hot baths or packs of paraffin. First 
line drug therapy existed of “rapidly acting” therapy in the form of aspirin, if necessary 
supplemented with corticosteroids, either oral or intra-articular. Second line, “slow-
acting” therapy consisted of crysotherapy (intramuscular gold) and antimalarial agents 
or D-penicillamine.8 In the early 1980s other non-steroidal anti-inflammatory drugs 
(NSAIDs) were approved for JIA and replaced aspirin as the first choice of treatment.9 
During the 1980s synthetic disease modifying anti-rheumatic drugs (DMARDs), which 
had been tested more extensively in adults with rheumatoid arthritis (RA), slowly came 
into use for JIA.10 Two of these DMARDs, methotrexate and sulfasalazine, were both 
tested in randomized controlled trials (RCTs) and are currently part of the treatment 
of JIA.11 12 Of the early slow-acting anti-rheumatic drugs (gold, D-penicillamine and 
antimalarians) the efficacy could not be demonstrated and these are now rarely used.13 
14 Methotrexate is effective to some extent in practically all patients, although still only 
10-45% achieve a remission within one year of treatment.11 15 16 At present, methotrexate 
is the recommended second-line drug after failure of NSAIDs and intra-articular 
corticosteroid injections.17 All the drugs mentioned were unspecific with regard to their 
working mechanism. They were used in the treatment of JIA because of their apparent 
anti-inflammatory or immunosuppressive effects; however they did not affect the disease 
via a clearly understood mechanism of action. 
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BIOLOGIC TREATMENT OF JIA
This changed at the end of the 20th century. As a result of the increasing understanding of 
the inflammatory pathway, drugs were developed targeting specific components of this 
pathway. Because these new drugs are produced using recombinant DNA in living cells 
and are composed of natural products such as proteins, they are known collectively as 
biologicals or biologic agents.
The first biologic agents were inhibitors of tumour necrosis factor-alpha (TNF). TNF is 
an important cytokine that is predominantly produced by macrophages. It is generally 
thought of as a pro-inflammatory cytokine, which at low concentrations increases host 
defence mechanisms in tissues. Increased expression of TNF however results in excess 
inflammation and tissue damage. This is also the role TNF is thought to have in JIA as a 
result of innate and adaptive immune responses. It is placed at the head of an inflammatory 
cascade, itself mediating a variety of pathogenic effects and inducing the production of 
other pro-inflammatory cytokines. This results in synovial proliferation, recruitment and 
activation of inflammatory cells, neoangiogenesis and joint destruction.18 
Etanercept, a TNF-receptor Fc-fusion protein that binds TNF, was the first biologic agent to 
be approved by the Food and Drugs Administration (FDA) and European Medicines Agency 
(EMA) for the treatment of JIA in 1999/2000. This followed an RCT that proved its short-
term efficacy and safety in JIA patients.19 Since then, an increasing number of biologic 
agents have been developed. 
Growing understanding of pathophysiology of JIA led to the recognition of the systemic 
form of JIA as an auto-inflammatory rather than an auto-immune disease, requiring a 
different approach targeting different cytokines.20 Instead of TNF-alpha which was the major 
cytokine targeted by the first biologic agents, IL-1 became a target for the treatment of 
systemic JIA. The biologic agents that are currently being used or tested for the treatment 
of JIA are listed in table 2. 
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Table 2 Biologic agents currently used or under investigation for JIA 
Target Biologic agent Structure Indication FDA/EMA  
approval
TNF alpha Etanercept 
 
 
Infliximab
Adalimumab
Golimumab
Certolizumab-
pegol
Receptor  
Fc-fusion protein
 
 
Chimeric mAb
Human mAb
Human mAb
Pegylated human 
mAb
pJIA, ERA, psJIA
 
 
 
pJIA, ERA, psJIA
pJIA
pJIA-trial
pJIA-trial
1999/2000 
(approval for ERA 
and psJIA in 2012)
 
Not approved
2008
Not approved
Not approved
IL-1 Anakinra 
Canakinumab
Rilonacept
Receptor 
antagonist
Human mAb
Receptor  
Fc-fusion protein
sJIA
 
sJIA
sJIA
Not approved
 
Not approved
Not approved
IL-6 Tocilizumab Human mAb sJIA, pJIA 2011 (2013 for 
pJIA)
CD80/86 (T-cell 
co-stimulation)
Abatacept Receptor Fc-fusion 
protein
pJIA 2009, only after 
failure of TNF-
inhibition
CD20 (B-cell) Rituximab Chimeric mAb RF+ pJIA (rarely 
used)
Not approved
JAK Tofacitinib Small molecular 
inhibitor
pJIA-trial Not approved
 
TNF=tumour necrosis factor, JIA=juvenile idiopathic arthritis, pJIA=polyarticular course JIA, ERA=enthesitis related arthritis, 
psJIA=psoriatic JIA, mAb=monoclonal antibody, sJIA=systemic JIA, IL=interleukin, RF+=rheumatoid factor positive, 
JAK=Janus kinase
STUDYING A NEW DRUG: THE ARTHRITIS AND BIOLOGICALS IN CHILDREN REGISTER
Aims and objectives
Proof of efficacy in an RCT is often mandatory for approval of a new drug by FDA and 
EMA. RCTs are characterized by strong control: a standardized treatment is uniformly 
provided within a standardized context to specified subjects who adhere completely to 
the treatment as delivered. Because of this strict standardization, each effect is assumed 
to be the direct result of the intervention being studied.21 However, proven efficacy in an 
RCT does not directly imply effectiveness in real-world patients. The circumstances under 
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which RCTs are performed are not reflective of what happens in daily practice. Because 
the patients in RCTs are included according to very strict inclusion criteria, they may not 
reflect the real world JIA-population. The number of patients included is often too small to 
comment on predictive factors for response. Also, the time patients are followed is often 
too brief to conclude long term effects, delayed adverse events and the costs real world 
treatment will imply. Prospective observational studies are crucial to evaluate these factors 
in a non-selected patient population. Additionally these studies reflect decision-making in 
daily clinical practice and provide information on the effectiveness of drugs that are used 
off-label.
When etanercept was first marketed in the Netherlands and it was expected that other 
biologic agents would soon follow, this was the rationale behind the constitution of the 
Arthritis and Biologicals in Children (ABC) register.
Study design of the ABC register
The ABC register was founded in 2003 with the primary goal of determining the long-term 
effectiveness and safety of biologic therapies in JIA. It contains data prospectively collected 
from the introduction of etanercept in 1999 until data collection has stopped in 2014. It was 
a multicentre prospective observational study and aimed to include all JIA patients starting 
biologic treatment in the Netherlands. At first, it focused on including patients starting 
TNF-inhibitors, however because of the rapid development of other biologic treatments, 
the register widened its scope to include all biologic agents. Data was collected on paper, 
until in 2008, when the register became web-based to facilitate easy use for participating 
investigators and to guarantee accuracy and up-to-date information.22 Ethical approval for the 
ABC register was granted by the Medical Ethics Committee at the Erasmus MC in Rotterdam 
and all other participating hospitals. Since the initial approval, ten amendments were made to 
the study protocol including radiological and bone mineral density evaluation and long-term 
follow-up of quality of life and disability.
In 2014 approximately 500 patients were registered. More than 3000 follow-up moments have 
been entered and the total follow-up duration of included patients has exceeded 1500 patient-
years. Etanercept was the most frequently prescribed first biologic agent, but adalimumab and 
anakinra were increasingly prescribed during the course of the register.
Data collection in the ABC register
Upon inclusion in the ABC register, patient and disease characteristics were recorded. 
These included gender, date of birth, date of JIA onset, JIA category, laboratory findings, 
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medical history and previously used medication. Data was entered at the start of each 
biologic agent, and after three, six months and 15 months of treatment, and yearly 
thereafter, until the patient was transferred to adult care. In addition to these follow-up 
moments, data was entered at the time of any important events including when biologics 
were discontinued, the patient switched to a different type of biologic agent or when there 
were safety concerns. 
At all of these follow-up moments, medication use and disease activity were recorded. The 
disease activity was recorded using the following variables:
1.  Physicians’ global assessment of disease activity on a visual analogue scale (VAS) 
(range 0-100mm, 0 best score)
2. Childhood Health Assessment Questionnaire (CHAQ) by patient/parent (range 0-3, 0 
best score) 
3. Global assessment of pain by patient/parent on a VAS (range 0-100mm, 0 best score) 
4. Global assessment of wellbeing by patient/parent on a VAS (range 0-100mm, 0 best 
score) 
5. Number of joints with active arthritis
6. Number of joints with limited range of motion
7. Erythrocyte sedimentation rate (ESR, mm/hour)
Using these disease activity variables, the Juvenile Arthritis Disease Activity Score 
(JADAS-10) could be calculated. JADAS-10 ranges from 0-40 and is calculated as the sum 
of four of the variables taken from the JIA core set: the scores of the physician and parent/
patient global assessment (VAS 0-10), the reduced 10-active joint count and a normalized 
value of ESR to a 0-10 scale.23
Previous lessons from the ABC register
Two previous theses presenting results of the ABC register have been published. Firstly, the 
development of the web-based register itself was investigated.22
Most of the research performed in the ABC register focused on etanercept, because the 
majority of patients included in the register was treated with this biologic agent. Etanercept 
proved to be safe and effective, not only in suppressing disease activity, but also in 
improving quality of life and diminishing disability.24 25 Cost-effectiveness was studied and 
although costs were substantial, the large gain in utility was deemed more important.26 
In addition to the investigation of etanercept in the total – very heterogeneous – group 
of JIA patients included in the register, case studies were published on the effectiveness 
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of etanercept in the specific JIA categories psoriatic JIA and enthesitis related arthritis. 
Etanercept proved to be effective in both groups.27 28
The investigators looked deeper into the response to etanercept. Some patients were found 
to have a delayed response when treatment was continued after response criteria were 
not met after three months of treatment. Clinical factors associated with the response to 
etanercept were identified and dosing regimens were explored.29-31
At first only the response to etanercept was of interest, however, when patients appeared to 
be very responsive, and clinically inactive disease was achieved by a large part of patients, 
the possibility of discontinuing medication after successful treatment was investigated. 
The small study conducted in the ABC register indicated that at least half of patients 
discontinuing etanercept flared within a year.32 Serum levels of MRP8/14, a potential 
biomarker associated with disease activity, were able to predict a flare after discontinuation 
of etanercept in patients with systemic JIA.33
OBJECTIVE AND OUTLINE THESIS
The objective of the ABC register is thus to evaluate the long-term effectiveness and safety 
of biologic agents and to observe the prescription patterns of these agents in daily clinical 
practice. This thesis will build on the previous results of the ABC register by investigating 
not only the effectiveness of etanercept, but other biologic agents as well. In addition it 
explores possibilities for improving care of JIA patients by looking at various new methods 
for monitoring JIA patients during their treatment.
Chapter 2 extends the investigation of the efficacy of TNF-inhibitors. In chapter 2.1 the 
effectiveness of TNF-inhibitors is studied in patients with the oligoarticular JIA category, 
who are normally not eligible for treatment with this agent. In chapter 2.2 we investigate 
whether the previously shown improvement in quality of life and functional outcome is 
sustained more than 5 years after start of etanercept.  
Because an increasing number of biologic agents have become available for the treatment 
of JIA, chapter 3 is focused on these newly available drugs and the changes in prescription 
patterns due to these drugs in daily practice. In chapter 3.1 these prescription patterns 
are studied in more detail by describing the general trends in biologic treatment in the ABC 
register, while the decisions paediatric rheumatologists make when they have to choose 
between two TNF-inhibitors are the subject of chapter 3.2. In chapter 3.3 comparative 
efficacy of the available biologic agents is investigated in an indirect comparison of the 
clinical trials and in chapter 3.4 switches in biologic treatment after failure of etanercept 
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and their effectiveness are studied. In chapter 3.5 the possibilities of comparing different 
biologic agents are examined and the difficulties that can be encountered in doing so 
discussed.  
Chapter 4 deals with new developments in the monitoring of JIA. In chapter 4.1 a patient 
reported joint count is investigated and in chapter 4.2 and chapter 4.3 the feasibility 
and reliability of a new automated method for determining bone age and bone health are 
explored. In chapter 4 also biomarkers are studied, such as the previously mentioned 
MRP8/14 (now in non-systemic JIA, chapter 4.4) and anti-carbamylated proteins (anti-
CarP, chapter 4.5).  
In chapter 5 the conclusions of this thesis are discussed in light of current practice, 
methodological considerations, and implications for future research.  
Finally, chapter 6 is a summary of the complete thesis.
16
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Chapter 2.  Effectiveness of the first available biologic 
treatment: TNF-inhibitors
18
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ABSTRACT
Objective. Because TNF inhibitors are not approved for persistent oligoarticular JIA 
(oJIA), although they are used off-label, we evaluated their effectiveness in patients in this 
category.
Methods. Persistent oJIA patients were selected from the Dutch Arthritis and Biologicals 
in Children (ABC) register, an ongoing multicentre prospective study that aims to include all 
Dutch children with JIA using biologic agents. Response was assessed by the JIA core-set 
disease activity variables and modified Wallace criteria for inactive disease.
Results. Until February 2011, 16 persistent oJIA patients (68.8% females) had been 
included in the register. Median age of onset was 8.4 years [interquartile range (IQR) 2.1–
13.5 years]; history of uveitis in 18.8%; ANA-positive 56.3%. All had previously used MTX, 
and 81.3% had used IA CSs. Median follow-up after the introduction of biologic treatment 
was 13.7 months (IQR 8.3–16.7 months). Fourteen patients started etanercept and two 
patients who had active arthritis as well as uveitis started adalimumab. Although patients 
with persistent oJIA had few affected joints [median of two active joints at the start of 
biologic (IQR 1–3)], the patient/parent assessments of pain [median visual analogue score 
(VAS) 51 (IQR 1–64)] and well-being [median VAS 44 (IQR 6–66)] were high. Additionally, 
their physician evaluated the disease activity as moderately high [median VAS 36 (IQR 
4–65)]. After 3 months this decreased to 0 (IQR 0–30) and 63% achieved inactive disease. 
After 15 months the disease was inactive in 9/10 observed patients. TNF inhibitors were 
tolerated well.
Conclusion. TNF blocking agents seem an effective and justifiable option in persistent oJIA 
when treatment with IA CS injections and MTX has failed.
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INTRODUCTION
The International League of Associations for Rheumatology (ILAR) distinguishes 
oligoarticular JIA (oJIA) as one of the seven categories of JIA,1 defining it as arthritis 
affecting four or fewer joints during the first 6 months of disease. Based on the number of 
joints affected thereafter, oJIA is subdivided into the persistent form (four or fewer joints) 
and the extended form (over four joints).
Persistent oJIA is a well-defined subset. Typically, it starts before the age of 6 years, and 
affects girls more often than boys. Patients have asymmetric arthritis, predominantly in 
knees and ankles. They have a high risk of chronic anterior uveitis (up to 30%), and ANAs 
are often present (70–80%).34
For many years, persistent oJIA was treated with NSAIDs and IA CS injections. In recent 
years a more aggressive treatment regimen has been adopted, including synthetic 
DMARDs, such as MTX, in order to achieve inactive disease. However, additional treatment 
with DMARDs does not lead to inactive disease in all patients. Figures on long-term 
outcome vary greatly between cohort studies.35-38 Although persistent oJIA patients are 
thought to have the best outcome, a recent comprehensive cohort study reports 15% of 
patients to have joint destruction and/or visual impairment in the long term.3 
For patients at risk, the ACR now recommends adding TNF-α-blocking agents.17
The TNF-α-receptor blocking agent etanercept has proved to be effective in polyarticular JIA.39 
40 However, persistent oJIA patients have always been excluded from clinical trials. Since 2000 
etanercept is registered worldwide only for refractory JIA patients with a polyarticular course. 
In 2008, adalimumab was registered for the same indication.41 This monoclonal antibody 
against TNF-α is also used effectively for treatment of JIA-associated uveitis.42 
As more experience is gained, TNF-α blockers are also prescribed off-label for refractory 
persistent oJIA. However, no detailed studies have focused on their effectiveness in this 
category. The present study evaluates the effectiveness of TNF-blocking agents in all Dutch 
persistent oJIA patients included in the Arthritis and Biologicals in Children (ABC) register. 
Additionally, we compared persistent oJIA patients with other patients in the register.
METHODS
Data were retrieved from the ABC register, an ongoing multicentre prospective observational 
register that aims to include all Dutch JIA patients treated with biologic agents since 1999 to 
monitor effectiveness and safety.22 In the ABC register, patient characteristics were retrieved 
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at start and data on disease activity variables at start, at 3 months and yearly thereafter. All 
patients were seen regularly by their treating physician. Data were also entered at time of 
important events, including discontinuation or switch of biologic agents. Adverse events 
(AEs) and serious AEs (SAEs) were reported on a continuous basis.22 43 Flaring of arthritis or 
uveitis was regarded as a measure of treatment response. This study is embedded in the 
ABC register; no additional approval was needed to perform the study.
We selected patients fulfilling the ILAR criteria for persistent oJIA,1 included in the ABC 
register from its foundation to February 2011. Patients without active arthritis starting 
biologic treatment for uveitis were not included. Patient records of persistent oJIA patients 
were retrospectively checked for consistency and disease flares. Of the baseline data 
12.5% and of the follow-up data 14% on disease activity variables were missing {median 0 
variables missing/patient [interquartile range (IQR) 0–3]}.
We compared baseline characteristics of persistent oJIA patients with those of other JIA 
patients included in our register. In this analysis, we excluded patients with systemic JIA 
(n=68). We divided the non-systemic JIA patients in two groups: patients with four or fewer 
active joints and patients with over four active joints at start of biologic treatment.
The response to treatment was assessed with variables of the JIA core set according to 
an intention-to-treat analysis.44 A modified definition of inactive disease was used: no 
active arthritis, no uveitis, normal ESR (values under 20 mm/h) and a physician’s global 
assessment of disease activity <10 mm indicating no disease activity.45 This last cut-off was 
chosen because we experience that physicians are reluctant to set disease activity at zero, 
as the disease is not cured and patients still require medication. Descriptive statistics were 
reported as absolute frequencies or as medians with IQR. Fisher’s exact, Kruskal–Wallis 
and Mann–Whitney U-tests were used to perform comparisons as applicable. A P < 0.05 
was considered statistically significant. SPSS version 17.0.1 was used for all analyses.
RESULTS
Of the 408 patients included in the register until February 2011, 16 patients had persistent 
oJIA (3.9%). Patient and disease characteristics of patients with persistent oJIA and 
patients with other non-systemic JIA categories in the register are shown in table 1. 
Patients with other non-systemic JIA categories had higher disease activity and were 
treated more extensively than persistent oJIA patients. Persistent oJIA patients differed 
from the non-systemic patients with over four active joints at start, especially with regard to 
uveitis and ANA positivity. They resembled the patients with non-systemic JIA categories 
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with four or fewer active joints at initiation of biologic therapy on most characteristics, 
extended oJIA being the most common JIA category in this group.
Table 1 Patient and disease characteristics 
Characteristic Persistent oJIA  
(n=16)
Non-systemic JIA categories other 
than persistent oJIA
Four or fewer ac-
tive joints at start 
of biologic (n=69)
Over four active 
joints at start of 
biologic (n=258)
Female, n (%) 11 (68.8) 44 (63.8) 185 (71.7)
Median age at onset (IQR), years 8.4 (2.1–13.5) 6.8 (2.8–10.6) 8.3 (3.5–11.5)
Median age at start of first biologic 
(IQR), years
12.1 (8.5–16.1) 13.4 (9.4–15.5) 12.5 (9.2–15.2)
Median JIA disease duration before 
start of biologic (IQR), years
2.0 (1.2–6.0) 4.1 (1.8–7.9) 2.7 (1.3–5.7)
History of uveitis, n (%) 3 (18.8) 10 (14.5) 12 (4.7)**
ANA positivity, n (%) 9 (56.3) 33 (47.8) 67 (26.0)*
HLA-B27 positivity, n (%) 2 (12.5) 10 (14.5) 16 (6.2)
RF positivity, n (%) – 6 (8.7) 30 (11.6)
Category JIA, n (%)
  Polyarticular RF negative – 18 (26.1) 136 (52.7)
  Polyarticular RF positive – 8 (11.6) 29 (11.2)
  Oligoarticular persistent 16 (100) – –
  Oligoarticular extended – 27 (39.1) 58 (22.5)
  PsJIA – 7 (10.1) 19 (7.4)
  Enthesitis-related arthritis – 9 (13.0) 16 (6.2)
First-introduced biologic, n (%)
  Etanercept 14 (87.5) 61 (88.4) 252 (97.7)
  Adalimumab 2 (12.5) 7 (10.1) 4 (1.6)
  Infliximab – 1 (1.4) 2 (0.8)
Previously used medications, n (%)
  NSAID 15 (93.8) 68 (98.6) 250 (96.9)
  Systemic CSs 3 (18.8) 26 (37.7) 108 (41.9)*
  IA CSs 13 (81.3) 36 (52.2)* 59 (22.9)**
  MTX 16 (100.0) 68 (98.6) 238 (92.2)
  Other DMARDs besides MTX 2 (12.5) 9 (13.0) 52 (20.2)
25
Co-medication at start of biologic, 
n (%)
  NSAID 7 (43.8) 46 (66.7)** 217 (84.1)**
  Systemic CSs – 8 (11.6) 70 (27.1)*
  IA CSs 3 (18.8) 7 (10.1) 7 (2.7)*
  MTX 10 (62.5) 50 (72.5) 231 (89.5)**
  DMARD other than MTX 1 (6.3) 6 (8.7) 13 (5.0)
Median disease activity parameters 
of patients with active arthritis at 
baseline (IQR)
VAS physician 36 (24–51) 40 (30–60) 60 (45–73)**
Total CHAQ score 0.30 (0.00–0.75) 0.88 (0.27–1.40)* 1.50 (1.00–2.00)**
VAS pain 51 (1–64) 41 (12–65) 60 (30–77)*
VAS well-being 44 (6–66) 48 (13–64) 54 (31–75)
Number of active joints 2 (1–3) 3 (2–4)* 10 (6–16)**
Number of limited joints 1 (1–2) 2 (1–4)* 6 (4–12)**
ESR 10 (4–20) 13 (7–28) 15 (7–32)
 
*P ≤ 0.05, **P ≤ 0.001, persistent oJIA patients compared with the two groups of other non-systemic JIA patients. 
CHAQ=Childhood HAQ.
Most persistent oJIA patients (n=14) started TNF inhibitors because of persistent arthritis, 
all started etanercept. The two patients starting adalimumab had active arthritis as well as 
uveitis. Median follow-up after introduction of a TNF inhibitor was 13.7 months (IQR 8.3–
16.7 months). All patients were previously treated with MTX; nine up to a maximum dose of 
≥15 mg/m2 for >6 months, the other seven patients did not reach the maximum dose due 
to intolerance. Of these seven patients three received MTX for <6 months. Three patients 
were not treated with IA CSs, because of a disease course dominated by severe refractory 
uveitis and/or arthritis in joints less accessible for injections. The other 13 patients were 
treated with one or multiple injections (range 2–5 injections/joint). In most patients knees 
were involved (a total of 22 knees). Other affected joints were ankles (nine), elbows (three), 
fingers (three), hip (two), shoulder (one) and TM joint (one). Eleven patients had conventional 
radiographs taken of the affected joints. Two patients had erosive deformities of the ankle. 
Two other patients had growth disturbances of the knees.
Effectiveness
Table 2 shows the response to treatment in persistent oJIA patients. All disease activity 
variables decreased within 3 months. An even greater decrease could be seen after 15 
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months of follow-up. Inactive disease was reached by 10 patients (63%) within 3 months. 
Seven of these patients had an observed follow-up of 15 months and had by then achieved 
remission on medication. At 15 months, in total 9 out of 10 observed patients had achieved 
inactive disease.
Table 2 Change of disease activity variables 
Disease activity variables Start (n=16) 3 Months (n=16) 15 Months (n=10)
Median 
(range)
Median 
(range)
No. 
normalized/ 
no. 
observed
Median 
(range)
No. 
normalized/ 
no. 
observed
VAS physician 36 (4–65) 2 (0–13) 10/12 0 (0–30) 9/10
Total CHAQ score 0.3 (0.0–0.9) 0.1 (0.0–1.0) 6/13 0.1 (0.0–0.6) 3/6
VAS pain 51 (0–71) 6 (0–75) 3/13 0 (0–34) 4/7
VAS well-being 44 (0–74) 5 (0–75) 5/13 0 (0–20) 5/7
Number of active joints 2 (1–4) 0 (0–1) 13/16 0 (0–2) 9/10
Number of limited joints 1 (0–3) 0 (0–2) 8/14 0 (0–2) 8/10
ESR 10 (2–60) 3 (2–30) 11/15 3 (2–29) 9/10
Patients with inactive 
disease, %
NA NA 10/16 NA 9/10
 
All variables presented as median (range). Definition of normalized: VAS physician <10; total CHAQ score=0; VAS pain=0; 
VAS well-being=0; number of active joints=0; number of limited joints=0; ESR <20 mm/h; CHAQ=Childhood HAQ;  
NA=not applicable.
The majority of patients continued concomitant MTX. Most patients (n=13) were not treated 
with IA CSs during anti-TNF treatment. Three patients received IA CSs simultaneously 
with the start of etanercept. These patients had been treated with IA CSs in several joints 
before, with insufficient response (lasting <5 months). All three patients achieved inactive 
disease within 3 months, which was sustained for the observed follow-up of 14 months 
in one patient. The other two patients had a disease flare after 10 months. One patient 
switched from etanercept to adalimumab and achieved inactive disease thereafter.
Two of 16 persistent oJIA patients discontinued TNF inhibitor because of disease remission 
after 10 months. One of these patients showed lasting remission during the observed 
follow-up (4 months); the other patient flared within 1 month. The other 14 patients 
continued using TNF inhibitor.
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Safety
A total of 18.2 patient-years after introduction of TNF inhibitor (16.0 patient-years on 
etanercept and 2.2 patient-years on adalimumab) were observed. Two SAEs were reported 
during etanercept use (restrictive pulmonary function and perforated appendicitis). No AEs 
were reported during adalimumab use. No permanent discontinuation due to AEs occurred.
DISCUSSION
This is the first study that extensively evaluates the effectiveness of TNF blocking agents in 
persistent oJIA patients. Since most patients started etanercept, our results mainly reflect 
the effectiveness of etanercept.
After introduction of a TNF blocking agent, disease activity rapidly declined. This result 
was maintained and even improved after 15 months, when almost all of the patients with 
available follow-up had achieved inactive disease. A decrease in disease activity was found 
in patients included in our register comparable to that in other (non-systemic) categories 
of JIA.40 One recent observational study also reports on 38 persistent oJIA patients (5% 
of the total studied population) being treated with etanercept. Of these oJIA patients 
53% achieved inactive disease (using the modified inactive disease criteria as defined in 
the present study) and 13% remission on medication.46 No additional patient or disease 
characteristics are described and follow-up duration of persistent oJIA patients is not 
provided. These combined results provide support for treatment with TNF inhibitors in 
some persistent oJIA patients.
Despite the fact that biologic agents were not tested in persistent oJIA patients in clinical 
trials, and therefore not licensed for this JIA category, paediatric rheumatologists perceived 
the need to prescribe TNF blocking agents to a small number of persistent oJIA patients. 
One might argue that this is related to the higher prevalence of uveitis in this group; 
another indication for biologic treatment. However, only in two patients did the presence of 
refractory uveitis contribute to the decision to prescribe the TNF inhibitor.
The persistent oJIA patients in our study may represent a specific oJIA subset, requiring 
a different treatment approach. The onset age of our patients is higher (comparable to 
other non-systemic JIA patients) and the prevalence of ANA is lower than in persistent 
oJIA patients described in the literature.34 The categorization of JIA is subject to ongoing 
debate; classifying JIA by other factors than number of joints at onset has been proposed.47 
48 The recently published ACR recommendations for management of JIA use an alternative 
way of categorizing: treatment choice is not purely based on JIA category, but rather on 
28
disease activity, prognostic features and response to previous therapy.17 When applied 
to our study, only six patients were treated according to these recommendations. The 
10 patients not fulfilling the criteria had ongoing relapsing arthritis despite use of IA CSs 
and DMARDs. Their scores for patient/parent assessments of pain and well-being were 
identical to other non-systemic JIA patients treated with TNF inhibitors. It seems that these 
recommendations are not fully applicable in daily practice.
A reason to be reticent with prescribing TNF inhibitors to persistent oJIA patients may be a 
safety concern. In this study, insufficient patient-years are observed to be able to evaluate 
the safety of TNF inhibitors. Although TNF blockers are observed to be well tolerated in 
previous reports on patients with all JIA categories,40 49 there is still insufficient knowledge 
about the long-term effects. Balancing the risks and benefits remains important when 
considering treatment with TNF blockers.
The present study has some limitations: the small number of patients and the short follow-
up duration. The 16 patients included in this study were the only persistent oJIA patients in 
the Netherlands initiating TNF blocking agents since its introduction. To our knowledge this 
is the largest case series to date reporting detailed information on persistent oJIA patients 
only.
We further chose not to use the ACR Pedi 30, 50, 70 response criteria, which in our 
opinion are more appropriate for polyarticular disease. They do not capture the full degree 
of change in disease activity when individual baseline variables are low, as is the case in 
persistent oJIA. Today no specific instrument evaluating oligoarticular patients is available; 
therefore, the response to treatment was evaluated by change on the single core-set 
disease activity variables and the composite score for inactive disease.
Three of our patients were treated with IA CSs at start of etanercept and subsequently 
achieved inactive disease within 3 months. This inevitably results in a biased evaluation of 
response to the newly introduced TNF inhibitor. However, this is inherent to the nature of 
the current study and reflects daily clinical practice.
In conclusion, the results suggest that TNF blockers are effective in persistent oJIA patients 
who were refractory to MTX treatment and IA CS injections. Persistent oJIA patients treated 
with TNF inhibitors resemble other non-systemic JIA patients from our register with regard 
to age at onset and certain measures of disease activity. In these more severely affected 
persistent oJIA patients treatment with TNF inhibitors is a justifiable option.
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ABSTRACT
Objectives. To longitudinally investigate functional outcome, health related quality of life 
(HRQoL) and treatment strategies in juvenile idiopathic arthritis (JIA) patients who started 
etanercept more than 5 years ago.
Methods. We approached patients whose HRQoL changes were described previously in 
a sub-analysis of the Dutch Arthritis and Biologicals in Children register. Recent disease 
status, comorbidities and structural damage were retrieved. Disability and HRQoL were 
assessed by (Child) Health Assessment Questionnaire ((C)HAQ), Child Health Questionnaire, 
Short Form 36 (SF-36) and Health Utilities Index Mark 3. Changes over time were analysed 
with linear mixed models. 
Results. 43 patients (81% response) started etanercept median 8.5 years ago. Median age 
at time of long-term analysis was 22 (IQR: 18 to 24), 42% had a (C)HAQ of 0.00. HRQoL 
outcome was similar to HRQoL after start of etanercept, except for bodily pain, which 
deteriorated to baseline levels at start of etanercept. VAS pain also worsened, but less than 
bodily pain on the SF-36. Unemployment (12%) was comparable to the general population; 
educational level was higher. Use of biologic agents: 40% etanercept, 40% other biologic 
agents, and 20% none. Joint surgery occurred in 14% of patients.
Conclusions. The HRQoL improvement was sustained after 8.5 years. Disability scores 
were low. On daily life aspects, patients functioned comparable or better than their peers. 
Persistence and possible deterioration of radiologic damage stress the importance of early 
treatment. Chronic pain - even in inactive disease - remains an important issue, affecting 
patients’ quality of life.
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INTRODUCTION
Juvenile idiopathic arthritis (JIA) is a chronic disease, with many JIA patients having 
ongoing active disease into adulthood.35 38 50-52 During the last decades, several long-term 
follow-up studies indicated that JIA causes chronic disability and impairments in social life, 
due to both articular and extra-articular manifestations of the disease.4
Most of these studies however, were performed in the 1990’s, when biologic treatment was 
not yet available. With the introduction of biologic agents, short term outcomes improved 
significantly, specifically for JIA patients in whom the disease could not be controlled with 
conventional DMARDs.40 46 Only one cross-sectional study has been published investigating 
the long-term outcomes of JIA patients starting biologic treatment (etanercept) as a child.53 
Patients in this study had less JIA related damage and disability and a better health related 
quality of life (HRQoL) compared to JIA patients from a historical cohort not treated with 
biologic agents. 
In 2010, a sub-analysis of the Dutch Arthritis and Biologicals in Children (ABC) register 
longitudinally investigated disease activity and HRQoL of 53 patients from the start of 
etanercept onwards until 27 months after start.24 Not only did the arthritis subside rapidly 
in a large proportion of these patients, HRQoL also improved substantially. For the present 
study we contacted these 53 patients, aiming to investigate whether: 1. the control of 
active disease with etanercept in these patients was persistent, 2. patients needed to be 
treated with other biologic agents, and 3. improvement in HRQoL was sustained. Functional 
outcome, structural damage and comorbidities were additional topics of interest.
METHODS
The ABC register
The ABC register is a multicentre prospective observational study. It aimed to include 
all Dutch JIA patients who initiated biologic agents. Patients were followed up until they 
transitioned to adult care. The register was founded in 2003 and contains prospectively 
collected data since 1999. The study protocol was approved by the Medical Ethics 
Committee at Erasmus MC Rotterdam and by all participating hospitals.40 
Patient selection and additional data collection
53 patients whose HRQoL following etanercept treatment was studied previously were 
asked to participate.24 All were included in the ABC register before 2007. At that time, 71 
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patients from the centres participating in this sub-analysis had been included in the ABC 
register. The 53 patients that participated in the previous study were not different from 
the 18 patients that did not participate with regard to patient and disease characteristics. 
Patients were contacted through their last known physician. Written consent was obtained 
according to the declaration of Helsinki. Contact details of 47 patients were retrieved. The 
other six patients were lost to follow-up (patient flow-chart in supplementary files).
Permission was asked to retrieve information on disease status, comorbidity, structural and 
radiological damage and medication from the patient’s current physician. Structural damage 
was defined as persistent changes in joints or other organs resulting from disease activity or 
medication. Radiological damage was defined as any report of cartilage damage, joint space 
narrowing or erosive changes. Following the domains of the Juvenile Arthritis Damage Index for 
extra-articular damage (JADI-E), the following types of extra-articular damage were assessed: 
ocular, musculoskeletal non-articular, cutaneous, endocrine and secondary amyloidosis.54 
Through questionnaires, patients were asked to provide information on marital status, 
housing, education and employment. Highest achieved education level in Dutch categories 
were recoded into International Standard Classification of Education 2011 levels (ISCED 
2011).55 A patient-reported joint count was used when the physician could not provide a 
recent report of the disease activity. This was the case in 6 patients. 
In adult patients, disability and HRQoL were measured by Health assessment questionnaire 
(HAQ), the Medical Outcomes Short Form 36 (SF-36) and the Health Utility Index mark 
3 (HUI3) self-assessment.56-58 In patients younger than 17, the CHAQ, Child Health 
Questionnaire (CHQ, which is closely related to SF-36) and the proxy assessment of the 
HUI3 were used.59-61 An extensive description of all questionnaires can be found in the 
supplementary files. For the purpose of the current study, only the identical domains and 
the two summary scores of CHQ and SF-36 were reported and combined for figures and 
analyses. The reference values of these concepts were nearly the same, and therefore a 
comparison with the normal population would not be affected.57 61
The scores on the preference based HUI3 result in single and multi-attribute utilities on a 
scale from 0 (dead) to 1 (perfect health).62 
HRQoL measured in this long-term follow-up study was graphically compared to the 
patients’ own reported HRQoL at start of treatment and at the last available follow-up 
measurement, as described in the prior study by our group.24 In figures and tables, the latter 
was referred to as “the intermediate follow-up” in the present manuscript. Measurements of 
the intermediate follow-up were at a mean of 15 months for the CHQ, and at a mean of 27 
months for HUI3 and CHAQ.
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Treatment effectiveness measures
Response was defined as having achieved at least an ACRpedi50 response after 3 months 
of treatment. Non-response was defined as having achieved a response lower than 
ACRpedi50. The ACRpedi50 response implies that a patient has improved ≥50% on three 
of the JIA core set variables and has worsened ≤30% on no more than one variable.44 
The disease was said to be inactive when the physician stated the disease was inactive 
and/or there were no joints with active arthritis, ESR <20 mm/hr (if available) and the 
physician’s global assessment was < 10 mm.45 In cases where the physician did not provide 
a recent report of disease activity a patient’s VAS < 10 mm was required for assignment of 
inactive disease, combined with 0 active joints on the patient-reported joint count.
Statistical analysis
Descriptive statistics were reported as absolute frequencies, median with interquartile range 
(IQR) or mean with standard deviation (SD). For evaluating change in HRQoL measures over 
time we used linear mixed models with time as fixed covariate, a random intercept, and 
variance components as covariance structure (the default). For this analysis all available 
follow-up moments were used. A P-value <0.05 was considered statistically significant. 
IBM SPSS Statistics for Windows, Version 21.0 (Armonk NY: IBM Corp.) was used for all 
analyses.
RESULTS
Patients
Of the 53 patients in the original study, 43 participated in the long-term follow-up (81% 
response, for flowchart see supplementary files). One patient filled out the questionnaires, 
but did not give permission to contact the current treating rheumatologist. The patients who 
did not participate did not differ substantially from those who did. The characteristics of all 
patients are shown in table 1. The majority of patients was still in rheumatologic care (n=41 
(95%)) of which 31 patients (76%) had transferred to adult care. 
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Table 1 Patient and disease characteristics 
Characteristic Patients included 
in this study n=43
Patients lost to 
follow-up n=10
Female, n (%) 28 (65) 5 (50)
Age at onset JIA, median (IQR), yrs 8.2 (5.0-10.0) 5.5 (1.7-10.4)
Disease duration at start etanercept, median (IQR), yrs 3.1 (1.4-5.1) 2.6 (0.9-5.1)
Age at long-term follow-up, median (IQR), yrs 22.0 (17.9-24.5) 18.9 (15.4-22.7)
Age at long-term follow-up, categorized
  < 17 years of age, n (%) 8 (19) 3 (30)
  > 17 years of age, n (%) 35 (81) 7 (70)
Time between start etanercept and long-term follow-up, 
median (IQR), yrs
8.5 (7.7-10.3) 10.0 (8.2-11.0)
JIA category, n (%)
  Systemic JIA 12 (28) 2 (20)
  Polyarticular RF negative JIA 12 (28) 4 (40)
  Polyarticular RF positive JIA 7 (16) 1 (10)
  Oligoarticular Extended JIA 8 (19) 2 (20)
  Psoriatic JIA 3 (7) -
  ERA 1 (2) 1 (10)
Disease activity at start etanercept
  JADAS-10,23 median (IQR) (range 0-40) 23 (18-25) 21 (19-27)
  CHAQ, median (IQR) (range 0-3) 1.85 (1.25-2.33) 2.00 (1.43-2.18)
Responders to etanercept after 3 months of treatment 
(≥ACRpedi50)
33 (77) 7 (70)
HRQoL (CHQ) at start etanercept
  MCS, median (IQR) (range 0-100) 48 (42-54) 37 (24-48)
  PCS, median (IQR) (range 0-100) 27 (11-45) 13 (0-32)
Inactive disease at long term follow-up, n (%) 29 (67) NA
 
JIA=juvenile idiopathic arthritis, ERA=enthesitis related arthritis, JADAS=juvenile arthritis disease activity score, 
CHAQ=childhood health assessment questionnaire, HRQoL=health related quality of life, CHQ=child health questionnaire, 
MCS=mental component summary score, PCS=physical component summary score
Etanercept treatment
Most patients (81%) discontinued etanercept at some point during their disease course. 
Reasons for stopping were unsatisfactory response (n=7), loss of response (n=4), adverse 
events (n=2), uveitis flare (n=1) and a pregnancy wish (n=2). However, the majority 
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discontinued etanercept because of inactive disease (n=18 (56%)). The disease flared in 
14 of these patients (79%) within a median of 9 months (range: 1-69 months). The other 4 
patients remained flare-free until last follow-up (10 to 78 months). 
Other biological and synthetic DMARD treatment
During the disease course, 16 patients (38%) used other biologic agents. At last follow-
up, 41% of patients were still or again using etanercept. One fifth of our patients (n=8) 
were not using any anti-rheumatic drug. The majority (n=6) of these patients were male, 
and 63% (n=5) had systemic JIA. Of the remaining 34 patients who were still treated, 3 
only used synthetic DMARDs, 16 only used a biologic agent and 15 were treated with a 
combination of a synthetic DMARD and a biologic agent. Details on current and previous 
treatment are shown in table 2. 
Table 2 Treatment characteristics 
Treatment characteristics N=42
Current DMARD treatment, n (%) 18 (43)
  Methotrexate 14 (38)
  Hydroxychloroquine 3 (8)
  Leflunomide 1 (3)
  Sulfasalazine 2 (5)
  Mycophenolate mofetil 1 (3)
Current biologic treatment, n (%) 31 (74)
  Etanercept 17 (40)
  Adalimumab 5 (12)
  Infliximab 4 (10)
  Anakinra 2 (5)
  Tocilizumab 2 (5)
  Rituximab 1 (2)
  None 11 (26)
Duration off biologic medication, median (range), months (n=11) 42 (3-78)
No current anti-rheumatic treatment, n (%) 8 (19)
Number of ever used biologic agents, median (range) 1 (1-5)
Ever used biologics other than etanercept, n (%) 17 (40)
  Adalimumab 14 (33)
  Infliximab 8 (19)
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  Anakinra 5 (12)
  Abatacept 3 (7)
  Tocilizumab 3 (7)
  Rituximab 1 (2)
 
DMARD=disease modifying anti-rheumatic drug
Structural damage and comorbidity
Half of our patients reported structural damage (n=21) (table 3), most frequently articular 
damage (n=17). In 14 of the 17 patients with joint destruction, some form of radiological 
damage was already present before start of etanercept. The systemic and polyarticular 
RF positive subtypes more often had radiological damage than other subtypes. (p=0.002, 
Fisher’s Exact test). 
More than half of our patients (55%) reported one or more comorbidities (table 3). Most 
were diagnosed after the start of etanercept. There were no reports of demyelinating 
conditions or malignancies. 
Table 3 Structural damage and comorbidity 
Structural damage N=42
Number of patients with structural damage, n (%) 21 (50)
Type of damage, n (%)
  Severe joint destruction, joint surgery needed 6 (14)
  Joint destruction, no joint surgery needed (yet) 11 (26)
  Residual joint abnormalities and contractures 5 (12)
  Severe osteoporosis 2 (5)
  Severe growth impairment (deviation of > 2SD) 3 (7)
  Debilitating rheumatoid nodule 1
  Scapular dyskinesia 1
  Ruptured Baker’s cyst 1
Comorbidity
Patients with comorbidity, n (%) 23 (55)
Comorbidity (diagnosed before start of etanercept)
  Pyramidal syndrome 1
  Epilepsy 1
  Recurrent infections 1
  Cardiac arrhythmia 1 
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Comorbidity (diagnosed after start of etanercept)
  Generalized problems
Chronic pain syndrome/ fibromyalgia 3 
Chronic stomach complaints (no IBD) 3 
Serious/recurrent infections 7
Anaemia 1
Angioneurotic oedema (probably infectious) 1
  Neurological
Tension headache 2 
Carpal tunnel syndrome 1
Epilepsy 1
  Mental health problems 2 
  Cardiovascular/haematological
Pericarditis 1 
Pernicious anaemia 1
  Auto-immune phenomena
IBD 2
Psoriasis 1
Uveitis 2
  Other
Perthes 1
Angiofibroma 1
 
SD=standard deviation; IBD=inflammatory bowel disease
Quality of life - living arrangements, education and employment
Patients were relatively highly educated compared to the general population in the 
Netherlands in the age range of 15-25 years (table 4).63 The percentage of patients without 
work was comparable to the unemployment rate for the general population in the age range 
of 15-25 years in 2013 (12% and 16% respectively), although a higher percentage receives 
some form of disability benefit.63 Almost 50% of patients >17 years old (n=16) indicated 
they felt limited in their choice of work or education. Half of our patients participated in 
some form of sport, in which they exercised for an average of 3.7 hours per week.
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Table 4 Living, education and employment 
Living, education and employment ≤ 17 years (n=8) ≥ 18 years (n=35)
Living arrangements, n (%)
  With parents 8 (100) 23 (66)
  Alone - 2 (6)
  With partner - 7 (20)
  With partner and child - 1 (3)
  With roommates - 2 (6)
Adapted housing, n (%) 1 (13) 6 (17)
Type of adaptation
  Stair lift 1 2 (6)
  Adapted bathroom - 1 (3)
  Ground floor bedroom, specially build - 2 (6)
  Adapted furniture - 3 (9)
Highest achieved education ISCED 2011 level, n (%)
  Special needs - 1 (3)
  ISCED 1 (primary education) 7 (88) 1 (3)
  ISCED 2 (lower secondary education) 1 (13) 6 (17)
  ISCED 3/4 (upper secondary/ post-secondary non-tertiary) - 19 (54)
  ISCED 6/7* (bachelor/master) - 8 (23)
Employment
  Paid employment part time 2 (25) 14 (40)
  Paid employment full time - 6 (17)
  Student - 19 (54)
  Unemployed - 2 (6)
  Social security/ disability benefit - 2 (6)
 
*ISCED level 5 not applicable
Quality of life - disease specific HRQoL
Disease-specific HRQoL was measured by CHAQ or HAQ, depending on the age of 
the patient. CHAQ scores (median 0-83, IQR: 0.33-0.97) at the long-term follow-up 
evaluation were higher than HAQ scores (median 0.00, IQR: 0.00-0.63). CHAQ and HAQ 
scores combined did not change between the follow-up at 15, 27 months and the long-
term evaluation (p=0.686 for comparison with the 27 month measurement). Level of 
disability was low, 18 patients (42%) had a CHAQ/HAQ score of 0. VAS pain (median 12, 
IQR: 2-43) and VAS wellbeing (median 16, IQR: 3-41) were significantly higher than the 
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earlier measurements when entered into a linear mixed model (p=0.003 and p=0.037 for 
comparison with the 27 months measurement). They were however still significantly lower 
than those at start of etanercept (median 65 and median 51 respectively, p<0.001 for both). 
Quality of life - generic HRQoL
Figure 1A shows the scores of patients at different time points on the identical domains of 
the CHQ/SF-36; it includes the norm scores for the Dutch population for the age group 16-
40 years.57 
On a utility scale patients maintained the improvement they had shown in the intermediate 
follow-up at all levels and also at the multi-attribute level, as shown in figure 2A and 2B. 
Both single and multi-attribute functions did not change between the intermediate and the 
long-term follow-up measurement in a linear mixed model.
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Figure 1A Scores on the six identical domains of CHQ and SF-36 at the different time points 
PF=physical functioning, RE=emotional role functioning, RP=physical role functioning, BP=bodily pain, 
GH=general health perceptions, MH=mental health
The initial improvement in psychological functioning (figure 1B) seemed to continue, 
although patients did not significantly improve between the intermediate and the long-term 
evaluation (mean MCS: 57 (±13), p=0.389 for comparison with the 27 month measurement). 
Physical functioning improved during the first years of follow-up, but remained at a lower 
level than the general population at the intermediate and long-term evaluation (mean 
PCS: 33 (±16), p=0.175 for comparison of the long-term follow-up with the 27 month 
measurement). 
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No difference was found in the summary scores at long-term follow-up between non-
responders and responders to etanercept, nor was there a difference between patients with 
and without structural damage (data not shown).
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Figure 1B Summary scores of physical (PCS) and psychological (MCS) functioning in standard deviations 
from normal at the different time points
On a utility scale patients maintained the improvement they had shown in the intermediate follow-up at all levels 
and also at the multi-attribute level, as shown in figure 2A and 2B. Both single and multi-attribute functions did 
not change between the intermediate and the long-term follow-up measurement in a linear mixed model.
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Figure 2A Health Utility Index mark 3 (HUI3) – single attribute function 
Changes in the single-attribute functions of the HUI3 at three different time points (range 0 (death) to 1 
(perfect health)).
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Figure 2B Health Utility Index mark 3 (HUI3) – multi-attribute function 
Changes in the multi-attribute function of the HUI3 at three different time points (range 0 (death) to 1 
(perfect health)).
DISCUSSION
The objective of this study was to longitudinally investigate the long-term follow-up of 
biologic-naïve JIA patients treated with etanercept, with a special focus on HRQoL. After a 
median of 8.5 years, HRQoL on most physical health domains was comparable to the initial 
response seen after the start of etanercept. Domains related to mental health had improved 
even further. This suggests that the gain in HRQoL as shown by our research group was 
maintained.24 On other aspects of daily life, such as employment and education, patients 
functioned comparably to or better than their peers. Nevertheless, half of our patients had 
developed structural damage related to JIA, signs of which were often already present 
before start of etanercept. Articular damage was reported in part of our patients (mostly 
with systemic JIA), and some even needed joint surgery despite successful treatment with 
etanercept or other biologicals. 
The majority of patients did not switch to other biologic agents; 40% of patients were still 
treated with etanercept at the long-term follow-up measurement. At last follow-up, almost 
20% of the patients were not using any anti-rheumatic treatment. This is remarkable, 
considering these patients were all refractory to conventional DMARD treatment. 
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Comparison to other studies - HRQoL
Two studies investigated long-term HRQoL in JIA patients before biologic agents were 
available (n=44 and n=82).52 64 Only one other study investigated long-term disability and 
HRQoL in the biologic era.53 This last study had a response of only 56%, and the risk of 
selection bias towards the severe end of the JIA spectrum is therefore high. The patients 
studied differed between all publications with regard to age and included JIA categories, 
due to the setting from which patients were selected. This is especially true for the study 
by Peterson et al., as it included a large proportion of patients with oligoarticular JIA (73%), 
who are known to have a better long-term prognosis.52 These differences should be taken 
into account, when comparing these cohorts to our patients. The characteristics of the 
patients included in all four studies (including the present one), HAQ scores and HRQoL 
scores on the SF-36 are reported in the table in the supplementary files.
The patients included in the study by Peterson et al.52 seem too different from the other 
three to really be used as a comparison cohort. The other three studies are quite similar 
with regard to HRQoL scores. It appears that patients in the current study are functioning 
better than the patients who did not have access to biologic treatment,64 but somewhat 
less than the patients in the more recent study by Minden et al.53 However, the differences 
are small. Our patients differ most evidently in the domain for mental health, where they 
functioned particularly well; and the domain of bodily pain, where our patients scored 
lowest. 
Patients reported as much bodily pain on the SF-36 as they did at start of etanercept, the 
level was comparable to that reported in the study by Foster at al.64 We were surprised 
that patients reported pain despite successful treatment. The other indices for pain in 
our study only partly showed the same result. The VAS pain also showed an increase 
between the intermediate and the long-term follow-up, but did not increase to the level 
at start. The single attribute utility for pain on the HUI3 remained around the same level. 
This discrepancy may be related to the different ways these questionnaires assess pain. 
Overall, it seems that pain perception might not be consistent with the presence of active 
inflammation, as is also suggested by other studies.6 65-67 Our findings indicate that even 
when the disease activity is decreased by medication, the pain our patients perceive still 
affects their HRQoL.
Compared to other studies, outcomes on education and employment of our patients are 
favourable. Our patients had achieved higher education level compared to their peers from 
the general population, which is consistent with findings by Packham et al.68 However, 
in that study, also a high unemployment level was found in adult JIA patients, which was 
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confirmed by other studies.52 53 64 68 In our study, unemployment is in accordance with the 
employment rate of the general population, although half of our patients did feel limited in 
their choice of work or education.63 
Although half of our patients had acquired some form of structural damage, the percentage 
needing joint surgery was surprisingly low compared to other studies.53 It has to be taken 
into account that some of these studies included older patients with a longer disease 
duration. Most physicians will wait as long as possible to perform a join replacement. Most 
of the patients with radiological damage already showed signs of this on radiographs taken 
before the start of etanercept and in the majority this damage remained present or even 
worsened, despite treatment. It has to be said that radiological damage was not quantified 
using a standardized scoring method. Therefore we cannot be definite on progression 
or improvement of radiological damage. The fact that part of patients did need surgery 
however, does stress the need for early aggressive treatment to achieve and maintain 
remission as early as possible, preferably before radiological damage is present, to prevent 
disability due to joint destruction in the long run.
The majority of our patients had inactive disease, which is noteworthy considering these 
patients were previously refractory to conventional DMARD treatment. Inactive disease was 
much less common in the study by Minden et al., which is probably caused by a selection 
bias in that study.53 Most of our patients were still in rheumatologic care and using anti-
rheumatic medication. Remission off medication, the treatment goal, was therefore not 
yet reached. Nonetheless, this finding shows that even in these patients, remission on 
medication is an achievable goal.
Strengths and limitations of the study
This is the first study investigating HRQoL and other long-term outcomes of patients 
starting etanercept in a longitudinal fashion. The response rate was high, which reduces 
possible selection bias. It may however be that some selection bias was already introduced 
in the previous study, as the response rate in that study was 75%. This could be reflected 
for instance in the high educational level of our patients. It is possible that the patients 
included in the current study are patients who are very willing to take part in research and 
are therefore different from the patients we already lost in the first stage of this project.  
We studied the same patients longitudinally; however there was a large gap between 
the last intermediate follow-up and the long-term follow-up moment. Some information 
had to be gathered retrospectively from the rheumatologists, and may therefore be less 
reliable. An ideal longitudinal study would follow patients through the transition from 
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paediatric to adult care, recording data also on this important phase. Following patients 
from childhood into adulthood poses some difficulties regarding outcome measures, 
as currently few questionnaires are suitable both for paediatric and adult patients. Even 
when two questionnaires measure the same construct (as is the case with the CHAQ and 
HAQ questionnaire), this does not mean that the two questionnaires will have perfect 
agreement.69 
Conclusions
Concluding, JIA patients treated with etanercept maintain most of the improvement in 
HRQoL seen after the start of etanercept. Although disability scores are low, chronic pain 
is an issue that needs to be addressed. Early radiological changes were present at start of 
etanercept, leading to surgery in 14% of patients in later life, despite effective treatment. 
This stresses the importance of early treatment of JIA, before radiological damage is 
present, and the need to treat towards disease remission. Since part of our patients were 
able to stop all anti-rheumatic medication, clinical remission off medication seems to be an 
achievable goal, even for this group long thought to be refractory to all medication. 
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SUPPLEMENTARY TEXT: FLOW CHART 
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N=4
N=1
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N =48
N=1
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N=1
No permission to retrieve 
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permission to use quesonnaires
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study (possible parcipants)
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SUPPLEMENTARY TEXT: DESCRIPTION OF HRQOL QUESTIONNAIRES
SF-36 (Medical Outcomes Short Form 36)
The SF-36 is one of the most widely used generic HRQoL measures and has been validated 
in the general population in the Netherlands.57 Additionally, several studies validated the 
use of the SF-36 in rheumatic diseases, and it is used in most studies in RA that reported 
a HRQOL measure.70-74 The SF-36 assesses eight aspects of health; physical functioning 
(PF), role functioning: emotional limitations (RE), role functioning: physical limitations (RP), 
bodily pain (BP), general health perceptions (GH), mental health (MH), vitality (VT) and social 
functioning (SF). These health concepts can be summarized in two domains; physical and 
emotional functioning (PCS and MCS). It is designed for use in adults. Scores on both the 
SF-36 and the CHQ are scaled from 0 to 100, with 100 indicating perfect health. 
CHQ (Child Health Questionnaire)
The CHQ is a generic health measure closely related to the SF-36, but specifically designed 
for the use in younger patients. We applied the Dutch proxy version (CHQ-PF50).60 The 
CHQ assesses 13 health concepts; physical functioning (PF), role functioning: emotional/
behavioral limitations (REB), role functioning: physical limitations (RP), bodily pain/
discomfort (BP), general health perceptions (GH), mental health (MH), general behavior 
perception (BE), self-esteem (SE), change in health (CH), emotional impact on the parent 
(PE), impact on the parent’s personal time (PT), limitations on family activities (FA) and 
family cohesion (FC). Also from these concepts two summary scores can be calculated 
(PCS and MCS).
HUI3 (Health Utility Index Mark 3)
The HUI3 is a preference-based HRQoL measure that classifies level of impairment in eight 
domains (attributes) based on information retrieved by a 15-item questionnaire. These 
single attributes are vision, hearing, speech, ambulation, dexterity, emotion, cognition and 
pain, with each five or six levels representing the range of functioning from not impaired 
(1) to severely impaired (5 or 6). Subsequently, single and multi-attribute utilities can be 
assigned to the scoring on the HUI3. 62 These utilities are scored on a scale from 0 (dead) to 
1 (perfect health).
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SUPPLEMENTARY TABLE OVERVIEW STUDIES HRQOL AND DISABILITY 
  Study (year, n) 
Peterson52 
(1997, 44)
 
Foster64 
(2003, 82)
 
Minden53 
(2012, 346)
 
Anink 
(2014, 43)
Patient selection Population- 
based
(Adult) clinic- 
based
Register-based 
(etanercept)
Register based 
(etanercept)
Design Cross sectional Cross sectional Cross sectional Longitudinal
Response, % 88 82 56 81
Age 34 (mean) 30 (median) 21 (median) 22 (median) 
JIA Categories (%)
  Systemic JIA 11 15 7 28
  Polyarticular RF negative JIA 16 24 26 28
  Polyarticular RF positive JIA 15 16 16
  Oligoarticular Extended JIA 73 10 15 19
  Oligoarticular persistent JIA 16 3 -
  Psoriatic JIA NA 9 11 7
  ERA NA 12 22 2
  Undifferentiated JIA NA - 4 -
HAQ score > 0, % ±35 >50 51 58
Domain SF-36, mean*
  PF 86 53 78 79
  VT** 56 50 55 70
  BP 78 51 65 48
  GH 67 50 54 53
  RP 87 62 77 66
  SF** 91 76 84 80
  RE 86 77 86 80
  MH 77 71 71 89
Summary score SF-36***
  PCS NA 40 45 33
  MCS NA 52 56 57
 
HRQoL=health related quality of life, JIA=juvenile idiopathic arthritis, HAQ=health assessment questionnaire, PF=physical 
functioning, RE=emotional role functioning, RP=physical role functioning, BP=bodily pain, GH=general health perceptions, 
MH=mental health, PCS=physical component summary score, MCS=mental component summary score
*Mean scores for the study by Anink et al. are based on combined scores from CHQ for patients < 17 years of age (n=8) 
and scores from SF-36 for patient >17 years of age (n=35). 
**Mean scores for the study by Anink et al. on the domains vitality and social functioning are based only on patients > 17 
years old. 
***For the study by Foster et al. the summary scores for patients < 30 years of age are reported.
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Chapter 3.  Increasing options in biologic treatment: 
what to do?
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ABSTRACT
Background. Treatment of juvenile idiopathic arthritis (JIA) has changed dramatically since 
the introduction of biological agents in 1999.
Objectives. To evaluate trends in prescription patterns of biological agents and the 
subsequent outcome of JIA.
Methods. The ABC register (multicentre prospective observational study) aimed to include 
all consecutive patients with JIA in the Netherlands who had started biological agents 
since 1999. Patients were divided according to year of introduction of first biological agent. 
Patient characteristics at introduction of the first biological agent and its effectiveness were 
analysed over 12 years. 
Results. 335 patients with non-systemic JIA and 86 patients with systemic JIA started a 
biological agent between 1999 and 2010. Etanercept remained the most often prescribed 
biological for non-systemic JIA; anakinra became first choice for systemic JIA. The use 
of systemic glucocorticoids and synthetic disease-modifying anti-rheumatic drugs before 
biological agents decreased. During these 12 years of observation, biological agents were 
prescribed earlier in the disease course and to patients with lower baseline JADAS (Juvenile 
Arthritis Disease Activity Score) disease activity. All baseline disease activity parameters 
were lowered in patients with non-systemic JIA. In systemic JIA, prescription patterns 
changed towards very early introduction of biological agents (median 0.4 years of disease 
duration) in patients with less severe active arthritis and high erythrocyte sedimentation rate 
levels. These changes for both systemic and non-systemic JIA resulted in more patients 
with inactive disease after 3 and 15 months of treatment. 
Conclusions. Biological agents are increasingly prescribed, earlier in the disease, and in 
patients with JIA with lower disease activity. These changes are accompanied by better 
short-term disease outcomes.
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INTRODUCTION
Treatment of juvenile idiopathic arthritis (JIA) has changed dramatically since the 
introduction of biological agents in 1999. An increasing number of biological agents 
targeting different cytokines, such as tumour necrosis factor α, interleukin (IL)-1 and IL-6, 
have become available during the past decade. Recently, studies have shown that earlier 
and more aggressive treatment for JIA may result in better outcomes.29 75-78 The treatment 
goal has moved to the achievement of inactive disease with prevention of structural joint 
damage and functional decline. Whether the new insights into the treatment of JIA have led 
to changes in prescription of biological treatment in daily practice and have affected the 
outcomes of JIA is still largely unknown. 
We evaluated the use of biological agents, the patient characteristics and disease 
outcomes in the Dutch JIA patient population who started their first biological agent 
between 1999 and 2010. 
METHODS 
The Dutch national Arthritis and Biologicals in Children (ABC) register
The ABC register is a multicentre prospective observational study that aimed to include 
all patients with JIA in the Netherlands who started biological agents. This register was 
founded in 2003 and contains prospectively collected data since 1999. Between 1999 
and 2008 data collection on patients starting biological treatment was required for 
reimbursement. This resulted in a high awareness of the register even after 2008 to include 
all consecutive patients. Patients enrolled in clinical trials could not be included in the ABC 
register because of competing interests. The study protocol was approved by the Medical 
Ethics Committee at Erasmus MC Rotterdam and by all participating hospitals. 
Patient selection and assessments
This analysis was limited to biologically-naïve patients who started their first biological 
agent between 1999 and 2010. We excluded patients with uveitis as the only indication for 
starting a biological agent.
Patient and disease characteristics at baseline and after 3 and 15 months of treatment 
were analysed. Disease characteristics include the JIA core set variables: physician’s 
global assessment of disease activity on a visual analogue scale (VAS) (range 0-100 mm, 
0 best score), Childhood Health Assessment Questionnaire (CHAQ) (range 0-3, 0 best 
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score) by patients/parents, including global assessment of wellbeing and pain by a VAS, 
number of joints with active arthritis, number of joints with limited motion and erythrocyte 
sedimentation rate (ESR). The modified definition for inactive disease was specified as no 
active arthritis, no systemic features, no uveitis, normal ESR (≤ 20 mm/h) and physician’s 
global assessment of disease activity indicating no disease activity (defined as a score ≤ 
10 mm).45 JADAS-10 (Juvenile Arthritis Disease Activity Score) ranges from 0 to 40 and is 
calculated as the simple linear sum of the scores of the physician and parent/patient global 
assessment (VAS 0-10), the reduced 10-active joint count and a normalised value of ESR 
on a 0-10 scale.23
Analysis
To investigate time trends, patients were divided in time periods according to the year 
of introduction of their first biological agent. Results for the years 1999 and 2000 were 
combined, because the first biological agent became available in 1999 and reimbursement 
started in 2000. Results for patients with systemic JIA and patients with non-systemic 
JIA categories (i.e., all JIA categories besides systemic JIA) were presented separately. 
Descriptive statistics are reported as absolute frequencies, or as median values with an 
IQR. Treatment effect was evaluated using drug survival and the achievement of inactive 
disease and the JADAS-10 score. One-year and 2-year drug survival were estimated using 
Kaplan-Meier analysis. To account for patients who had withdrawn from treatment, the 
LUNDEX-corrected inactive disease was calculated by multiplying the fraction of patients 
still receiving the drug with the proportion of patients with inactive disease after 3 and 15 
months, respectively.79 
Analyses of time trends were performed for continuous variables with the Jonckheere-
Terpstra test for trend, for categorical variables with the linear-by-linear association test and 
for data regarding drug survival with a Cox proportional hazards model with the year of start 
as covariate. 
A second analysis was conducted to identify patients in homogeneous clusters for values 
of the JADAS-10; the JIA core set variables and disease duration at time of introduction 
of the first biological agent. The two-step auto-cluster procedure developed by SPSS 
was used to identify the optimal number of clusters based on the Akaike Information 
Criterion (AIC, a measurement of goodness of fit) together with the log-likelihood criterion 
as distance measure. Additional baseline characteristics and treatment outcomes were 
compared among patients within the different clusters.
Missing were 11.7% of variables of the JIA core set (including VAS pain), with a mean of 
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0.8 variables (SD ±1.6) per core set. If a minimum of three (out of seven) variables per core 
set was present, the remaining variables were imputed with the aregImpute function of the 
R statistical package. One of the imputed datasets was used to perform the analysis. All 
reported p-values were based on two-sided tests for significance, and p-values <0.05 were 
considered statistically significant. SPSS V.20.0 and R statistical package 2.12.1 were used 
for the analyses.
RESULTS
A total of 335 patients with non-systemic JIA and 86 patients with systemic JIA started their 
first biological agent between 1999 and 2010. The number of biologically-naive patients 
with JIA who started a biological agent increased from 12 in 1999-2000 to 82 in 2010, as 
shown in figure 1. 
Figure 1 Number of biologically naive patients with non-systemic and systemic juvenile idiopathic arthritis 
(JIA) who started biological treatment between 1999 and 2010.
Non-systemic JIA categories
For each year, patient characteristics at baseline and outcomes after 3 and 15 months are 
presented in table 1. During the first years etanercept was prescribed almost exclusively. 
In 2010, most patients (90%) started etanercept and 9% of patients started adalimumab. 
Furthermore, the use of systemic corticosteroids before introduction of biological agents 
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decreased (76% in 1999-2001 to 38% in 2008-2010), as well as the use of other sDMARDs 
besides methotrexate (76% in 1999-2001 to 33% in 2008-2010). In the first 5 years, it was 
mainly patients with JIA with a polyarticular course who were treated with biological agents. 
More recently, patients with other categories of JIA have started biological treatment. Over 
time, biological treatment has been started earlier in the disease course; disease duration 
before the start of treatment has changed significantly from a median of 6.9 years (IQR 
4.9-11.9) in 1999-2001 to 2.2 (1.2-4.9) in 2008-2010. Lower disease activity was seen in 
patients who started biological agents in more recent years (Table 1).
Of patients who started treatment between 1999 and 2010, disease outcome improved 
after 3 and 15 months of treatment; although median JADAS-10 scores decreased non-
significantly, an increasing proportion of patients fulfilled the inactive disease criteria 
according to Wallace (Figure 2). Drug survival after 1 and 2 years of treatment was 87% and 
75% overall and did not change (p=0.16 and p=0.20). 
Because disease activity and disease duration at baseline differed significantly over time, 
a cluster analysis was performed to identify more homogeneous groups of patients. The 
patient and disease characteristics of the three resulting clusters of patients are presented 
in Table 2. The level of JADAS-10 at baseline was found to be the most important 
distinguishing factor between the clusters. Cluster 1 represents patients with lower 
disease activity at baseline (mean JADAS-10: 12 (95% CI 11 to 13)); cluster 2 patients 
with moderately high disease activity (mean JADAS-10: 18 (95% CI 17 to 19) and cluster 
3 represents patients with the highest disease activity (mean JADAS-10: 25 (95% CI 24 
to 26)). Disease duration did not differ significantly between clusters and was the least 
important clustering variable. Outcomes of the three clusters were different. Patients with 
higher disease activity at baseline less often achieved inactive disease and discontinued 
the first agent more often because of ineffectiveness or intolerance. 
Table 1 Characteristics and outcomes of non-systemic JIA patients considered for biological treatment 
between 1999 and 2010 
Patient characteristics at 
baseline
1999-2001 2002- 2004 2005-2007 2008-2010 p for trend
N=17 N=41 N=96 N=181
Female 15 (88) 30 (73) 73 (76) 120 (66) 0.02
Age onset JIA, median (IQR), 
years
3.4 (2.0-6.3) 8.0 (3.9-
11.0)
8.2 (3.8-
11.4)
8.5 (3.0-
11.9)
0.64
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Disease duration before start, 
median (IQR), years
6.9 (4.9-
11.9)
3.4 (2.0-7.3) 3.0 (1.5-7.0) 2.2 (1.2-4.9) 0.005
JIA category
  Polyarticular RF+ 3 (18) 5 (12) 8 (8) 20 (11) -
  Polyarticular RF- 9 (53) 24 (59) 41 (43) 76 (42) -
  Oligoarticular extended 4 (24) 6 (15) 31 (32) 39 (22) -
  Oligoarticular persistent - - 1 (1) 18 (10) -
  Psoriatic Arthritis - 4 (10) 9 (9) 11 (6) -
  ERA 1 (6) 2 (5) 6 (6) 16 (9) -
  Undifferentiated arthritis - - - 1 (1) -
Medication history before 
introduction of first biological 
agent
  Systemic steroid 13 (76) 18 (44) 38 (40) 68 (38) 0.004
  Methotrexate 13 (76) 34 (83) 86 (90) 181 (100) 0.46
  Other sDMARDs (besides 
methotrexate)
13 (76) 22 (54) 48 (50) 60 (33) <0.001
First biological agent started
  Etanercept 17 (100) 40 (98) 93 (97) 166 (92) -
  Adalimumab - - 1 (1) 12 (7) -
  Infliximab - 1 (2) 2 (2) 3 (2) -
Disease activity at baseline
  Physician’s global 
assessment, median (IQR)
75 (45-83) 70 (56-80) 60 (46-71) 50 (35-65) <0.001
  Number of active joints, 
median (IQR)
18 (10-23) 12 (8-22) 10 (6-17) 6 (3-10) <0.001
  Number of limited joints, 
median (IQR)
12 (7-16) 8 (4-15) 7 (4-14) 3 (1-6) <0.001
  CHAQ score, median (IQR) 1.8 (1.2-2.2) 1.8 (1.0-2.4) 1.5 (1.0-2.0) 1.1 (0.5-1.8) <0.001
  VAS pain, median (IQR) 53 (26-75) 52 (20-74) 60 (37-76) 52 (22-72) 0.021
  VAS well-being, median (IQR) 60 (27-71) 51 (27-74) 61 (36-75) 50 (21-70) 0.001
  ESR, median (IQR), mm/h 22 (9-39) 25 (12-35) 18 (8-31) 11 (6-26) <0.001
  JADAS-10, median (IQR) 22 (19-25) 21 (18-26) 21 (16-24) 16 (12-21) <0.001
 
Results are shown as numbers of patient (%) unless stated otherwise.
CHAQ=childhood health questionnaire; ERA=enthesitis related arthritis; ESR=erythrocyte sedimentation 
rate; JADAS=Juvenile Arthritis Disease Activity Score; JIA=juvenile idiopathic arthritis; RF=rheumatoid factor; 
sDMARD=synthetic disease modifying drugs; VAS=visual analogue scale
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Table 2 Cluster analysis of non-systemic JIA patients 
Cluster* Importance 
of variable 
in cluster 
differentiation 
(1-0)
1 2 3
  (N=96) (N=137) (N=95) p-value†
Variables of the JIA core set at  
baseline
Physician’s global assessment, 
mean (95% CI), range 0-100
42  
(37-47)
51  
(48-54)
71  
(68-73)
<0.001 0.37
CHAQ score, mean (95% CI), range 
0-3
0.71 (0.60 
to 0.82)
1.40 (1.29 
to 1.51)
1.97 (1.85 
to 2.09)
<0.001 0.54
VAS pain, mean (95% CI), range 
0-100
19  
(16 to 22)
59  
(56 to 62)
71  
(67 to 76)
<0.001 0.87
VAS wellbeing, mean (95% CI), 
range 0-100
17  
(14 to 19)
60  
(57 to 64)
69  
(64 to 74)
<0.001 0.90
Number of joints with active 
arthritis, mean (95% CI)
6  
(5 to 7)
7  
(6 to 8)
21  
(18 to 23)
<0.001 0.67
Number of joints with limited 
motion, mean (95% CI)
4  
(3 to 5)
5  
(4 to 6)
15  
(13 to 16)
<0.001 0.52
ESR, mean (95% CI), mm/h 17  
(15 to 20)
19  
(16 to 22)
28  
(23 to 33)
<0.001 0.06
JADAS-10, mean (95% CI), range 
0-40
12  
(11 to 13)
18  
(17 to 19)
25  
(24 to 26)
<0.001 1.00
Disease duration before start, mean 
(95% CI), years
4.6 (3.9 to 
5.3)
4.2 (3.6 to 
4.8)
3.9 (3.2 to 
4.7)
0.475 0.01
Additional characteristics and  
measurements
Female (n=237) 66 (69) 97 (71) 70 (74) 0.557
JIA categories
  Polyarticular RF- (n=150) 38 (40) 52 (38) 58 (61) 0.001
  Polyarticular RF+ (n=36) 7 (7) 16 (12) 13 (14) 0.312
  Oligoarticular extended (n=81) 29 (30) 38 (28) 13 (14) 0.016
  Oligoarticular persistent (n=20) 11 (12) 7 (5) - 0.001
  Psoriatic Arthritis (n=24) 6 (6) 9 (7) 7 (7) 0.902
  ERA (n=23) 5 (5) 14 (10) 4 (4) 0.144
  Undifferentiated arthritis (n=1) - 1 (1) - -
Year of start biological treatment, 
median (IQR)
2009 
(2006-
2010)
2008 
(2007-
2009)
2006 
(2004-
2008)
<0.001
60
Number of patients with inactive 
disease after 3 months (n=73 of 
305 patients with measurement at 
3 months)
28 (32) 28 (20) 17 (19) 0.036
Number of patients with inactive 
disease after 15 months (n=100 of 
236 patients with measurement at 
3 months)
42 (59) 33 (37) 25 (33) 0.002
% of patients still on drug after 1 
year
91 88 84 0.051
 
On the basis of the JIA core set variables and disease duration before start first biological agent (i.e., at baseline), cases 
were assigned to cluster groups with the use of the two-step auto-cluster procedure developed by SPSS. This procedure 
selected three cluster groups on the basis of AIC and the ratio of distance measures
* Seven patients were excluded because of outlying or missing values
† p Values on the basis of analysis of variance(differences of mean values of JIA core set at baseline), Kruskal-Wallis test 
(non-parametric, continuous variables), Pearson χ2 test (non-parametric, categorical variables) or Log rank (drug survival 
analysis)
AIC=Akaike information criterion; CHAQ=childhood health questionnaire; ERA=enthesitis related arthritis; ESR=erythrocyte 
sedimentation rate; JADAS=Juvenile Arthritis Disease Activity Score; JIA=juvenile idiopathic arthritis; RF=rheumatoid factor; 
sDMARD=synthetic disease modifying drugs; VAS=visual analogue scale. 
Systemic JIA
The characteristics and disease outcome of patients with systemic JIA who started a 
biological agent between 1999 and 2010 are reported in Table 3. Until 2007 etanercept was 
most frequently prescribed for systemic JIA in the Netherlands. In 2008 anakinra became 
the preferred choice and biological treatment was started earlier (after median of 0.4 years of 
disease duration). In half of patients it was started even before the use of corticosteroids and 
synthetic disease-modifying anti-rheumatic drugs. Over time biological treatment was started 
in patients with less severe arthritis. Patient-reported indices (VAS pain and VAS well-being) 
remained similar. The ESR was significantly higher in patients included in later years. 
While at baseline JADAS-10 did not differ significantly, after 3 months of treatment 
JADAS-10 decreased from a median of 15 (IQR 9-26) points in the years 1999-2001 to 
1 (IQR 0-5) points in 2008-2010. As in the group with non-systemic JIA, more patients 
achieved inactive disease after 3 and 15 months of treatment during more recent years 
(Figure 2). Overall drug survival was 71% after 1 year and 65% after 2 years, and did not 
change over time (p=0.14 and p=0.19). 
For the same reasons as in the non-systemic JIA categories, cluster analysis was 
performed, identifying three clusters of patients with systemic JIA. The characteristics 
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of the patients classified in these clusters are presented in Table 4. Most important 
distinguishing factors were the number of active joints and the JADAS-10 score. 
Cluster 1 comprises patients with relatively low JADAS-scores (mean JADAS-10: 13 (95% CI 
11-15)). Cluster 2 consists of patients with high JADAS-scores (mean JADAS-10: 26 (95%CI: 
25 to 28)), mostly resulting from high ESR values (mean ESR: 94 mm/h (95% CI 82 to 106)). 
Patients in clusters 1 and 2 were usually treated later in the study period (median start year 
2008). Patients in the third cluster had relatively high JADAS-10 scores (mean: 25 (95% CI 23 
to 27)), with these high scores mostly resulting from a severe polyarthritis (mean: 22 joints with 
arthritis (95% CI 19 to 26)). These were the patients treated in the earlier years (median start 
year 2001), when biological treatment had just become available. This last cluster seems to 
have the worst outcome, with only 5% of patients achieving inactive disease after 3 months.
Table 3 Characteristics and outcomes of patients with systemic JIA starting biological treatment between 
1999 and 2010 
Patient characteristics at baseline 1999-
2001 
N=20
2002- 
2004 
N=18
2005-
2007 
N=13
2008-
2010 
N=40*
p for 
trend
Female 10 (50) 8 (62) 10 (77) 17 (43) 0.65
Age onset JIA, median (IQR), years 4.5 (2.8-
5.5)
5.2 (2.5-
10.6)
4.9 (3.8-
11.1)
5.4 (2.4-
11.0)
0.31
Disease duration before start, median 
(IQR), years
3.5 (2.2-
5.2)
1.9 (1.0-
4.3)
1.5 (0.9-
7.5)
0.4 (0.1-
1.6)
<0.001
Medication history before introduction of 
first biological agent
  Systemic steroid 18 (90) 13 (100) 13 (100) 20 (50) <0.001
  Methotrexate 19 (95) 13 (100) 13 (100) 24 (60) 0.001
  Other sDMARDs (besides 
methotrexate)
6 (30) 3 (23) 4 (31) 3 (8) 0.02
First biological agent started 
  Etanercept 18 (90) 13 (100) 11 (84) 11 (28) -
  Anakinra - - 2 (15) 29 (73) -
  Infliximab 2 (10) - - - -
Disease activity at baseline
  Physician’s global assessment, median 
(IQR)
72 (52-82) 69 (57-72) 63 (36-84) 40 (29-53) <0.001
  Number of active joints, median (IQR) 18 (9-26) 13 (8-20) 6 (4-10) 3 (2-5) <0.001
  Number of limited joints, median (IQR) 12 (8-17) 9 (6-21) 8 (4-13) 2 (1-4) <0.001
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  CHAQ score, median (IQR) 2.2 (1.9-
2.6)
2.0 (1.0-
2.6)
2.1 (1.1-
2.7)
1.8 (0.5-
2.4)
0.02
  VAS pain, median (IQR) 54 (14-65) 75 (32-88) 70 (39-85) 62 (35-77) 0.44
  VAS wellbeing, median (IQR) 41 (9-76) 51 (32-79) 60 (34-88) 60 (27-74) 0.30
  ESR, median (IQR), mm/h 45 (24-84) 38 (18-62) 66 (40-91) 101 (28-
134)
0.02
  JADAS-10, median (IQR) 24 (19-29) 22 (20-26) 25 (15-28) 22 (13-27) 0.06* 
 
One patient was previously diagnosed as systemic JIA in 2006, but diagnosis was changed to poly-articular course JIA in 
2008.
CHAQ=childhood health questionnaire; ERA=enthesitis related arthritis; ESR=erythrocyte sedimentation 
rate; JADAS=Juvenile Arthritis Disease Activity Score; JIA=juvenile idiopathic arthritis; RF=rheumatoid factor; 
sDMARD=synthetic disease modifying drugs; VAS=visual analogue scale.
Table 4 Cluster analysis of systemic JIA patients  
 
Cluster* Importance of 
variable in cluster 
differentiation 
(1-0)
1 2 3
 (N=26) (N=37) (N=21) p value†
Variables of the JIA core set at  
baseline
Physician’s global assessment, 
mean (95% CI), range 0-100
34 (27 to 
42)
59 (52 to 
66)
71 (65 to 
78)
<0.001 0.37
CHAQ score, mean (95% CI), range 
0-3
0.95 
(0.63 to 
1.26)
2.09 
(1.84 to 
2.33)
2.25 
(2.01 to 
2.48)
<0.001 0.41
VAS pain, mean (95% CI), range 
0-100
28 (20 to 
37)
76 (71 to 
81)
54 (41 to 
68)
<0.001 0.53
VAS wellbeing, mean (95% CI), 
range 0-100
28 (20 to 
36)
73 (67 to 
79)
44 (28 to 
60)
<0.001 0.43
Number of joints with active arthritis, 
mean (95% CI)
5 (3 to 6) 6 (5 to 7) 22 (19 to 
26)
<0.001 1.00
Number of joints with limited 
motion, mean (95% CI)
4 (2 to 6) 5 (4 to 6) 18 (14 to 
22)
<0.001 0.57
ESR, mean (95% CI), mm/h 46 (28 to 
63)
94 (82 to 
106)
54 (37 to 
71)
<0.001 0.24
JADAS-10, mean (95% CI), range 
0-40
13 (11 to 
15)
26 (25 to 
28)
25 (23 to 
27)
<0.001 0.72
Disease duration before start, mean 
(95% CI), years
3.5 (1.8 
to 5.2)
1.8 (1.0 
to 2.6)
3.7 (2.1 
to 5.2)
0.050 0.06
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Additional characteristics and  
measurements
Female 12 (46) 19 (51) 9 (43) 0.811
% of patients on anakinra 39 51 10 0.005
Year of start biological treatment, 
median (IQR)
2008 
(2003-
2009)
2008 
(2006-
2009)
2001 
(2001-
2004)
<0.001
Number of patients with inactive 
disease after 3 months (n=79 
patients with measurement at 3 
months)
11 (46) 16 (46) 1 (5) 0.006
Number of patients with inactive 
disease after 15 months (n=69 
patients with measurement at 15 
months)
12 (55) 14 (44) 6 (29) 0.630
% of patients still on drug after 1 
year
81 66 67 0.075
 
On the basis of the JIA core set variables and disease duration before start first biological agent (i.e., at baseline), cases 
were assigned to cluster groups with the use of the two-step auto-cluster procedure developed by SPSS. This procedure 
selected three cluster groups on the basis of AIC and the ratio of distance measures
* Two patients were excluded because of outlying or missing values
† p-values on the basis of analysis of variance (differences of mean values of JIA core set at baseline), Kruskal-Wallis test (non-
parametric, continuous variables), Pearson χ2 test (non-parametric, categorical variables) or Log rank (drug survival analysis)
AIC=Akaike information criterion; CHAQ=childhood health questionnaire; ERA=enthesitis related arthritis; ESR=erythrocyte 
sedimentation rate; JADAS=Juvenile Arthritis Disease Activity Score; JIA=juvenile idiopathic arthritis; RF=rheumatoid factor; 
sDMARD=synthetic disease modifying drugs; VAS=visual analogue scale. 
 
DISCUSSION
This overview of 12 years’ observation of biological treatment in the Netherlands allows us 
to conclude that biological agents are prescribed more often, earlier and at lower disease 
activity in patients with JIA. These changes in prescription behaviour of doctors are 
accompanied by a better short-term disease outcome. Better treatment outcome is mainly 
seen in patients who have lower disease activity at the start of biological treatment. The 
group with systemic JIA that starts biological treatment has changed most significantly. 
Prescription of biological agents for JIA increased over time. This trend is not likely to be 
influenced by an overall increase in the incidence of JIA; a recent study in a North American 
population (1996-2009) does not suggest a change in incidence over the years.79-82 It 
64
is more likely that this trend is the result of the observed effectiveness of the biological 
treatment, the growing reliance of the doctors on biological agents and the increasing 
availability of the drugs. Over time, additional biological agents with different mechanisms 
of action have become available for JIA. During the past 12 years, etanercept remained the 
preferred choice for patients with non-systemic JIA and adalimumab was mainly prescribed 
for a subset of patients. Most patients with JIA treated with adalimumab had (a history of) 
uveitis.83 Patients with systemic JIA are nowadays more often treated with IL-1 antagonists 
than tumour necrosis factor α inhibitors. This change in prescribed biological agents 
for systemic JIA is expected, because increasing knowledge about the immunological 
pathways involved in the development of arthritis and associated systemic features has 
resulted in IL-1 antagonists becoming more favoured.84 85 
Strategies for treatment of JIA are constantly developing. The goal of treatment has moved 
towards disease remission in all patients. To achieve this, some doctors promote a treat-
to-target strategy using an aggressive step-up regimen.86 The time-trends of prescription 
earlier in the disease course and at lower levels of disease activity, show us that a more 
aggressive treatment strategy has been adopted in the Netherlands. That these trends 
towards a more aggressive treatment are accompanied by better outcomes might support 
the effectiveness of this approach. We have to keep in mind, however, that this is an 
observational study and no control group was included. Therefore a causal relation between 
changing treatment strategies and outcome cannot be assessed. Our results reflect clinical 
practice and do not investigate very early introduction of biological agents, as researched in 
the TREAT and ACUTE-JIA studies.77 78
This is, to the best of our knowledge, the first study that describes trends in prescription 
patterns of biological agents and outcomes of JIA. Similar patterns in prescription of 
biological agents have been described in rheumatoid arthritis (RA). Studies in RA all 
demonstrated decreasing baseline disease activity and subsequently better clinical 
outcomes during the observed treatment years.87-91 Two of these studies in RA found, also, 
as we did in our study in JIA, a decrease in disease duration before starting biological 
treatment.88 92 
The treatment goal of inactive disease has been increasingly achieved during the past 12 
years for all JIA categories. This observed trend is likely to be influenced by a changing JIA 
population for whom biological treatment is prescribed as is also indicated by changing 
baseline characteristics. Numerous baseline and disease activity variables were tested for 
trends. Even though 5% of these test results might be spurious, over time a clear tendency 
towards lower disease activity at baseline and better disease outcomes was seen. Patients 
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with non-systemic JIA who were included more recently had better outcome, but they 
might also reflect a patient group who had a better intrinsic prognosis too. For instance, 
the distribution of JIA categories for which biological agents are prescribed changed, now 
including more patients with the oligoarticular persistent subtype. The American College of 
Rheumatology treatment recommendations for JIA focus more on treating according to the 
level of disease activity rather than treating patients according to JIA category; this trend 
is also seen in Europe.17 In this study, we performed a cluster analysis, which identified 
patients with similar patterns of disease activity and disease duration, which allowed us to 
compare outcomes in more homogeneous patient groups.
Patients with non-systemic JIA with lower baseline disease activity achieved inactive 
disease more often. This relationship seemed unaffected by disease duration, which 
appeared to be the least important factor in cluster formation.
The changes in prescription patterns for patients with systemic JIA are more striking than 
those for patients with non-systemic JIA and have become most evident since 2008. In 
the early years biological treatment was reserved for patients with polyarticular course JIA, 
while now these agents are also prescribed for patients with more prominently present 
systemic features and less severe arthritis. Over time, in the group with systemic JIA, 
inactive disease was achieved by an increasing number of patients. The cluster analysis 
identified one cluster of patients with systemic JIA treated during the earlier years, with 
mainly polyarthritis, in whom outcomes were worst. Patients in the remaining two clusters 
were treated more recently and achieved better disease outcomes. These two clusters 
represent patients with either low disease activity or patients with high JADAS-scores, 
mainly based on high ESR levels and fewer joints with arthritis. Patients in this last cluster 
were treated in a more acute phase of the disease and earlier during the disease course. 
The favourable outcomes in these patients might also in part be related to the natural 
course of the disease, because it is known that around one-third of patients with systemic 
JIA have a mono-phasic disease course.93-95 Detailed evaluation of this group is needed to 
investigate which factors are contributing to the differences in treatment response. 
A strong feature of this observational study is the inclusion of almost all patients with JIA 
who started biological treatment in the Netherlands, making the role of selection bias 
negligible. Selection bias may have been introduced by excluding patients participating 
in clinical trials, although the number of patients included in trials was small, and those 
patients were from one centre only. The lack of a control group and the observational 
nature of the study make it difficult to identify a causal relationship between trends in 
baseline characteristics and a trend in outcome. Besides the trend analysis, we attempted 
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to shed light on the different profiles of patients included in the study by balancing out two 
important changing baseline factors: disease activity and disease duration. In this way, 
treating doctors are provided with profiles they might recognise from their clinical practice. 
In these clusters, patients from different time periods could be identified, which shows us 
by an alternative route that the patient population treated with biological agents definitely 
changed over time. This is an extra indication that any statements of the effect of changing 
treatment strategies on the outcomes of patients should be made with caution.
In conclusion, since their introduction, biological agents are being prescribed increasingly 
often and the threshold for prescribing biological treatment has decreased. The patients 
with JIA who start biological treatment have changed towards a group with lower disease 
activity and these changes are accompanied by better short-term disease outcomes.
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ABSTRACT
Objectives. To evaluate differences in baseline characteristics between etanercept- 
and adalimumab-treated JIA patients and to reveal factors that influence the choice 
between these TNF inhibitors, which are considered equally effective in the recent ACR 
recommendations for JIA treatment.
Methods. Biologic-naïve JIA patients with active arthritis who started treatment with 
adalimumab or etanercept between March 2008 and December 2011 were selected from 
the Dutch Arthritis and Biologicals in Children register. Baseline characteristics were 
compared. Focus group interviews with paediatric rheumatologists were performed to 
evaluate factors determining treatment choices.
Results. A total of 193 patients started treatment with etanercept and 21 with adalimumab. 
Adalimumab-treated patients had longer disease duration prior to the start of biologics 
(median 5.7 vs 2.0 years) and more often a history of uveitis (71% vs 4%). Etanercept-
treated patients had more disability at baseline (median Childhood Health Assessment 
Questionnaire score 1.1 vs 0.4) and more active arthritis (median number of active joints 
6 vs 4). The presence of uveitis was the most important factor directing the choice towards 
adalimumab. Factors specific for the paediatric population—such as painful adalimumab 
injections—as well as the physician’s familiarity with the drug accounted for the preference 
for etanercept.
Conclusion. Although the two TNF inhibitors are considered equally effective, in daily 
practice etanercept is most often prescribed; adalimumab is mainly preferred when uveitis 
is present. In choosing the most suitable biologic treatment, paediatric rheumatologists 
take into account drug and patient factors, considering newly published data and 
cautiously implementing this into daily care.
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INTRODUCTION
JIA patients refractory to MTX treatment (dosed ≥15 mg/m2/wk) are eligible for treatment 
with biologics. In 1999, etanercept, an anti-TNF-α receptor fusion protein, was the first 
biologic to be approved by the U.S. Food and Drug Administration for the treatment of 
JIA (in 2000 the European Medicines Evaluating Agency followed). Its efficacy and safety 
have been demonstrated in a randomized controlled withdrawal trial and several long-
term observational studies, including the Dutch Arthritis and Biologicals in Children (ABC) 
register.19 40 96 In 2008, a second biologic agent, adalimumab, a monoclonal anti-TNF 
antibody, was approved for polyarticular JIA after its efficacy was established in a placebo-
controlled withdrawal trial.41 Adalimumab is considered to be the preferred biologic in 
treating uveitis, a condition strongly associated with JIA.42 97-100 Observational data on the 
use of adalimumab for JIA are limited.101 102 
The ACR recommendations for JIA consider these anti-TNF agents equally.17 In RA, 
adalimumab is considered as effective as etanercept.103 Neither JIA nor adult RA head-to-
head trials exist that compare etanercept and adalimumab. When deciding between these 
biologics, physicians can only rely on limited evidence and have to consider other factors.
Qualitative research can provide insight into how and why physicians make decisions when 
prescribing medication, which cannot be deduced from quantitative studies.104
We compared baseline characteristics of biologic-naïve patients initiating adalimumab or 
etanercept included in the Dutch ABC register to observe the real-life prescription patterns. 
Additionally we performed focus group interviews with paediatric rheumatologists and 
rheumatologists to evaluate the factors that determined their treatment choice.
PATIENTS AND METHODS
Patient population and baseline data
This study is part of the ABC register—a national ongoing multicentre study that aims 
to include all Dutch patients with JIA treated with biologics. The ABC register contains 
prospectively obtained data since the introduction of etanercept for JIA in 1999. The 
register was approved by the Medical Ethics Committee at Erasmus Medical Centre and all 
participating hospitals. Subjects’ written consent was obtained according to the Declaration 
of Helsinki. At baseline, data on demographics and disease characteristics were collected as 
well as variables of the JIA disease activity core set.22 At baseline, 9.9% of the variables were 
missing, with a median of zero missing variables per patient [interquartile range (IQR) 0–1].
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For this analysis, we included biologic-naïve patients who initiated etanercept or 
adalimumab between March 2008 (when adalimumab became available) and December 
2011. JIA patients without active arthritis initiating biologics to treat uveitis only were 
not included in the analyses (as this would have biased the results), nor were patients 
participating in treatment strategy trials.
Focus-group methods
The qualitative part consisted of two focus group interviews, carried out in autumn 2011. 
Twenty paediatric rheumatologists and rheumatologists involved in the care of paediatric 
patients, all members of the Dutch Society for Paediatric Rheumatology prescribing 
biologic treatment, were recruited by e-mail. Forty percent participated. The first focus 
group comprised two rheumatologists and three paediatric rheumatologists, and the 
second comprised three paediatric rheumatologists. The participants worked in six different 
areas in seven different hospitals.
The first interview lasted 1 h and the second 37 min. Two researchers were present, the 
moderator (S.G.) and a research physician (J.A.). The interview guide comprised questions 
on perceived effectiveness, motivation for initiation, experience with the different therapies 
and possible contraindications. In addition, participants were confronted with data retrieved 
from the ABC register comparing baseline characteristics of the two patient groups and 
asked for their interpretation.
J.A. audio-recorded and transcribed the focus group interviews verbatim. Transcripts were 
checked for accuracy and sent to participants for checking.
Data analysis
Descriptive statistics were presented as absolute frequencies or median values with IQR. 
Differences in patient and disease characteristics at baseline were compared using Fisher’s 
exact test or Mann–Whitney U test whenever applicable. Differences were considered 
significant at a two-sided P-value <0.05. Data were analysed using the SPSS for Windows 
package, version 17.0.2 (SPSS Inc., Chicago, IL, USA).
For transcript analysis, a phenomenological approach was used.105 Transcripts were read and 
reread to get a global impression and subsequently coded following an open coding strategy 
by J.A. S.G. checked the coding; J.A. and S.G. discussed coding until consensus was 
reached. Subsequently key units were identified from the codes and summarized in broader 
themes. A theme was considered more important according to the frequency of occurrence 
during the interviews. MAXQDA 10 software was used for analysis of qualitative data.
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RESULTS
Data from the ABC-register
Patient and disease characteristics are presented in Table 1. A total of 193 previously 
biologic-naïve JIA patients initiated etanercept and 21 initiated adalimumab. Patients 
treated with adalimumab had longer disease duration and were more often diagnosed 
with persistent oligoarticular JIA. Most adalimumab-treated patients (71%) had a history 
of uveitis. Six patients did not have a history of uveitis and presented with extended 
oligoarticular (one), PsA (one) and enthesitis-related arthritis (ERA) (four) JIA categories. 
Etanercept-treated patients had higher disease activity indicated by higher Childhood 
Health Assessment Questionnaire (CHAQ) scores and more joints with active arthritis.
Table 1 Patient and disease characteristics
Characteristics ETN (193) ADA (21)
Median age at onset JIA, years (IQR) 8.3 (2.8–11.6) 7.2 (2.8–11.6)
Median age at start first biologic, years (IQR) 11.9 (7.5–15.0) 12.7 (10.1–15.8)
Female, n (%) 127 (66) 14 (67)
Onset JIA category, n (%)
Systemic JIA 16 (8) 0 (0)
  Polyarticular RF negative 75 (39) 5 (24)
  Polyarticular RF positive 23 (12) 0 (0)
  Oligoarticular extended 41 (21) 5 (24)
  Oligoarticular persistent* 14 (7) 5 (24)
  Juvenile arthritis psoriatica 10 (5) 2 (10)
  ERA 14 (7) 4 (19)
Median JIA disease duration before start biologic in years 
(IQR)*
2.0 (1.2–4.7) 5.7 (1.8–8.1)
History of uveitis, n (%)* 7 (4) 15 (71)
ANA positive, n (%) 81/191 (42) 13/20 (65)
HLA B27 positive, n (%) 17/66 (26) 2/10 (20)
RF positive, n (%) 23/181 (13) 0 (0)
Previously used medications, n (%)
  Systemic prednisone 75 (39) 8 (38)
  IA prednisone 66 (34) 10 (48)
  MTX 193 (100) 21 (100)
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  Other synthetic DMARDs (besides MTX) 63 (33) 9 (43)
Concomitant co-medication at baseline, n (%)
  Systemic prednisone 41 (21) 1 (5)
  IA prednisone 17 (9) 3 (14)
  MTX 158 (82) 15 (71)
  Other synthetic DMARDs (besides MTX) 10 (5) 2 (10)
Frequency of prescription per year
  March 2008–December 2008 46 1
  January 2009–December 2009 60 6
  January 2010–December 2010 58 6
  January 2011–December 2011 29 8
Median disease activity scores at baseline
  VAS physician (IQR) 50 (36–65) 40 (30–70)
  CHAQ total (IQR)* 1.13 (0.50–1.80) 0.40 (0.07–0.94)
  VAS pain (IQR) 55 (25–75) 46 (6–65)
  VAS well-being (IQR) 50 (24–73) 32 (6–57)
  Active joints (IQR)* 6 (4–10) 4 (2–5)
  Limited joints (IQR) 3 (1–6) 2 (2–4)
  ESR (IQR), mm/h 12 (6–29) 7 (3–21)
 
* significance level p<0.05
ETN=etanercept; ADA=adalimumab; JIA=juvenile idiopathic arthritis; IQR=interquartile range; RF=rheumatoid factor; 
ERA=enthesitis related arthritis; ANA=anti-nuclear antibodies; DMARD=disease modifying anti-rheumatic drug; VAS=visual 
analogue scale; ESR=erythrocyte sedimentation rate 
Focus-group results
The main factors influencing decision making are presented in Table 2. These factors can 
be summarized in three broad categories: internal factors (related to the drug, the patient’s 
characteristics or the doctor), external factors (related to brand awareness, governmental 
regulations and drug availability) and costs. 
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Table 2 Factors that influence the choice between etanercept and adalimumab mentioned by focus-group 
participants 
  
Theme  
 Internal factors
 Drug related
  Side effects/safety
   Short term
    Pain/fear 
    Infection risk equal
   Long term
    Immunogenicity: more with adalimumab
    Growth: unknown influence of adalimumab 
  Dosage and administration of the drug
  Different mechanisms of action
 Patient related
  Disease characteristics
   Uveitis
   ERA/ PsJIA/ IBD symptoms
   Other categories of JIA
  Patient/parents’ choice
  Low age: etanercept preferred
  Wrist involved: etanercept preferred
 Doctor related
  Personal familiarity, clear preference for etanercept
  Amount of published data on the drug
  Gaining experience with a new drug
  Feeling/morality
  External factors
 Brand awareness
 Governmental regulations
 Drug availability
  Costs (when other than standard dosing)
 
ERA=enthesitis related arthritis; PsJIA=juvenile psoriatic arthritis; IBD=inflammatory bowel disease; JIA=juvenile idiopathic arthritis
Pain on injection was the most important drug-related factor mentioned. All physicians 
agreed that paediatric patients experience the injections of adalimumab as painful.
The prefilled formulation of etanercept is also perceived to be irritating; its self-dissoluble 
formula was therefore preferred by most. The availability of a formulation specifically 
adapted for paediatric use was seen as an advantage of etanercept. Although adalimumab 
has recently improved its paediatric formulation, it was thought to be less practical, as it 
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still contains the adult dose.
The subject of costs featured less prominently in the discussion than other factors. 
Costs were considered especially important when dosages other than the adult dosage 
were prescribed. In adult dosage, etanercept and adalimumab are equally expensive.39 
Government regulations with regard to reimbursement were mentioned in relation to costs; 
if these change, costs could become more important.
Adalimumab was preferred by all physicians when a history of uveitis or active uveitis was 
present: ‘In recent years it has been shown that etanercept might be less effective for uveitis 
… resulting in the fact that when I am considering prescribing anti-TNF to a child who has 
or has had uveitis I would choose adalimumab in the first place’. Two physicians considered 
it for all patients with a higher risk of developing uveitis.
Treatment with adalimumab was considered in patients with complaints suggestive of IBD, 
but in whom IBD could not be confirmed. ‘We also have—I know, this is absolutely not 
evidence based—children with nonspecific intestinal complaints. They have been seen by 
gastro-enterologists, they have had endoscopies, everything, and then, suddenly out of 
the blue, they are diagnosed with JIA. In that group I am sometimes a little more inclined 
to prescribe adalimumab’. Other indications mentioned for prescribing adalimumab rather 
than etanercept were ERA and PsJIA.
A doctor-related factor that received a lot of attention was experience. For three physicians, 
gaining experience with a new treatment was a reason to prescribe adalimumab. However, 
most physicians strongly indicated etanercept to be their first choice, relying heavily on 
available efficacy data, their personal familiarity with the drug and the favourable safety 
profile without immunogenicity. The rheumatologists also treating adult RA patients had 
more extensive experience with adalimumab and were therefore less reluctant to prescribe 
it to children, as illustrated by this quote: ‘we obviously have this long-lasting experience 
with adalimumab, for me at least [lack of experience] is not a reason not to start treatment 
with adalimumab in a child’.
Finally, practising evidence-based medicine featured prominently in the discussions. During 
the interviews physicians were constantly referring to literature and evidently trying to base 
their decisions on the latest available data.
No pressure from the industry was noted, apart from a few comments on advertisements 
received from and questions asked by visiting representatives of pharmaceutical 
companies. However, three physicians did suggest that marketing and brand awareness 
played a role: ‘to be honest, you do hear the name adalimumab more and more, as a result 
of which I think: this might be a suitable treatment for this specific patient’.
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DISCUSSION
This study shows that for JIA both etanercept and adalimumab are being prescribed. Focus 
group interviews identified a preference for etanercept. This was reflected in the absolute 
numbers, as 90% of the biologic-naïve patients were started on etanercept. Adalimumab-
treated patients were characterized by a history of uveitis, longer disease duration and 
lower disease activity. The presence of uveitis was acknowledged by interviewees to 
be one of the most important factors that directed their choice towards adalimumab. 
Painful adalimumab injections and more extensive personal and scientific experience with 
etanercept were the most important reasons to be reticent with prescription of adalimumab.
The observation that JIA-associated uveitis is a reason to consider treatment with 
biologics is consistent with the literature. In contrast to its proven efficacy in JIA, results 
for etanercept in the treatment of refractory uveitis are less satisfactory and adalimumab 
is now preferred for uveitis.42 97 98 100 106 107 Uveitis develops most often in the oligoarticular 
categories, which formed the largest part of the adalimumab-treated group. These 
categories are generally controlled for longer by treatment modalities other than TNF 
blockers, which may account for the longer disease duration in the adalimumab-treated 
group. The presence of uveitis may also explain why disease activity scores (related to 
arthritis) were lower in patients treated with adalimumab.
ERA and PsJIA were overrepresented in the adalimumab-treated group. This is in line 
with indications to consider adalimumab mentioned during the focus group interviews. 
Spondylarthritides are associated with psoriasis and IBD, and TNF-α also plays a role in the 
pathogenesis of psoriasis and IBD. TNF inhibitors seem equally effective for joint symptoms 
and skin symptoms, but on gut manifestations monoclonal antibodies against TNF-α seem 
to be more effective.108 109
The present study indicates that the process of prescribing new drugs and implementing 
them in daily care is complex and takes time, a finding also recognized in other qualitative 
studies investigating prescription patterns.110-114 Although the ACR recommendations do 
not differentiate between the two TNF inhibitors, the adaptation of the prescription pattern 
apparently involves many factors in addition to the effectiveness of the drug for JIA. These 
factors were put together in three categories: internal factors, external factors and costs.111 
Experience with the drug was considered a major factor. Etanercept has had a head 
start concerning safety, with over 10 years of safety data compared with only 4 years for 
adalimumab.
Costs of TNF inhibitors are approximately the same when prescribed in adult dosages and 
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might therefore play a less important role, especially in older children. Cost is apparently 
a secondary factor that comes into play when more experience is acquired with the new 
drug, and this could change when reimbursement regulations change. It could also be 
that moral resistance is felt against cost-conscious statements, and therefore they are less 
often mentioned in focus group interviews. Although a notion of cost-effectiveness has 
to be present, often doctors feel the emphasis should be on patient-centred factors. The 
fact that brand awareness and pressure from pharmaceutical companies were mentioned 
infrequently may be related to this same idea, and their influence might therefore be 
underestimated.
This study is limited in its size. Because only a few patients received adalimumab, these 
data should be interpreted with caution.
Not all rheumatologists and paediatric rheumatologists invited for focus group interviews 
were able to participate. Therefore the influential factors identified might not be 
representative for all Dutch physicians treating JIA patients with biologics. Nevertheless, 
physicians originated from different regions, covering the whole of the Netherlands. In both 
interviews, the same considerations were mentioned and we feel no topics were left out.
The researcher who moderated the interview was experienced in qualitative research. She 
was a rheumatologist herself, which brings a risk of peer review. However, this possible 
problem was recognized beforehand and she focused on her role as moderator.
In conclusion, both etanercept and adalimumab are prescribed for JIA. Even though both 
TNF inhibitors are considered equally effective, paediatric rheumatologists still prefer 
etanercept. Patient characteristics differed between the two treatment groups, the most 
important being the presence or risk of uveitis in the adalimumab-treated group. In deciding 
which biologic to prescribe to the biologic-naïve patient, paediatric rheumatologists take 
into account drug and patient factors to tailor prescriptions. They consider newly published 
data and cautiously implement this into daily care. Existing experience with an already 
established drug, in this case etanercept, makes it more difficult to shift preferences. Drug 
marketing and costs seem to play a minimal role in this process.
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ABSTRACT
Objective. Over the past decade, the availability of biological agents for the treatment of 
juvenile idiopathic arthritis (JIA) has increased substantially. Because direct head-to-head 
trials comparing these agents are lacking, we indirectly compared their efficacy.
Methods. In a systematic review, all available efficacy data from randomised controlled 
trials performed in JIA with inclusion of biological agents were retrieved. Indirect 
between-drug comparisons (based on Bucher’s method) were conducted only if trials 
were comparable with regard to design and patients’ characteristics related to treatment 
outcome.
Results. We identified 11 randomised controlled trials. On the basis of the equality of 
the trials, six trials were grouped into two networks of evidence. Network 1 included 
withdrawal trials which evaluated etanercept, adalimumab and abatacept in polyarticular 
course JIA. Indirect comparisons identified no significant differences in short-term efficacy. 
Network 2 indirectly compared trials with a parallel study design investigating anakinra, 
tocilizumab and canakinumab in systemic JIA; no differences in comparative efficacy were 
identified. Although the two networks were constructed on the basis of comparability, small 
differences in trial design and case mix still existed.
Conclusions. Because of the small number of trials and the observed differences between 
trials, no definite conclusions could be drawn about the comparative effectiveness of the 
indirectly compared biological agents. Therefore, for now, the paediatric rheumatologist has 
to rely on observational data and safety, practical and financial arguments. Comparability 
of future trials needs to be improved, and head-to-head trials are required to decide on the 
best biological treatment for JIA.
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INTRODUCTION
Since 1999, the treatment of juvenile idiopathic arthritis (JIA) has been extended with 
a new category of drugs: biological agents that target different cytokines and different 
steps in the immune response. Etanercept, a tumour necrosis factor (TNF)-α receptor 
antagonist, was the first biological agent approved for the treatment of polyarticular 
JIA. At present, infliximab (TNF-α antibody), adalimumab (TNF-α antibody), anakinra 
(interleukin (IL)-1 receptor antagonist), canakinumab (IL-1 antibody), rilonacept (IL-1 
receptor antagonist), tocilizumab (IL-6 receptor antibody) and abatacept (selective T-cell 
co-stimulation modulator) are also available options or under investigation for the treatment 
of JIA. Physicians involved in the treatment of JIA have an increasing number of biological 
treatment options and choosing between them is often difficult.
The efficacy of each agent has been described in one or more randomised controlled trials 
(RCTs), but head-to-head trials comparing agents directly are still lacking. A few studies 
have compared the short-term efficacy of biological agents in patients with rheumatoid 
arthritis (RA) using indirect comparison methods.115-120 This technique allows comparison 
of two biological agents indirectly (i.e., a trial comparing treatment A vs comparator C 
and treatment B vs comparator C results in a comparison of A vs B), while preserving the 
randomisation of the originally assigned patient groups.116 121 Efforts to indirectly compare 
these agents in JIA are to our knowledge still lacking. We therefore conducted a systematic 
review and described the RCTs with regard to their design and patient characteristics and, 
where possible, compared the efficacy of different biological agents indirectly. We hope that 
these results will eventually guide physicians in their biological treatment choices for JIA.
PATIENTS AND METHODS
Search strategy and selection criteria
A systematic search on PubMed, Embase and Cochrane clinical trials was performed using the 
terms: (‘JIA’ OR ‘juvenile RA (JRA)’) AND ‘randomised controlled trial’ AND (‘tumour necrosis 
factor’ OR ‘interleukin-1’ OR ‘interleukin-6’ OR ‘etanercept’ OR ‘adalimumab’ OR ‘infliximab’ 
OR ‘abatacept’ OR ‘anakinra’ OR ‘tocilizumab’ OR ‘canakinumab’ OR ‘certolizumab’ OR 
‘golimumab’ OR ‘rituximab’ OR ‘rilonacept’). See online supplementary text for the detailed 
search strategy. The search included studies up to and including January 2012. To identify 
unpublished trials, the trial register clinicaltrials.gov, and abstracts from international 
rheumatology congresses were searched. We aimed to include the following studies: RCTs 
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with data on efficacy, comparing a biological agent with control treatment (placebo, synthetic 
disease-modifying anti-rheumatic drugs (sDMARDs), or a second biological agent), and 
including patients with JIA (or the previously used criteria for JRA; any onset category).
Data extraction
Two authors (MHO and JA) independently selected the studies from the search and 
extracted information from published articles and congress abstracts on design, inclusion 
and exclusion criteria, medication regimens, baseline characteristics and efficacy results 
during the double-blind phase. Corresponding authors and involved pharmaceutical 
industries were contacted for any missing data in the publications. Slides of an oral 
presentation given at an international meeting provided additional information on a selected 
publication. The trial quality was assessed independently using the Jadad criteria, a widely 
used five-point score that appraises the quality of trial reporting. The score assesses 
trial quality on three aspects: randomisation, blinding and handling of withdrawals and 
drop-outs.122 If scoring was not unanimous, scoring was discussed with a third person 
(LWAvS-S). Figure 1 shows the flow of the 685 retrieved citations.
 
Figure 1 Flow of included studies. RCT=randomised controlled trial.
Trial design
For this systematic review with indirect comparisons, all RCTs conducted with biological 
agents were included, irrespective of trial design. In the field of paediatric rheumatology, 
Potenally relevant citaons idenfied 
(Pubmed n=308, Embase n=316, Cochrane 
clinical trials n=61)
37 citaons retrieved for more detailed 
informaon
648 citaons excluded on the basis of tle and 
abstract informaon, reasons: 
• Duplicate publicaon (n=163)
• Did not meet inclusion criteria (n=485)
17 citaons (including congress abstracts and 
slides of oral presentaons) describing 11 
different clinical trials were included
21 citaons excluded aer review of full arcle, 
reasons: 
• No RCT (n=10)
• Efficacy of treatment not as outcome (n=10)
• Change of outcome from efficacy to safety 
(n=1)
1 addional clinical trial aer checking 
references and congress abstracts
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in general, two different types of clinical trial are conducted. The randomised placebo-
controlled withdrawal trial design (called ‘withdrawal trial’) consists of an open-label lead-in 
phase where all patients receive the drug. After this lead-in period, only those patients who 
respond to treatment enter the double-blind phase and are randomised to remain on the 
drug or receive placebo. For this withdrawal design, the primary outcome chosen is disease 
flare. The other type of trial used is a ‘classic’ randomised controlled parallel design. 
These trials often include concomitant treatment with sDMARDs (e.g., biological agent 
plus methotrexate vs methotrexate only), short duration of double-blind phase, or a rescue 
regimen to limit the time without treatment.
Outcome
We identified three major outcomes beforehand: percentage of patients with disease flare 
and percentage of patients achieving an American College of Rheumatology paediatric 
(ACRpedi) 30 response or inactive disease. These outcomes are based on changes in 
the following six variables: physician’s global assessment of disease activity on a visual 
analogue scale (VAS; range 0–100 mm, 0 best score), Childhood Health Assessment 
Questionnaire (CHAQ; range 0–3, 0 best score) by patients/parents, global assessment of 
well-being by patients/parents (VAS, range 0–100 mm, 0 best score), number of active joints 
with arthritis, number of joints with limited motion, and a marker of inflammation (erythrocyte 
sedimentation rate (ESR) and/or C-reactive protein (CRP)). A disease flare is defined as 
worsening of 30% or more in at least three of these six variables with an improvement of 
30% or more in no more than one variable. An ACRpedi30 response is achieved if three 
or more of these variables improve by at least 30% from baseline, with no more than 
one variable worsening by more than 30%.44 For the systemic JIA category, a modified 
ACRpedi30 response is often used with the addition of absence of systemic features. 
Inactive disease is defined as a disease state with no active arthritis, no systemic features, 
no uveitis, normal ESR and physician’s global assessment indicating no disease activity.123
Statistical analyses
Relative risk (RR) and corresponding 95% CI were calculated for each trial independently. An 
appropriate statistical method for conducting adjusted indirect treatment comparisons is the 
Bucher method.121 Because in the present study each comparison consisted of two trials (one 
trial vs the other), random-effects meta-analysis and meta-regression were not applicable. In 
the Bucher method, the relative efficacy of two treatments (A and B) versus a common control 
group (C) are compared according to the following formula: LnRR’AB=LnRRAC−LnRRBC (where 
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LnRR=natural logarithm of the risk ratio). The underlying similarity assumption of the Bucher 
method dictates that trials may differ on study and patient characteristics not related to the 
treatment outcome, but, if these characteristics are modifiers of the relative treatment effects, 
then the estimates of the indirect comparisons are biased. To ensure that the same relative 
effects of a certain drug could have been expected across included trials in the indirect 
comparisons, indirect comparisons were conducted only between clinical trials with the same 
design (withdrawal trial with an open-label lead-in phase vs parallel RCTs), and with inclusion 
of approximately the same patient group with regard to disease duration at baseline and JIA 
categories included. The results of the adjusted indirect comparisons are given as RR with 
95% CIs. Two-sided p values of < 0.05 were considered significant. Analyses were performed 
with Stata V.12. For data structure and statistical code in Stata, see online supplementary text.
We report outcomes according to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) and the ISPOR Task Force on Indirect Treatment Comparisons 
Good Research Practices.124 125 See online supplementary table S1 for the PRISMA Checklist.
RESULTS
A total of 17 citations (including citations of congress abstracts and slides of oral 
presentation) describing 11 different trials were included. Design and patients’ 
characteristics of the included trials are described in table 1 (for a detailed description, see 
online supplementary tables S2 and S3). Four withdrawal trials and seven ‘classic’ RCTs 
with a parallel study design were included. Overall, eight of the 11 trials met the primary end 
point in favour of the biological agent. The primary outcome was not met by the infliximab 
trial, TREAT trial and rilonacept trial.77 126 127 On the basis of the design and quality of the 
trials and the characteristics of the patients included, two networks for indirect comparisons 
were selected, and these are presented in figure 2. Three of the four withdrawal trials (the 
trials evaluating etanercept, adalimumab and abatacept) included patients with resistant 
polyarticular course JIA and were compared indirectly (network 1). Polyarticular course 
JIA (or JRA) was defined in all trials as JIA with five or more active joints at any time during 
the disease course, and also included patients with systemic arthritis with a polyarticular 
course. For the details of the categories included, see online supplementary table S2. The 
fourth withdrawal trial evaluated tocilizumab in only patients with systemic JIA, and 50% 
of these patients did not have a polyarticular course. In addition, the outcome measure of 
maintaining a modified ACRpedi30 was different from the other three withdrawal trials. This 
trial could therefore not be included in the indirect comparison analysis.
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Author  
(acronym)
Year  
published
Comparison Study design Selected out-
come
Treatment 
duration (until 
evaluation 
outcome)
Included JIA/
JRA categories
No. of patients* Systemic JIA 
included (%)
Mean disease 
duration (years)
Previous bio-
logic use (%)
JADAD score 
for quality
Lovell19 2000 Etanercept vs 
placebo
Withdrawal trial† Disease flare 4 months Polyarticular 
course JRA
51 33 5.8 0 4
Ruperto127 2007 Infliximab vs 
placebo
Randomised 
placebo-
controlled trial
ACRpedi30 14 weeks Polyarticular 
course JRA
122 16 3.9 0 4
Lovell41 2008 Adalimumab 
vs placebo 
(stratification 
according to 
MTX use)
Withdrawal trial† Disease flare 32 weeks Polyarticular 
course JRA
133 ? 3.8 0 4
Ruperto128 2008 Abatacept vs 
placebo
Withdrawal trial† Disease flare 6 months Polyarticular 
course JIA
122 19 3.9 17 5
Yokota129 130 2008 Tocilizumab vs 
placebo
Withdrawal trial‡ Maintenance 
of ACRpedi30 
response
12 weeks Systemic JIA 43 100 4.7 ? 5
Ruperto131 2011 Canakinumab vs 
placebo
Randomised 
placebo-
controlled trial
Modified 
ACRpedi30 
response§
15 days Systemic JIA 84 100 3.4 ? 3¶
Quartier 
(ANAJIS)132
2010 Anakinra vs 
placebo
Randomised 
placebo-
controlled trial
Modified 
ACRpedi30 
response§
1 month Systemic JIA 24 100 3.7 54 4
De Benedetti
(TENDER)133-137
2010–2011 Tocilizumab vs 
placebo
Randomised 
placebo-
controlled trial
Modified 
ACRpedi30 
response§
12 weeks Systemic JIA 112 100 5.2 ? 3¶
Lovell126 2011 Rilonacept vs 
placebo
Randomised 
placebo-
controlled trial
Modified 
ACRpedi30 
response§
1 month Systemic JIA 24 100 3.1 29 (prior 
anakinra use)
2¶
Tynjala
(ACUTE-JIA)78 138
2011 Infliximab+
MTX vs MTX
Randomised 
open-label trial
Inactive disease 54 weeks Early 
polyarticular 
course JIA
60 0 0.16 0 2
Wallace
(TREAT)77 
2012 Etanercept+
tapered 
prednisone
+MTX vs 
placebo
+MTX
Randomised 
placebo-
controlled trial
Inactive disease 6 months Early 
polyarticular 
course JIA (RF 
pos and neg 
categories only)
85 0 0.42 0 3
Table 1 Description of included studies (for detailed description see online supplementary Table S2 and S3)
*Number of patients included in randomised phase.
†Only ACRpedi30 responders included in double-blind phase.
‡Only ACRpedi30 responders with CRP<5mg/l were included in double-blind phase.
§Modified ACRpedi30 response varied between ACRpedi30 response plus absence of fever, and an ACRpedi30 response 
together with no fever over the past 8 days and 50% decrease or normalisation of both ESR and CRP levels.
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Author  
(acronym)
Year  
published
Comparison Study design Selected out-
come
Treatment 
duration (until 
evaluation 
outcome)
Included JIA/
JRA categories
No. of patients* Systemic JIA 
included (%)
Mean disease 
duration (years)
Previous bio-
logic use (%)
JADAD score 
for quality
Lovell19 2000 Etanercept vs 
placebo
Withdrawal trial† Disease flare 4 months Polyarticular 
course JRA
51 33 5.8 0 4
Ruperto127 2007 Infliximab vs 
placebo
Randomised 
placebo-
controlled trial
ACRpedi30 14 weeks Polyarticular 
course JRA
122 16 3.9 0 4
Lovell41 2008 Adalimumab 
vs placebo 
(stratification 
according to 
MTX use)
Withdrawal trial† Disease flare 32 weeks Polyarticular 
course JRA
133 ? 3.8 0 4
Ruperto128 2008 Abatacept vs 
placebo
Withdrawal trial† Disease flare 6 months Polyarticular 
course JIA
122 19 3.9 17 5
Yokota129 130 2008 Tocilizumab vs 
placebo
Withdrawal trial‡ Maintenance 
of ACRpedi30 
response
12 weeks Systemic JIA 43 100 4.7 ? 5
Ruperto131 2011 Canakinumab vs 
placebo
Randomised 
placebo-
controlled trial
Modified 
ACRpedi30 
response§
15 days Systemic JIA 84 100 3.4 ? 3¶
Quartier 
(ANAJIS)132
2010 Anakinra vs 
placebo
Randomised 
placebo-
controlled trial
Modified 
ACRpedi30 
response§
1 month Systemic JIA 24 100 3.7 54 4
De Benedetti
(TENDER)133-137
2010–2011 Tocilizumab vs 
placebo
Randomised 
placebo-
controlled trial
Modified 
ACRpedi30 
response§
12 weeks Systemic JIA 112 100 5.2 ? 3¶
Lovell126 2011 Rilonacept vs 
placebo
Randomised 
placebo-
controlled trial
Modified 
ACRpedi30 
response§
1 month Systemic JIA 24 100 3.1 29 (prior 
anakinra use)
2¶
Tynjala
(ACUTE-JIA)78 138
2011 Infliximab+
MTX vs MTX
Randomised 
open-label trial
Inactive disease 54 weeks Early 
polyarticular 
course JIA
60 0 0.16 0 2
Wallace
(TREAT)77 
2012 Etanercept+
tapered 
prednisone
+MTX vs 
placebo
+MTX
Randomised 
placebo-
controlled trial
Inactive disease 6 months Early 
polyarticular 
course JIA (RF 
pos and neg 
categories only)
85 0 0.42 0 3
¶Assessment of quality of trial not complete because of insufficient information available (congress abstracts only).
ACRpedi30 response=American College of Rheumatology paediatric 30 response; CRP=C-reactive protein; 
ESR=erythrocyte sedimentation rate; JIA=juvenile idiopathic arthritis; JRA=juvenile rheumatoid arthritis; MTX=methotrexate; 
neg=negative; pos=positive; RF=rheumatoid factor.
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Figure 2 Network diagrams of selected indirect comparisons. JIA=juvenile idiopathic arthritis. Access the 
article online to view this figure in colour.
Of the seven randomised controlled parallel trials, four only included patients with systemic 
JIA. These trials compared anakinra, tocilizumab, canakinumab and rilonacept with placebo. 
No detailed efficacy data of the double-blind phase in the rilonacept trial was given, and 
rilonacept could therefore not be included in this indirect comparison analysis (network 2). 
The RCT evaluating infliximab by Ruperto et al127 included patients with polyarticular course 
JIA and could not be included in either network 1 (withdrawal trials) or network 2 (systemic 
JIA). Finally, two RCTs included patients with early JIA (after mean disease duration of 
0.16–0.42 year). However, because of significant differences in the inclusion of rheumatoid 
factor positive patients (36% vs 2%), no valid indirect comparisons could be made.77 138
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Network 1. Withdrawal trials in poly-articular course JIA
For the three comparable withdrawal trials, the disease duration at baseline varied between 
3.8 and 5.8 years, and the mean baseline age was between 10.6 and 12.3 years. The 
percentage of patients with systemic JIA with polyarthritis in the adalimumab withdrawal 
trial was unclear. Inclusion of systemic JIA varied between the etanercept and abatacept 
trials (33% and 19% patients with systemic JIA, respectively), but inclusion of rheumatoid 
factor positive patients was similar across all three trials (21–24%). Seventeen per cent of 
patients who were previously non-responsive to TNF-α antagonists were included in the 
abatacept trial compared with none in the etanercept and adalimumab trials. Of the patients 
who started treatment in the open-label lead-in phase, 64–78% entered the double-blind 
phase. Baseline disease characteristics of the patients included in the double-blind phase 
with regard to number of joints with arthritis, physician’s assessment of disease activity, and 
CHAQ scores were comparable between the three trials. Indirect comparisons indicated no 
differences in efficacy between these three drugs (table 2).
Network 2. Randomized placebo-controlled parallel trials in systemic JIA
The three selected randomised placebo-controlled parallel trials compared anakinra, tocilizumab 
and canakinumab with placebo. The duration of the double-blind phase was 12 weeks for the 
tocilizumab trial, 1 month for the anakinra trial, and 15 days for the canakinumab trial. The 
inclusion criteria with regard to disease duration and non-response to oral corticosteroids were 
similar. Indirect comparisons identified no significant differences between the drugs with regard 
to the achievement of a modified ACRpedi30 response (table 2).
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Table 2 Outcomes of trials and indirect comparisons 
Author Comparison Outcome Patients 
included (n)
Patients 
with 
outcome 
active drug 
arm (n/N)
Patients 
with 
outcome 
control arm 
(n/N)
RR (95% CI) 
for outcome
Network 1
Lovell et 
al19
Etanercept vs 
placebo 
Disease flare 51 7/25 21/26 0.35 (0.18 to 
0.67)
Lovell et 
al41
Adalimumab 
(combined)* vs 
placebo
Disease flare 133 27/68 44/65 0.59 (0.42 to 
0.82)
Adalimumab 
(no MTX) vs 
placebo
Disease flare 58 13/30 20/28 0.61 (0.38 to 
0.97)
Adalimumab 
(plus MTX) vs 
placebo
Disease flare 75 14/38 24/37 0.57 (0.35 to 
0.92)
Ruperto  
et al128
Abatacept vs 
placebo 
Disease flare 122 12/60 33/62 0.38 (0.22 to 
0.66)
Network 2
Quartier  
et al132 
Anakinra vs 
Placebo 
Modified 
ACRpedi30 
response†
24 8/12 1/12 8.00 (1.17 to 
54.50)
De 
Benedetti 
et al133 
135-137 
Tocilizumab vs 
Placebo 
Modified 
ACRpedi30 
response†
112 64/75 9/37 3.51 (1.97 to 
6.24)
Ruperto  
et al131
Canakinumab 
vs Placebo
Modified 
ACRpedi30 
response†
84 36/43 4/41 8.58 (3.35 to 
21.97)
Indirect Comparison RR (95% CI) p Value 
Network 1 Disease flare
 Etanercept vs adalimumab (combined)* 0.59 (0.28 to 1.24) 0.16
 Etanercept vs adalimumab (no MTX) 0.57 (0.25 to 1.28) 0.17
 Etanercept vs adalimumab (plus MTX) 0.61 (0.27 to 1.38) 0.23
 Etanercept vs abatacept 0.92 (0.39 to 2.18) 0.85
 Adalimumab (combined)* vs abatacept 1.56 (0.81 to 2.99) 0.18
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 Adalimumab (no MTX) vs abatacept 1.61 (0.78 to 3.33) 0.20
 Adalimumab (plus MTX) vs abatacept 1.51 (0.72 to 3.13) 0.27
 Adalimumab (no MTX) vs adalimumab (plus MTX) 1.07 (0.55 to 2.09) 0.85
Network 2 Modified ACRpedi30 response†
 Anakinra vs tocilizumab 2.28 (0.31 to 16.93) 0.42
 Anakinra vs canakinumab 0.93 (0.11 to 7.91) 0.95
 Tocilizumab vs canakinumab 0.41 (0.14 to 1.23) 0.11
 
*The stratified methotrexate arms combined.
†Modified ACRpedi30 response was defined in the anakinra trial as an ACRpedi30 response together with no fever over 
the past 8 days and 50% decrease or normalisation of both erythrocyte sedimentation rate and C-reactive protein levels, 
and in the tocilizumab and canakinumab trials as an ACRpedi30 response together with no fever.
ACRpedi30 response=American College of Rheumatology paediatric 30 response; RR=relative risk; MTX=methotrexate.
DISCUSSION
In this systematic review, we found that, in JIA, 11 trials compared biological agents with 
placebo or sDMARDs, and no trials compared biological agents directly. Because these 
trials differed with regard to design and patient characteristics, not all trials could be 
included in the indirect comparisons. Two networks of similar trials were identified in order 
to make valid indirect comparisons. For polyarticular course JIA, etanercept, adalimumab 
and abatacept seem equally efficacious in preventing disease flare after response 
to treatment. Canakinumab, tocilizumab and anakinra seem to produce comparable 
improvement in systemic JIA.
To the best of our knowledge, this is the first attempt to indirectly compare the efficacy 
of biological agents in JIA. The results of indirect comparisons in RA are not conclusive, 
but generally seem to indicate that TNF inhibitors are more effective than anakinra, and 
etanercept is more effective than other TNF inhibitors.103 118 139 Tocilizumab seems to be 
more effective in RA than TNF inhibitors and abatacept.117 140 In the present study, anakinra 
and tocilizumab were only investigated in systemic JIA.
Indirect comparisons of etanercept, adalimumab and abatacept in network 1 did not 
identify significant differences in efficacy. However, no definite conclusions could be drawn 
because of the differences in case mix and design of the trials. In addition, small differences 
were not likely to be detected because of the small number of patients included in the trials.
Some of the characteristics of the patients in the etanercept trial may be associated 
with poorer outcome. The mean disease duration before the start of biological treatment 
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was longer (5.8 years in the etanercept trial vs 3.8 and 3.9 years in the adalimumab and 
abatacept trials, respectively) and the proportion of patients with systemic JIA was higher 
(33% in the etanercept trial vs 19% in the abatacept trial). In contrast, in the abatacept trial, 
17% of the patients were previously non-responders to TNF inhibitors, indicating a more 
therapy-resistant group.
With regard to trial design, the observed treatment duration in the etanercept trial 
(4 months) was shorter than in the adalimumab and abatacept trials (8 and 6 months, 
respectively). Because shorter trial duration means that there is a smaller chance of 
reaching the time-dependent outcome (disease flare), shorter treatment duration may 
result in better outcomes. On the other hand, the elimination time for etanercept (t1/2 70 h) 
is shorter than that for adalimumab and abatacept (both t1/2 ~2 weeks), which might 
counteract the differences in trial duration. Owing to these differences, the estimate of 
comparative efficacy may be biased. An important conclusion from the comparisons in this 
network is that trials that are highly comparable with regard to design and case mix are 
needed in paediatric rheumatology.
Because these results could not be compared with similar analyses or with head-to-
head trials including patients with JIA, the only feasible comparison is with data from 
observational studies performed in JIA. Extensive observational data on etanercept for 
polyarticular course JIA are available, all showing impressive effects both short and long 
term.29 46 Observational studies analysing adalimumab and abatacept in polyarticular 
course JIA are scarce.102 141 Adalimumab seems to be mainly preferred when uveitis is 
present.42 A small number of observational studies did compare the effectiveness of 
etanercept with that of infliximab in polyarticular course JIA. No differences in effectiveness 
were found; however, because of the chimeric structure of infliximab and the associated 
immunogenicity, infliximab was discontinued more often.142-144 Unfortunately, an indirect 
comparison between etanercept and infliximab could not be performed because of trial 
design dissimilarities. Parallel trials in the second network were highly comparable, and the 
indirect comparisons found anakinra, canakinumab and tocilizumab to be equally effective 
for systemic JIA. Unfortunately, no trials have investigated TNF inhibitors in systemic JIA 
only, and therefore the relative effect of TNF inhibitors compared with IL-1 and IL-6 blockers 
in systemic JIA could not be evaluated. Observational studies do indicate that etanercept is 
effective in some patients with systemic JIA.29 40 49 Many studies have found anakinra to be 
highly effective,145 146 but observational studies that evaluate canakinumab and tocilizumab 
in systemic JIA are still lacking.
Until conclusive differences are established, the choice of biological agent for JIA should 
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mainly depend on drug availability, safety, practical reasons (such as interval of injections) 
and treatment costs. Further, more insight into features other than clinical characteristics, 
such as cytokine and genetic profiling, may contribute to this decision making. Focus 
could be shifted from treatment of the heterogeneous group of all JIA categories to tailored 
patient-specific care.
A recent review indicated that the National Institute for Health and Clinical Excellence 
prefers direct comparisons in decision making. Even in the absence of direct comparisons, 
key decisions are based on information from original trials, rather than available indirect 
comparisons.147 Head-to-head trials are still required, but, until conclusive direct evidence 
is established, decisions will have to be based on existing sources. In contrast with 
observational studies and meta-analyses, the indirect treatment comparison method allows 
the opportunity to preserve the strengths of randomisation. Thereby it is less likely that 
any differences between treatments observed through indirect comparisons are due to 
differences between patients that are unrelated to treatment effect.
The internal validity of indirect treatment comparison is highly dependent on (i) appropriate 
identification of studies, (ii) quality and internal validity of the included trials, and (iii) 
fulfilment of the similarity assumption.148 149 We identified all studies systematically, and, to 
minimise publication bias, checked trial registers; no additional trials that were completed 
could be identified. To our knowledge, all performed trials were identified. Trial quality was 
assessed, but varied greatly. Unfortunately, not all trials could be fully assessed, because 
data had to be extracted from conference abstracts.150 Bias may have been introduced, 
because these abstracts were not part of peer-reviewed publications. Earlier trials for 
registration commissioned by pharmaceutical industries gained the best scores, while more 
recent trials that evaluated treatment strategies for approved biological agents performed 
worst. The inferior trial quality of the TREAT trial was one of the reasons for excluding this 
trial from the indirect comparison. It is very likely that patients in the prednisone arm will 
develop signs of Cushing’s syndrome, leading to unavoidable unblinding issues. The results 
of the withdrawal trials, although of high quality, should be placed in a different context. 
Instead of an estimation of the initial response to the treatment, the effect of treatment 
discontinuation has been researched. Better protection of flares after the primary response 
does not necessarily imply better initial treatment responses. It should be noted that, 
although the Jadad criteria assessed the most important aspects of quality of trial design, 
this does not guarantee that the trial was conducted perfectly.
The biggest challenge for this indirect comparison was fulfilling the similarity assumption, 
because of the heterogeneity of the disease and the scarcity of trials. Relying on clinical 
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judgement, six trials were found to be suitable for indirect comparisons. The two networks 
consisted of methodologically identical trials with inclusion of patients with approximately 
the same disease duration and JIA categories, which were thought to be the most 
important confounders.29 151 Although classification criteria for juvenile arthritis differed 
between withdrawal trials (JRA and JIA), patients included were identical with regard to 
number of joints with arthritis.
Nevertheless, the included trials were not perfectly identical. Treatment duration varied 
between trials and is likely to have influenced the measured outcome. Furthermore, 
although the similarities predominated, differences between the withdrawal trials included 
co-medication used and previous treatment of some patients with biological agents. 
Because of the small number of trials and the limited number of patients included, it 
was unfeasible to further adjust our results using meta-regression, subgroup analysis or 
sensitivity analysis.
In conclusion, this review provides a comprehensive overview of the conducted trials 
that evaluated biological agents for treatment of JIA. Taking into account the differences 
between trials, this is the first study to carefully conclude that the short-term efficacy of 
etanercept, adalimumab and abatacept seems similar for polyarticular course JIA, and that 
of anakinra, canakinumab and tocilizumab seems similar for systemic JIA. Because of the 
observed differences between trials, more comparable trials and head-to-head trials directly 
comparing biological agents are urgently needed. For now, the paediatric rheumatologist 
must rely on these indirect comparisons, supplemented by observational data derived from 
cohort studies and safety, practical and financial arguments.
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ONLINE SUPPLEMENTARY TEXT: SEARCH STRATEGY
PubMed, hits: 308
(arthritis, juvenile rheumatoid[MeSH] OR (arthrit*[tiab] AND (juvenil*[tiab] OR childhood[tw] 
OR child[tw] OR children[tw]) )AND (Biologic Agents[mesh] OR antirheumat*[tw] OR 
Biologic*[tiab] OR Tumor Necrosis Factors[mesh] OR Tumor Necrosis Factor*[tiab] OR 
Tumour Necrosis Factor*[tiab] OR TNFR-Fc fusion protein[tw] OR etanercept[tw] OR 
adalimumab[tw] OR infliximab[tw] OR abatacept[tw] OR interleukin 1*[tw] OR anakinra[tw] 
OR interleukin 6*[tw] OR tocilizumab[tw] OR canakinumab[tw] OR certolizumab[tw] OR 
golimumab[tw] OR rituximab[tw] OR rilonacept[tw]) AND (randomized controlled trial152 
OR controlled clinical trial152 OR randomized[tiab] OR placebo[tiab] OR randomly[tiab] OR 
trial[tiab] OR groups[tiab]) NOT (animals[mesh] NOT humans[mesh])
Embase, hits: 316 
(‘juvenile rheumatoid arthritis’/de OR ((juvenile* OR child*) NEAR/3 arthrit*):ab,ti) AND 
(‘antirheumatic agent ‘/exp OR (antirheumat* OR Biologic* OR ((‘Tumor Necrosis’ OR 
‘Tumour Necrosis’) NEXT/1 Factor*) OR ‘TNFR-Fc fusion protein’ OR etanercept OR 
adalimumab OR infliximab OR abatacept OR ‘interleukin 1’ OR ‘interleukin 6’ OR anakinra 
OR tocilizumab OR canakinumab OR certolizumab OR golimumab OR rituximab OR 
rilonacept):de,ab,ti) AND (random*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR (cross 
NEXT/1 over*):ab,ti OR placebo*:ab,ti OR ((doubl* OR singl*) NEXT/1 blind*):ab,ti OR 
assign*:ab,ti OR allocat*:ab,ti OR volunteer*:ab,ti OR ‘crossover procedure’/de OR ‘double-
blind procedure’/de OR ‘randomized controlled trial’/de OR ‘single-blind procedure’/de) 
NOT ([animals]/lim NOT [humans]/lim)
Cochrane, hits: 61
(arthrit* AND (juvenil* OR childhood OR child OR children) ) AND (Biologic Agents OR 
antirheumat* OR Biologic* OR Tumor Necrosis Factor* OR Tumour Necrosis Factor* OR 
TNFR-Fc fusion protein OR etanercept OR adalimumab OR infliximab OR abatacept 
OR interleukin 1* OR anakinra OR interleukin 6* OR tocilizumab OR canakinumab OR 
certolizumab OR golimumab OR rituximab OR rilonacept
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ONLINE SUPPLEMENTARY TEXT: DATA STRUCTURE AND STATISTICAL CODE (STATA)
control  =placebo
event_c =number of events in placebo group
noevent_c =number of patients without a event in placebo group 
sample_c =total number of observations in the placebo group
event_t =number of events in treatment group
noevent_t =number of patients without a event in treatment group
sample_t =total number of observations in the treatment group
compb  =comparison A vs B=1; A vs C =0
* Indirect comparison using the Bucher method: 
I: meta-analysis of trials of BvA (compb equal to 1)
metan event_t noevent_t event_c noevent_c if compb==1, rr randomi nograph
local logrr1=log($S_1)
local se1=$S_2
display `logrr1’
display `se1’
II: meta-analysis of trials of CvA (compb equal to 0)
metan event_t noevent_t event_c noevent_c if compb==0, rr randomi nograph
local logrr2=log($S_1)
local se2=$S_2
display `logrr2’
display `se2’
III: computation of log RR, RR and se for indirect comparison
local logrr_aic=`logrr1’-`logrr2’
display `logrr_aic’
local rr_aic=exp(`logrr_aic’)
display `rr_aic’
local se_aic=sqrt(`se1’^2+`se2’^2)
display `se_aic’
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IV: computation of confidence intervals, z-value and P-value
local ll_aic=exp(`logrr_aic’-(1.96*`se_aic’))
display `ll_aic’
local ul_aic=exp(`logrr_aic’+(1.96*`se_aic’))
display `ul_aic’
local z_aic=`logrr_aic’/`se_aic’ 
display `z_aic’
if `z_aic’>0 local p_aic=2*(1-normal(`z_aic’)) 
if `z_aic’<=0 local p_aic=2*normal(`z_aic’)
display `p_aic’
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ONLINE SUPPLEMENTARY TEXT: TABLE S2 DESCRIPTION OF INCLUDED STUDIES 
Etanercept
(Lovell)
Infliximab
(Ruperto)
Adalimumab
(Lovell)
Abatacept
(Ruperto)
Tocilizumab
(Yokota)
Anakinra
(Quartier)
Canakinumab 
(Ruperto)
Tocilizumab
(DeBenedetti)
Rilonacept (Lovell) Infliximab
(Tynjala)
Etanercept
(Wallace) 
Acronym - - - - - ANAJIS-trial - TENDER - ACUTE-JIA TREAT
Year published 2000 2007 2008 2008 2008 2010 2009 (congress 
abstract only)
2010-2011 (congress 
abstracts only)
2011 (congress 
abstract only)
2011 2012
Inclusion criteria* Aged 4-17 years,
JIA with presence of at 
least 5 swollen joints 
and at least 3 joints 
with limitation of motion 
and pain, tenderness 
or both, and inactive 
to NSAIDs and MTX at 
least 10mg/m2/ week
Aged 4-18 years, 
JIA with presence 
of at least 5 swollen 
joints and suboptimal 
response to MTX >=3 
months
Aged 4-17 years, JIA 
with presence of at 
least 5 swollen joints 
and at least 3 joints with 
limitation of motion, 
and not responded 
adequately to NSAIDs 
and patients either not 
previously treated with 
MTX or irresponsive/ 
intolerant to MTX
Aged 6-17 years, JIA 
with presence of at 
least 5 swollen joints, or 
in absence of swelling, 
with limited range of 
motion, and inadequate 
response to, or 
intolerance to, at least 
1 DMARD (including 
biologic agents)
Aged 2-19 years,
active systemic JIA, 
inadequate response to 
oral corticosteroids > 3 
months
Aged 2-20 years,
active** systemic 
JIA despite oral 
corticosteroids 
(>=0.3mg/day or 
10mg/ day, whichever 
was less), more than 
6 months disease 
duration and presence 
of active systemic 
disease
Aged 2-19 years, 
systemic JIA with 
active systemic 
features
Aged 2-17 years, 
active systemic JIA, 
disease duration 
>6 months and 
inadequate response 
to previous NSAIDs 
and corticosteroids
Aged 5-20 years, 
active systemic JIA 
with fever and/or rash
Aged 4-15 years, JIA 
with presence of at 
least 5 swollen joints 
and 3 joints with pain 
or tenderness and 
limitation of motion, 
and with arthritis for at 
least 6 weeks, but no 
longer than 6 months
Aged 2-17 years, 
poly-articular JIA (RF 
positive or RF negative 
and patients without 
psoriasis but with a 
first-degree relative 
with psoriasis) of 
less than 12 months 
duration
Exclusion criteria† Previously treated with 
other biologics
Previously treated 
with any TNF-alpha 
antagonist, presence 
of active systemic 
symptoms or active 
uveitis
Previously treated 
with other biologics or 
recently treated with 
IV-IG, cytotoxic agents, 
investigational agents, 
DMARDs other than 
MTX, or corticosteroids 
(IA, IM or IV). 
Active uveitis, active 
systemic symptoms
Development of MAS 
during pre-study 
hospital admission
Previously treated with 
IL-1 inhibitor
Unknown Unknown Unknown Systemic JIA and
ever use of DMARDs 
and/or steroids
Patients with past or 
current uveitis.
Previously treated with 
other biologics and 
DMARDs other than 
MTX
Design Randomized double-
blind placebo-controlled 
withdrawal trial
3 months open-label 
lead-in phase (all 
received drug), only 
ACRpedi30 responders 
included in 4 month 
double-blind phase
Randomized double-
blind placebo-controlled 
trial
first 14 weeks placebo-
controlled, than 
comparison of 2 dosing 
regimens
Randomized double-
blind placebo-controlled 
withdrawal trial
16 weeks open-label 
lead-in phase (all 
received drug), only 
ACRpedi30 responders 
in 32 week double-blind 
phase.
Stratification for MTX 
use
Randomized double-
blind placebo-controlled 
withdrawal trial
4 months open-label 
lead-in phase (all 
received drug), only 
ACRpedi30 responders 
in 6 month double-blind 
phase included.
Randomized double-
blind placebo-controlled 
withdrawal trial
6 weeks open-label 
lead-in phase (all 
received drug), only 
those ACRpedi30 
responders with CRP 
<5mg/L in 12 week 
double-blind phase
Randomized double-
blind placebo-
controlled trial
first month placebo-
controlled phase, than 
open-label treatment 
period with all patients 
receiving anakinra
Randomized double-
blind placebo-
controlled trial
4-week placebo-
controlled phase, than 
open-label treatment 
period with all patients 
receiving canakinumab
Randomized double-
blind placebo-
controlled trial
12-weeks placebo-
controlled phase 
(randomization 2:1) 
with a rescue phase 
after 2 weeks with 
standard of care 
therapy, than open-
label treatment period
Randomized double-
blind placebo-
controlled trial
4-week placebo-
controlled phase, than 
open-label treatment 
period with all patients 
receiving rilonacept
Randomized open-
label treatment 
strategy trial 
54 week open-label 
trial comparing 3 
treatment arms: 1)
infliximab + MTX, 2)
MTX only, and 3)
COMBO (MTX + SSZ + 
plaquenil)
Randomized double-
blind placebo-
controlled treatment 
strategy trial
12 month trial 
comparing: 1) MTX + 
Etanercept + tapered 
PRED, and
2) MTX + placebo 
etanercept + PLAC 
prednisone 
Medication 1) Etanercept 0.4mg/
kg (max 25mg) twice 
weekly;
2) placebo
1) Infliximab (3mg/kg) + 
MTX during 52 wks;
2) placebo infusions + 
MTX first 14 wks and 
then infliximab (6 mg/
kg) + MTX
MTX: 10-15mg/ m2/wk 
oral or IM
1)Adalimumab 24mg/
m2 (max 40mg) every 
other week;
2) placebo
For those in MTX 
stratum: stable doses of 
at least 10mg/m2/ wk.
1) Abatacept 10mg/kg 
(max 1000mg);
2) placebo
1) Tocilizumab 8mg/kg 
every 2 weeks;
2) placebo
1) Anakinra 2 mg/kg/
day (max 100mg/day); 
2) placebo
1)Canakinumab (single 
dose, 4mg/kg, max 
300mg)
2) Placebo
1) Tocilizumab 8mg/kg 
for patients ≥30kg and 
12mg/kg for patients 
<30kg;
2) placebo
1) Rilonacept (2.2mg/
kw/ week, max 
160mg);
2) Rilonacept (4.4mg/
kw/ week, max 
320mg);
3) placebo
1) Infliximab (3-5 mg/
kg) +MTX; 
2) MTX only;
3) SSZ (40mg/ kg/ 
day up to 2000mg/ 
day) +plaquenil (5mg/
kg/ day up to 300mg/ 
day)+MTX
MTX:15mg/m2/wk, 
max25mg
1) MTX (0.5mg/
kg/wk, max 40mg 
s.c.)+Etanercept 
(0.8mg/ kg/week, max 
50mg)+PRED (0.5mg/
kg/day, max 60mg, 
tapered to 0 by 17 
wks);
2) MTX+plac
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ONLINE SUPPLEMENTARY TEXT: TABLE S2 DESCRIPTION OF INCLUDED STUDIES 
Etanercept
(Lovell)
Infliximab
(Ruperto)
Adalimumab
(Lovell)
Abatacept
(Ruperto)
Tocilizumab
(Yokota)
Anakinra
(Quartier)
Canakinumab 
(Ruperto)
Tocilizumab
(DeBenedetti)
Rilonacept (Lovell) Infliximab
(Tynjala)
Etanercept
(Wallace) 
Acronym - - - - - ANAJIS-trial - TENDER - ACUTE-JIA TREAT
Year published 2000 2007 2008 2008 2008 2010 2009 (congress 
abstract only)
2010-2011 (congress 
abstracts only)
2011 (congress 
abstract only)
2011 2012
Inclusion criteria* Aged 4-17 years,
JIA with presence of at 
least 5 swollen joints 
and at least 3 joints 
with limitation of motion 
and pain, tenderness 
or both, and inactive 
to NSAIDs and MTX at 
least 10mg/m2/ week
Aged 4-18 years, 
JIA with presence 
of at least 5 swollen 
joints and suboptimal 
response to MTX >=3 
months
Aged 4-17 years, JIA 
with presence of at 
least 5 swollen joints 
and at least 3 joints with 
limitation of motion, 
and not responded 
adequately to NSAIDs 
and patients either not 
previously treated with 
MTX or irresponsive/ 
intolerant to MTX
Aged 6-17 years, JIA 
with presence of at 
least 5 swollen joints, or 
in absence of swelling, 
with limited range of 
motion, and inadequate 
response to, or 
intolerance to, at least 
1 DMARD (including 
biologic agents)
Aged 2-19 years,
active systemic JIA, 
inadequate response to 
oral corticosteroids > 3 
months
Aged 2-20 years,
active** systemic 
JIA despite oral 
corticosteroids 
(>=0.3mg/day or 
10mg/ day, whichever 
was less), more than 
6 months disease 
duration and presence 
of active systemic 
disease
Aged 2-19 years, 
systemic JIA with 
active systemic 
features
Aged 2-17 years, 
active systemic JIA, 
disease duration 
>6 months and 
inadequate response 
to previous NSAIDs 
and corticosteroids
Aged 5-20 years, 
active systemic JIA 
with fever and/or rash
Aged 4-15 years, JIA 
with presence of at 
least 5 swollen joints 
and 3 joints with pain 
or tenderness and 
limitation of motion, 
and with arthritis for at 
least 6 weeks, but no 
longer than 6 months
Aged 2-17 years, 
poly-articular JIA (RF 
positive or RF negative 
and patients without 
psoriasis but with a 
first-degree relative 
with psoriasis) of 
less than 12 months 
duration
Exclusion criteria† Previously treated with 
other biologics
Previously treated 
with any TNF-alpha 
antagonist, presence 
of active systemic 
symptoms or active 
uveitis
Previously treated 
with other biologics or 
recently treated with 
IV-IG, cytotoxic agents, 
investigational agents, 
DMARDs other than 
MTX, or corticosteroids 
(IA, IM or IV). 
Active uveitis, active 
systemic symptoms
Development of MAS 
during pre-study 
hospital admission
Previously treated with 
IL-1 inhibitor
Unknown Unknown Unknown Systemic JIA and
ever use of DMARDs 
and/or steroids
Patients with past or 
current uveitis.
Previously treated with 
other biologics and 
DMARDs other than 
MTX
Design Randomized double-
blind placebo-controlled 
withdrawal trial
3 months open-label 
lead-in phase (all 
received drug), only 
ACRpedi30 responders 
included in 4 month 
double-blind phase
Randomized double-
blind placebo-controlled 
trial
first 14 weeks placebo-
controlled, than 
comparison of 2 dosing 
regimens
Randomized double-
blind placebo-controlled 
withdrawal trial
16 weeks open-label 
lead-in phase (all 
received drug), only 
ACRpedi30 responders 
in 32 week double-blind 
phase.
Stratification for MTX 
use
Randomized double-
blind placebo-controlled 
withdrawal trial
4 months open-label 
lead-in phase (all 
received drug), only 
ACRpedi30 responders 
in 6 month double-blind 
phase included.
Randomized double-
blind placebo-controlled 
withdrawal trial
6 weeks open-label 
lead-in phase (all 
received drug), only 
those ACRpedi30 
responders with CRP 
<5mg/L in 12 week 
double-blind phase
Randomized double-
blind placebo-
controlled trial
first month placebo-
controlled phase, than 
open-label treatment 
period with all patients 
receiving anakinra
Randomized double-
blind placebo-
controlled trial
4-week placebo-
controlled phase, than 
open-label treatment 
period with all patients 
receiving canakinumab
Randomized double-
blind placebo-
controlled trial
12-weeks placebo-
controlled phase 
(randomization 2:1) 
with a rescue phase 
after 2 weeks with 
standard of care 
therapy, than open-
label treatment period
Randomized double-
blind placebo-
controlled trial
4-week placebo-
controlled phase, than 
open-label treatment 
period with all patients 
receiving rilonacept
Randomized open-
label treatment 
strategy trial 
54 week open-label 
trial comparing 3 
treatment arms: 1)
infliximab + MTX, 2)
MTX only, and 3)
COMBO (MTX + SSZ + 
plaquenil)
Randomized double-
blind placebo-
controlled treatment 
strategy trial
12 month trial 
comparing: 1) MTX + 
Etanercept + tapered 
PRED, and
2) MTX + placebo 
etanercept + PLAC 
prednisone 
Medication 1) Etanercept 0.4mg/
kg (max 25mg) twice 
weekly;
2) placebo
1) Infliximab (3mg/kg) + 
MTX during 52 wks;
2) placebo infusions + 
MTX first 14 wks and 
then infliximab (6 mg/
kg) + MTX
MTX: 10-15mg/ m2/wk 
oral or IM
1)Adalimumab 24mg/
m2 (max 40mg) every 
other week;
2) placebo
For those in MTX 
stratum: stable doses of 
at least 10mg/m2/ wk.
1) Abatacept 10mg/kg 
(max 1000mg);
2) placebo
1) Tocilizumab 8mg/kg 
every 2 weeks;
2) placebo
1) Anakinra 2 mg/kg/
day (max 100mg/day); 
2) placebo
1)Canakinumab (single 
dose, 4mg/kg, max 
300mg)
2) Placebo
1) Tocilizumab 8mg/kg 
for patients ≥30kg and 
12mg/kg for patients 
<30kg;
2) placebo
1) Rilonacept (2.2mg/
kw/ week, max 
160mg);
2) Rilonacept (4.4mg/
kw/ week, max 
320mg);
3) placebo
1) Infliximab (3-5 mg/
kg) +MTX; 
2) MTX only;
3) SSZ (40mg/ kg/ 
day up to 2000mg/ 
day) +plaquenil (5mg/
kg/ day up to 300mg/ 
day)+MTX
MTX:15mg/m2/wk, 
max25mg
1) MTX (0.5mg/
kg/wk, max 40mg 
s.c.)+Etanercept 
(0.8mg/ kg/week, max 
50mg)+PRED (0.5mg/
kg/day, max 60mg, 
tapered to 0 by 17 
wks);
2) MTX+plac
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Co-medication 
regimens
MTX needed to be 
discontinued at least 
14 days and other 
DMARDs and IA 
steroids 28 days before 
receipt etanercept.
Stable doses of 
NSAIDs, low doses 
of steroids (≤0.2 mg/
kg/day, max 10 mg) 
and pain medications 
(except during the 12 
hours before a joint 
assessment) were 
permitted during trial.
DMARDs other than 
MTX and IA steroids 
not permitted within 4 
weeks prior to study 
entry and during trial. 
Low-dose steroids 
(<0.2mg/kg/day or 
10mg/day, whichever 
was less), 1 NSAID, 1 
analgesic not NSAID, 
folic acids and narcotic 
or opoid analgestics 
permitted during trial.
Stable doses of 
NSAIDs and low dose 
corticosteroids (≤0.2 
mg/kg/day, max 10 mg) 
and pain medications 
(except during the 12 
hours before a joint 
assessment) permitted.
All DMARDs (including 
biologics, but 
excluding MTX) and 
IA steroids needed 
to be discontinued at 
least 4 weeks before 
receipt abatacept and 
were prohibited during 
trial. MTX at stable 
dose and NSAIDs/ 
analgesics and folic 
acids were allowed. 
Oral corticosteroids 
were stabilised 4 weeks 
before enrollment (at 
10mg/day or 0.2 mg/
kg, whichever was 
less).
IA steroids, methyl-
prednisone pulse, 
immunosuppressive 
drugs and DMARDs 
not allowed for 2 weeks 
before receipt study 
drug.
TNF-blockers not 
allowed for 12 weeks 
before receipt study 
drug.
Doses of oral 
corticosteroids had to 
be stable for 2 weeks 
prior study entry. During 
the study only stable 
doses of oral steroids 
were allowed. 
IV or IA steroids, 
immunosuppressive 
drugs and DMARDs 
had to be stopped 
at least 1 month 
before study entry. No 
immunosuppressive 
drugs or DMARDs 
allowed during trial. 
Doses of NSAIDs and 
corticosteroids had to 
remain stable 1 month 
before and during 
double blind phase.
Unknown Stable dose of MTX 
and NSAIDs continued. 
Tapering of oral 
corticosteroids was 
allowed at weeks 6 and 
8 for patients who met 
the ACRpedi70 criteria 
plus ESR<20mm/h 
plus no fever
Unknown IA steroids and NSAIDs 
permitted during trial
Escape regimen: if after 
12 weeks of treatment 
no ACRpedi75 then 
MTX dose doubled.
MTX (<=0.5mg/ kg/
week, max 40mg) 
started no longer 
than 6 weeks prior to 
enrolment and up to 2 
IA steroid injections at 
least 2 weeks before 
baseline and oral 
prednisone up to 4 
weeks before baseline 
allowed.
During the study use 
of 1 NSAID and folium 
acid and up to 2 IA 
steroid infections were 
allowed.
Primary endpoint Disease flare‡ ACRpedi30 Disease flare‡ Time to disease flare‡ Maintenance of 
ACRpedi30 response 
and CRP<15mg/L
Modified ACRpedi30*** Modified ACRpedi30*** Modified ACRpedi30*** Modified ACRpedi30*** ACRpedi75 Inactive disease after 6 
months
Secondary 
endpoints (open-
label extension file 
excluded)
ACRpedi 30/50/70 at 7 
months
ACRpedi50/70 ACRpedi 
30/50/70/90/100
% of patients with 
disease flare‡, 
ACRpedi30/50/70/90 
responses
ACRpedi30/50/70
Systemic feature score
ACRpedi 30
Modified 
ACRpedi50/70
Unknown ACRpedi50/70/90 Unknown Inactive disease, 
duration inactive 
disease, drug survival 
ACRpedi30/50/ 
70/90/100
ACRpedi70 after 4 
months
JADAD score Score: 4
Randomly assigned, 
but sequence of 
randomization not 
discussed (+1). 
Double-blind, placebo 
also injection (+2). 
Withdrawals described 
(+1)
Score: 4
Randomly assigned, 
but sequence of 
randomization not 
discussed (+1). 
Double-blind, placebo 
also injection (+2). 
Withdrawals described 
(+1)
Score: 4
Randomly assigned, 
but sequence of 
randomization not 
discussed (+1). 
Double-blind, placebo 
also injection (+2). 
Withdrawals described 
(+1)
Score: 5
Randomly assigned, 
and computer 
generated (+2). 
Double-blind, placebo 
also injection (+2). 
Withdrawals described 
(+1)
Score: 5
Randomly assigned, 
dynamic allocation (+2). 
Double-blind, placebo 
also injection (+2). 
Withdrawals described 
(+1)
Score: 4
Randomly assigned, 
computer generated 
random list (+2). 
Double-blind, placebo 
not described, 
(injection?) (+1). 
Withdrawals described 
(+1)
Score: 3
Randomly assigned, 
but sequence of 
randomization not 
discussed (+1). 
Double-blind, placebo 
not described, 
(injection?) (+1). 
Withdrawals described 
(+1)
Score: 3
Randomly assigned, 
but sequence of 
randomization not 
discussed (+1). 
Double-blind, placebo 
not described, 
(injection?) (+1). 
Withdrawals described 
(+1)
Score: 2
Randomly assigned, 
but sequence of 
randomization not 
discussed (+1). 
Double-blind, placebo 
not described, 
(injection?) (+1). 
Withdrawals not 
described (0)
Score: 2
Randomly assigned, 
but sequence not 
described (+1). Not 
double-blind (0). 
Withdrawals described 
(+1)
Score: 3
Randomly assigned, and 
computer generated (+2). 
Double-blind, however 
placebo for prednisone 
(max 60mg) must 
have let to unblinding 
issues because of the 
presence or absence of 
cushing’s syndrome (0). 
Withdrawals described 
(+1)
Etanercept
(Lovell)
Infliximab
(Ruperto)
Adalimumab
(Lovell)
Abatacept
(Ruperto)
Tocilizumab
(Yokota)
Anakinra
(Quartier)
Canakinumab 
(Ruperto)
Tocilizumab
(DeBenedetti)
Rilonacept (Lovell) Infliximab
(Tynjala)
Etanercept
(Wallace) 
* For all trials: patients had to have normal or nearly normal platelet, white-cell, and neutrophil counts, hepatic 
aminotransferase levels, and results of renal function test. Only the differences in inclusion criteria between trials are given 
in the table.
† For all trials: exclusion of pregnant and lactating patients and patients with major concurrent medical conditions 
(including serious infection, tuberculosis, malignancy). Girls with child-bearing potential were required to use contraception 
throughout the study. Only the differences in exclusion criteria between trials are given in the table.
** Active defined as at least 3 of the following criteria: 1) physicians’ global >=20/100, 2) parent/patient assessment of 
wellbeing >=20/100, 3) CHAQ>=0.375/3.0, 4) >=2 joints with arthritis, 5) >=2 joints with non-reversible limited range of 
motion, and 6) ESR>30mm/h.
‡  ACRpedi30 for a flare, defined as worsening of 30% or more in 3 of the 6 response variables, and improvement of 30% 
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or more in no more than one variable (changes from values at time of randomization). Added criterion in the etanercept 
trial: minimum of 2 joints with arthritis, and, if global assessments used to defined a flare, a minimal change of 20mm (on 
a 0-100mm scale). Added criterion in the adalimumab trial: if the number of active or limited joints were used to define 
a flare, at least 2 joints had to have arthritis or limited motion respectively. In the adalimumab trial no minimum increase 
for the global assessments was given. Ruperto et al. did not add a minimum joint count (active or limited), but, if global 
assessments were used to define a flare, a minimal change of 20mm (on a 0-100mm scale) needed to be present. 
*** Modified ACRpedi30 response was defined in anakinra (Quartier) trial as an ACRpedi30 response together with no fever 
over the past 8 days and 50% decrease or normalization of both ESR and CRP levels, in the Ruperto, De Benedetti and 
Lovell trial as an ACRpedi30 response together with no fever.
[SSZ= sulfasalazine; LOCF= last observation carried forward; IM= intra-muscular, IA= intra-articular, IV= intra-venous]
Co-medication 
regimens
MTX needed to be 
discontinued at least 
14 days and other 
DMARDs and IA 
steroids 28 days before 
receipt etanercept.
Stable doses of 
NSAIDs, low doses 
of steroids (≤0.2 mg/
kg/day, max 10 mg) 
and pain medications 
(except during the 12 
hours before a joint 
assessment) were 
permitted during trial.
DMARDs other than 
MTX and IA steroids 
not permitted within 4 
weeks prior to study 
entry and during trial. 
Low-dose steroids 
(<0.2mg/kg/day or 
10mg/day, whichever 
was less), 1 NSAID, 1 
analgesic not NSAID, 
folic acids and narcotic 
or opoid analgestics 
permitted during trial.
Stable doses of 
NSAIDs and low dose 
corticosteroids (≤0.2 
mg/kg/day, max 10 mg) 
and pain medications 
(except during the 12 
hours before a joint 
assessment) permitted.
All DMARDs (including 
biologics, but 
excluding MTX) and 
IA steroids needed 
to be discontinued at 
least 4 weeks before 
receipt abatacept and 
were prohibited during 
trial. MTX at stable 
dose and NSAIDs/ 
analgesics and folic 
acids were allowed. 
Oral corticosteroids 
were stabilised 4 weeks 
before enrollment (at 
10mg/day or 0.2 mg/
kg, whichever was 
less).
IA steroids, methyl-
prednisone pulse, 
immunosuppressive 
drugs and DMARDs 
not allowed for 2 weeks 
before receipt study 
drug.
TNF-blockers not 
allowed for 12 weeks 
before receipt study 
drug.
Doses of oral 
corticosteroids had to 
be stable for 2 weeks 
prior study entry. During 
the study only stable 
doses of oral steroids 
were allowed. 
IV or IA steroids, 
immunosuppressive 
drugs and DMARDs 
had to be stopped 
at least 1 month 
before study entry. No 
immunosuppressive 
drugs or DMARDs 
allowed during trial. 
Doses of NSAIDs and 
corticosteroids had to 
remain stable 1 month 
before and during 
double blind phase.
Unknown Stable dose of MTX 
and NSAIDs continued. 
Tapering of oral 
corticosteroids was 
allowed at weeks 6 and 
8 for patients who met 
the ACRpedi70 criteria 
plus ESR<20mm/h 
plus no fever
Unknown IA steroids and NSAIDs 
permitted during trial
Escape regimen: if after 
12 weeks of treatment 
no ACRpedi75 then 
MTX dose doubled.
MTX (<=0.5mg/ kg/
week, max 40mg) 
started no longer 
than 6 weeks prior to 
enrolment and up to 2 
IA steroid injections at 
least 2 weeks before 
baseline and oral 
prednisone up to 4 
weeks before baseline 
allowed.
During the study use 
of 1 NSAID and folium 
acid and up to 2 IA 
steroid infections were 
allowed.
Primary endpoint Disease flare‡ ACRpedi30 Disease flare‡ Time to disease flare‡ Maintenance of 
ACRpedi30 response 
and CRP<15mg/L
Modified ACRpedi30*** Modified ACRpedi30*** Modified ACRpedi30*** Modified ACRpedi30*** ACRpedi75 Inactive disease after 6 
months
Secondary 
endpoints (open-
label extension file 
excluded)
ACRpedi 30/50/70 at 7 
months
ACRpedi50/70 ACRpedi 
30/50/70/90/100
% of patients with 
disease flare‡, 
ACRpedi30/50/70/90 
responses
ACRpedi30/50/70
Systemic feature score
ACRpedi 30
Modified 
ACRpedi50/70
Unknown ACRpedi50/70/90 Unknown Inactive disease, 
duration inactive 
disease, drug survival 
ACRpedi30/50/ 
70/90/100
ACRpedi70 after 4 
months
JADAD score Score: 4
Randomly assigned, 
but sequence of 
randomization not 
discussed (+1). 
Double-blind, placebo 
also injection (+2). 
Withdrawals described 
(+1)
Score: 4
Randomly assigned, 
but sequence of 
randomization not 
discussed (+1). 
Double-blind, placebo 
also injection (+2). 
Withdrawals described 
(+1)
Score: 4
Randomly assigned, 
but sequence of 
randomization not 
discussed (+1). 
Double-blind, placebo 
also injection (+2). 
Withdrawals described 
(+1)
Score: 5
Randomly assigned, 
and computer 
generated (+2). 
Double-blind, placebo 
also injection (+2). 
Withdrawals described 
(+1)
Score: 5
Randomly assigned, 
dynamic allocation (+2). 
Double-blind, placebo 
also injection (+2). 
Withdrawals described 
(+1)
Score: 4
Randomly assigned, 
computer generated 
random list (+2). 
Double-blind, placebo 
not described, 
(injection?) (+1). 
Withdrawals described 
(+1)
Score: 3
Randomly assigned, 
but sequence of 
randomization not 
discussed (+1). 
Double-blind, placebo 
not described, 
(injection?) (+1). 
Withdrawals described 
(+1)
Score: 3
Randomly assigned, 
but sequence of 
randomization not 
discussed (+1). 
Double-blind, placebo 
not described, 
(injection?) (+1). 
Withdrawals described 
(+1)
Score: 2
Randomly assigned, 
but sequence of 
randomization not 
discussed (+1). 
Double-blind, placebo 
not described, 
(injection?) (+1). 
Withdrawals not 
described (0)
Score: 2
Randomly assigned, 
but sequence not 
described (+1). Not 
double-blind (0). 
Withdrawals described 
(+1)
Score: 3
Randomly assigned, and 
computer generated (+2). 
Double-blind, however 
placebo for prednisone 
(max 60mg) must 
have let to unblinding 
issues because of the 
presence or absence of 
cushing’s syndrome (0). 
Withdrawals described 
(+1)
Etanercept
(Lovell)
Infliximab
(Ruperto)
Adalimumab
(Lovell)
Abatacept
(Ruperto)
Tocilizumab
(Yokota)
Anakinra
(Quartier)
Canakinumab 
(Ruperto)
Tocilizumab
(DeBenedetti)
Rilonacept (Lovell) Infliximab
(Tynjala)
Etanercept
(Wallace) 
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ONLINE SUPPLEMENTARY TEXT: TABLE S3 PATIENT POPULATION INCLUDED  
AND REPORTED EFFICACY
Etanercept
(Lovell)
Infliximab
(Ruperto)
Adalimumab 
(Lovell)
Abatacept
(Ruperto)
Tocilizumab
(Yokota)
Anakinra
(Quartier)
Canakinumab 
(Ruperto)
Tocilizumab
(DeBenedetti)
Rilonacept (Lovell) ACUTE-JIA
(Tynjala)
TREAT
(Wallace)
N included in open-label phase 69 - 171 190 56 - - - - - -
N entering double-blind part 51 (74%) 122 (100%)
(efficacy analysis for 
117 patients)*
144 (84%) eligible 
for double blind part, 
133 (78%) entered
122 (64%) 43 (77%) 24 (100%) 84 (100%) 112 (100%) 24 (100%) 60 (100%)
(efficacy analysis for 59 
patients)*
85 (100%)
Baseline patient and disease characteristics (of patients in double blind part only)
Female 34 (67%) 102 (84%) 103 (77%) 88 (72%) 28 (65%) 15 (63%) ? ? 16 (67%) 38 (63%) 72 (85%)
Mean age (years) 10.6 11.2 11.3 12.3 8.7 8.5 ? ? 12.6 9.6 10.5
Mean disease duration (years) 5.8 3.9 3.8 3.9 4.7 3.7 3.4 5.2 3.1 0.16 0.42
JIA category
Oligo-articular extended 3 (6%) 28 (23%) ? 16 (13%) - - - - - ? ?
Oligo-articular persistent - - ? 2 (2%) - - - - - - -
Poly-articular RF pos or neg 31 (61%) 74 (61%) ? 80 (66%) - - - - - ? ?
Systemic 17 (33%) 19 (16%) ? 23 (19%) 43 (100%) 24 (100%) 84 (100%) 122 (100%) 24 (100%) - -
Unknown (numbers do not add) - 1 (1%) - 1 (1%) - - - - - - -
Positive for RF 12 (24%) 27 (22%) 28 (21%) 26 (21%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (2%) 31 (36%)
Previous MTX 51 (100%) 122 (100%) 87 (65%) At least 94 (77%) ? 19 (79%) ? ? ? 0 (0%) 10 (12%)
Previous Biologic 0 (0%) 0 (0%) 0 (0%) 21 (17%) ? 13 (54%) ? ? 7 (29%, anakinra use) 0 (0%) 0 (0%)
Disease characteristics at baseline (of patients in double blind part only †)
Mean no. active joints 29** 19 17 16 4** 16 14 20 11 18 22
Mean no. limited joints 7** 18 14 16 0** 17 ? ? 7 10 15
Mean physicians’ global (0-100) 65** 51 59 53 51** 60 ? ? 55 55 71
Mean global assessment of 
wellbeing (0-100)
50** 43 48 41 53** 52 ? ? 60 30 54
Mean CHAQ score (0-3) 1.4** 1.2 1.1 1.2 0.7** 1.6 ? ? 1.5 0.8 1.2
Mean ESR mm/hour 34** 33 ? 31 37** 50 ? ? ? 36 37
Efficacy (double blind part only)
Duration placebo-controlled part 4 months 14 weeks 32 weeks 6 months 12 weeks 1 month 15 days 12 weeks 4 weeks 54 weeks 4 months/ 6months ‡
Disease flare (%) DRUG: 28% 
PLAC: 81%
- Plus MTX:  
DRUG: 37%  
PLAC: 65% 
No MTX: 
DRUG: 43% 
PLAC: 71%
DRUG: 12 (20%) 
PLAC: 33 (53%)
- - - - - - -
Median time to flare DRUG: >116 days 
PLAC: 28 days
- - DRUG: insufficient 
events 
PLAC: 6 months
- - - - - - -
Maintenance of ACRpedi30 and 
CRP <5mg/L
- - - - DRUG: 80% 
PLAC: 17%
- - - - - -
Modified ACRpedi30*** - - - - - DRUG: 67% 
PLAC: 8%
DRUG: 84% 
PLAC: 10%
DRUG: 85% 
PLAC: 24%
? (numbers unknown) - -
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Etanercept
(Lovell)
Infliximab
(Ruperto)
Adalimumab 
(Lovell)
Abatacept
(Ruperto)
Tocilizumab
(Yokota)
Anakinra
(Quartier)
Canakinumab 
(Ruperto)
Tocilizumab
(DeBenedetti)
Rilonacept (Lovell) ACUTE-JIA
(Tynjala)
TREAT
(Wallace)
N included in open-label phase 69 - 171 190 56 - - - - - -
N entering double-blind part 51 (74%) 122 (100%)
(efficacy analysis for 
117 patients)*
144 (84%) eligible 
for double blind part, 
133 (78%) entered
122 (64%) 43 (77%) 24 (100%) 84 (100%) 112 (100%) 24 (100%) 60 (100%)
(efficacy analysis for 59 
patients)*
85 (100%)
Baseline patient and disease characteristics (of patients in double blind part only)
Female 34 (67%) 102 (84%) 103 (77%) 88 (72%) 28 (65%) 15 (63%) ? ? 16 (67%) 38 (63%) 72 (85%)
Mean age (years) 10.6 11.2 11.3 12.3 8.7 8.5 ? ? 12.6 9.6 10.5
Mean disease duration (years) 5.8 3.9 3.8 3.9 4.7 3.7 3.4 5.2 3.1 0.16 0.42
JIA category
Oligo-articular extended 3 (6%) 28 (23%) ? 16 (13%) - - - - - ? ?
Oligo-articular persistent - - ? 2 (2%) - - - - - - -
Poly-articular RF pos or neg 31 (61%) 74 (61%) ? 80 (66%) - - - - - ? ?
Systemic 17 (33%) 19 (16%) ? 23 (19%) 43 (100%) 24 (100%) 84 (100%) 122 (100%) 24 (100%) - -
Unknown (numbers do not add) - 1 (1%) - 1 (1%) - - - - - - -
Positive for RF 12 (24%) 27 (22%) 28 (21%) 26 (21%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (2%) 31 (36%)
Previous MTX 51 (100%) 122 (100%) 87 (65%) At least 94 (77%) ? 19 (79%) ? ? ? 0 (0%) 10 (12%)
Previous Biologic 0 (0%) 0 (0%) 0 (0%) 21 (17%) ? 13 (54%) ? ? 7 (29%, anakinra use) 0 (0%) 0 (0%)
Disease characteristics at baseline (of patients in double blind part only †)
Mean no. active joints 29** 19 17 16 4** 16 14 20 11 18 22
Mean no. limited joints 7** 18 14 16 0** 17 ? ? 7 10 15
Mean physicians’ global (0-100) 65** 51 59 53 51** 60 ? ? 55 55 71
Mean global assessment of 
wellbeing (0-100)
50** 43 48 41 53** 52 ? ? 60 30 54
Mean CHAQ score (0-3) 1.4** 1.2 1.1 1.2 0.7** 1.6 ? ? 1.5 0.8 1.2
Mean ESR mm/hour 34** 33 ? 31 37** 50 ? ? ? 36 37
Efficacy (double blind part only)
Duration placebo-controlled part 4 months 14 weeks 32 weeks 6 months 12 weeks 1 month 15 days 12 weeks 4 weeks 54 weeks 4 months/ 6months ‡
Disease flare (%) DRUG: 28% 
PLAC: 81%
- Plus MTX:  
DRUG: 37%  
PLAC: 65% 
No MTX: 
DRUG: 43% 
PLAC: 71%
DRUG: 12 (20%) 
PLAC: 33 (53%)
- - - - - - -
Median time to flare DRUG: >116 days 
PLAC: 28 days
- - DRUG: insufficient 
events 
PLAC: 6 months
- - - - - - -
Maintenance of ACRpedi30 and 
CRP <5mg/L
- - - - DRUG: 80% 
PLAC: 17%
- - - - - -
Modified ACRpedi30*** - - - - - DRUG: 67% 
PLAC: 8%
DRUG: 84% 
PLAC: 10%
DRUG: 85% 
PLAC: 24%
? (numbers unknown) - -
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ACRpedi30 - DRUG: 63.8% 
PLAC: 49.2%
- - - DRUG: 92% 
PLAC: 58%
- - - TNF: 100% 
COMBO: 85% 
MTX only: 60%
-
ACRpedi50 - DRUG: 50.0% 
PLAC: 33.9%
- - - - - DRUG: 85% 
PLAC: 11%
- TNF: 100% 
COMBO: 80% 
MTX only: 60%
-
ACRpedi70 - DRUG: 22.4% 
PLAC: 11.9%
- - - - - DRUG: 71% 
PLAC: 8%
- TNF: 100% 
COMBO: 70% 
MTX only: 60%
MTX+ETN+ PRED: 
71% 
MTX+PLAC: 44%
ACRpedi75 - - - - - - - - - TNF: 100% 
COMBO: 65% 
MTX only: 50%
-
ACRpedi90 - - - - - - - DRUG: 37% 
PLAC: 5%
- TNF: 84% 
COMBO: 60% 
MTX only: 45%
-
Inactive disease - - - - - - - - - TNF: 68% 
COMBO: 40% 
MTX only: 25%
MTX+ETN+ PRED: 
40% 
MTX+PLAC: 23%
 
Duration placebo-controlled part 4 months 14 weeks 32 weeks 6 months 12 weeks 1 month 15 days 12 weeks 4 weeks 54 weeks 4 months/ 6months ‡
Etanercept
(Lovell)
Infliximab
(Ruperto)
Adalimumab 
(Lovell)
Abatacept
(Ruperto)
Tocilizumab
(Yokota)
Anakinra
(Quartier)
Canakinumab 
(Ruperto)
Tocilizumab
(DeBenedetti)
Rilonacept (Lovell) ACUTE-JIA
(Tynjala)
TREAT
(Wallace)
Efficacy (double blind part only)
* In Infliximab trial 5 patients excluded from efficacy analysis: missing data of 3 patients in PLAC-group (1 withdrew consent, 2 
patients potential unblinding issues) and of 2 patients in DRUG group (both potential unblinding issues). In anakinra trial 1 patient 
excluded from efficacy analysis because of protocol violation
† For Adalimumab (Lovell et al.) trial disease characteristics of all patients included in open-label phase (MTX group n=85, no 
MTX n=86) are given, because values for patients entering double-blind phase only were not reported.
** Median given instead of mean
 ‡ ACRpedi70 score after 4 months, inactive disease after 6 months of double-blind period
*** Modified ACRpedi30 response was defined in Quartier trial as an ACRpedi30 response together with no fever over the past 
8 days and 50% decrease or normalization of both ESR and CRP levels and in the Lovell, De Benedetti and Ruperto trial as an 
ACRpedi30 response together with no fever
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ACRpedi30 - DRUG: 63.8% 
PLAC: 49.2%
- - - DRUG: 92% 
PLAC: 58%
- - - TNF: 100% 
COMBO: 85% 
MTX only: 60%
-
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- - - - - DRUG: 85% 
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-
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- TNF: 84% 
COMBO: 60% 
MTX only: 45%
-
Inactive disease - - - - - - - - - TNF: 68% 
COMBO: 40% 
MTX only: 25%
MTX+ETN+ PRED: 
40% 
MTX+PLAC: 23%
 
Duration placebo-controlled part 4 months 14 weeks 32 weeks 6 months 12 weeks 1 month 15 days 12 weeks 4 weeks 54 weeks 4 months/ 6months ‡
Etanercept
(Lovell)
Infliximab
(Ruperto)
Adalimumab 
(Lovell)
Abatacept
(Ruperto)
Tocilizumab
(Yokota)
Anakinra
(Quartier)
Canakinumab 
(Ruperto)
Tocilizumab
(DeBenedetti)
Rilonacept (Lovell) ACUTE-JIA
(Tynjala)
TREAT
(Wallace)
Efficacy (double blind part only)
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ABSTRACT
Objective. To evaluate the effectiveness and safety of switching to a second or third 
biological agent in juvenile idiopathic arthritis (JIA) after etanercept failure.
Methods. The Arthritis and Biologicals in Children Register aims to include all Dutch 
JIA patients who have used biological agents. Data on the disease course were used to 
estimate drug survival with Kaplan–Meier and calculate adverse event (AE) rates.
Results. Of 307 biologically naive JIA patients who started etanercept, 80 (26%) switched 
to a second and 22 (7%) to a third biological agent. During 1030 patient-years of follow-up 
after the introduction of etanercept, 49 switches to adalimumab, 28 infliximab, 17 anakinra, 
four abatacept and four trial drugs were evaluated. 84% (95% CI 80% to 88%) of patients 
who started etanercept as a first biological agent were, after 12 months, still on the drug, 
compared with 47% (95% CI 35% to 60%) who started a second and 51% (95% CI 26% 
to 76%) who started a third biological agent. Patients who switched because of primary 
ineffectiveness continued the second agent less often (32%, 95% CI 12% to 53%). After 
etanercept failure, drug continuation of adalimumab was similar to infliximab for patients 
with non-systemic JIA; anakinra was superior to a second TNF-blocker for systemic JIA. 
AE rates within first 12 months after initiation were comparable for each course and each 
biological agent.
Conclusions. Switching to another biological agent is common, especially for systemic JIA 
patients. A second (and third) agent was less effective than the first. The choice of second 
biological agent by the physician mainly depends on availability and JIA category.
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INTRODUCTION
The introduction of etanercept has much improved outcomes in juvenile idiopathic arthritis 
(JIA) patients. However, despite this treatment success in most patients, approximately 10–
22% of previously biologically naive JIA patients discontinue etanercept within 12 months 
because of a lack of effectiveness or intolerance.29 144 153 Different biological agents targeting 
different cytokines are now available. Tumour necrosis factor alpha (TNFα) antagonists are 
the most often prescribed biological agents for JIA patients. Etanercept (approved since 
2000), adalimumab (approved since 2008) and infliximab (not approved for JIA, but used 
off-label) all antagonise TNFα, but have different mechanisms of action.154 155 Therefore 
treating physicians consider a switch to a second TNFα antagonist after failing the first. 
Besides these TNFα antagonists, abatacept (a selective T-cell costimulation modulator) 
has been approved in 2010 for JIA patients who have failed at least one synthetic disease-
modifying antirheumatic drug and a TNFα blocker. For systemic JIA, blocking interleukin 
(IL)-1 and IL-6 cytokines seems to be of greater value and targeting these cytokines 
(tocilizumab (approved for systemic JIA since 2011) and anakinra and canakinumab (not 
approved for JIA, but used off-label)) appears promising.129 132 146 156 157
Besides a few case series,101 158-160 only one larger observational study regarding switching 
between TNFα blocking agents in JIA has been published up to now.144 That retrospective 
chart review from Tynjala et al144 mainly described patients switching from etanercept to 
infliximab (and vice versa) and concluded that a switch to a second anti-TNFα agent was 
a reasonable option. Studies focusing on switching from etanercept to agents targeting 
other cytokines are lacking for JIA; however, some do include patients with a history of 
TNF-blocking agents. On the basis of mainly case series combined with expert opinion, the 
American College of Rheumatology (ACR) recommended equally in 2011 a second TNFα 
inhibitor or abatacept for polyarticular JIA patients who failed the first TNFα inhibitor. For 
the systemic category with active arthritis they recommended a switch from anakinra to 
etanercept, or vice versa, or a switch to abatacept.161 As evidence with regard to switching 
in JIA is scarce, we evaluated the effectiveness and safety of switching to other biological 
agents after failing etanercept during a long follow-up period.
PATIENTS AND METHODS
Study design and subjects
This study was part of a multicentre prospective observational register; the Arthritis and 
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Biologicals in Children (ABC) Register. This register aims to include all Dutch JIA patients 
who use or previously used biological agents since the introduction of etanercept in 
1999. The study protocol was approved by the Medical Ethics Committee at Erasmus 
MC Rotterdam and by all participating hospitals. The treating physicians collected and 
entered patient and disease characteristics in the web-based register at baseline, followed 
after 3 months of treatment, after 15 months and yearly thereafter.22 These data included 
the variables of the JIA disease activity score (ie, the JIA core set): physician’s global 
assessment of disease activity on a visual analogue scale (VAS; range 0–100 mm, 0 best 
score), the childhood health assessment questionnaire (CHAQ; range 0–3, 0 best score) by 
patients/parents, including global assessment of wellbeing by a VAS, number of active and 
limited joints and erythrocyte sedimentation rate (ESR).
In addition to the follow-up outcome data entered at 3 months and yearly thereafter, extra 
data entry times were at the time of any important events, such as stopping or switching 
biological agents and adverse events (AE).
For this study we selected all JIA patients who started etanercept as a first biological 
agent before 1 January 2010, to allow for sufficient follow-up. The reported switches 
were restricted to the introduction of a second and third biological agent. Switches to trial 
drugs were mentioned; however, the outcomes of patients switching to trials had to be 
excluded from the analyses. Reasons for switching were based on the clinicians’ opinion 
and classified into: lack of effectiveness, intolerance/AE, uveitis and other reasons. Lack of 
effectiveness was subsequently categorised in primary non-response or partial response 
depending on whether patients had achieved an ACRpedi50 response at least once during 
follow-up exposed to etanercept or the second biological agent. An ACRpedi50 response 
has been defined as at least 50% improvement in three or more variables of the JIA core 
set and a worsening of no more than one variable by more than 30%.44
Effectiveness
As a proxy for effectiveness of treatment, drug adherence until discontinuation due to 
ineffectiveness of treatment, AE or non-compliance was estimated with Kaplan–Meier. 
Patients were censored when discontinuation because of disease remission occurred, or 
when still receiving the drug at the time of last study visit.
Furthermore, inactive disease was analysed only for those patients who switched to 
another biological agent because of lack of effectiveness (primary non-response and partial 
response) of etanercept on arthritis. Inactive disease was defined, according to a modified 
definition of Wallace with a physician’s global assessment of disease activity indicating no 
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disease activity defined as a score of 10 mm or less, on a scale of 0–100 mm.45 
Safety 
All medically important infectious and non-infectious AE and all serious adverse events 
(SAE, defined according to the US Food and Drug Administration) were documented. 
Flaring of JIA was not considered as an AE but as an outcome of treatment response. We 
calculated the overall AE rates (including SAE) and the SAE rates per patient-year within 
the first year after initiation of a biological agent, accounting for possible discontinuation 
of the biological agent. We limited our safety analyses to the first year after initiation of the 
biological agent, because the follow-up durations differed between the observed biological 
agents and AE rates are reported to be higher within the first year. We considered infections 
that recurred within a patient as separate AE, but non-infectious AE that recurred were 
counted only once.
Statistical analysis
The multiple imputation method of the AregImpute function of the R statistical package was 
applied to impute missing values of the JIA core sets at observed follow-up moments. Only 
when at least three of the six JIA core set variables were present were the remaining values 
of the core sets imputed.
For patients who switched from etanercept to a second and from a second to a third 
biological agent with lack of effectiveness as the reported reason (n=58 to a second and 
n=15 to a third agent), ACRpedi50 scores were calculated in order to categorise these 
patients as primary non-responder or partial responder. Five per cent of the JIA core set 
variables were missing at the start of etanercept (median of 0 missing variables per core 
set; IQR 0–0) and 34% at the start of the second agent (median of two missing variables 
per core set; IQR 2–4). A total of 244 follow-up visits was recorded, of which 128 visits were 
used in order to categorise these patients. Missing during these follow-up visits were: 26% 
of the variables and a median of 0.5 missing variables per core set (IQR 0–2.5).
Of all patients who switched to the second agent because of lack of effectiveness, inactive 
disease was calculated at the fixed follow-up visits after 3 and 15 months of treatment. Forty-
six of the 58 patients had a 3-month follow-up visit and 24% (11 of 46) of the ESR values, 7% 
(three of 46) of the reported active joint counts and 44% (20 of 46) of the physician’s global 
assessments for disease activity were missing. Forty-three patients had a follow-up visit 
15 months after switch, and 37% of the ESR values, 33% of the reported active joint counts 
and 65% of the physician’s global assessments for disease activity were missing.
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Descriptive statistics were reported as absolute frequencies, or as median values with an 
IQR. Depending on the tested baseline variable, Mann–Whitney U tests and χ2 test were 
used to perform comparisons between patients who switched and patients who never 
switched. In addition, a logistic regression was performed to adjust the associated factors 
for follow-up duration since the start of etanercept, which was thought to be an important 
confounder. Another logistic regression was performed to identify the association between 
the reason to discontinue a second agent and the reason to switch from a first to a second 
biological agent. Results of the logistic regression models are presented as OR with 95% 
CI, and p values were calculated using the Wald’s test.
Differences in drug continuation (according to Kaplan–Meier) were defined by the log-rank 
test when comparing two groups and by the log-rank Mantel–Cox when comparing multiple 
groups. All reported p values were based on two-sided tests for significance, and p values 
less than 0.05 were considered statistically significant. SPSS V.17.0.1 and R statistical 
package 2.10.1 were used for the analyses.
RESULTS
Of the 307 JIA patients included, 80 (26%) switched to a second and 22 (7%) to a third 
biological agent. A flow chart of switching patterns is given in figure 1. Patient and disease 
characteristics are listed in table 1. Median follow-up duration since the start of the second 
biological agent was 18 months (IQR 7–38), and since the start of the third 14 months (IQR 
6–35). Adjusted for follow-up duration, patients who switched to a second biological agent 
were more likely to have the systemic category, had shorter disease duration before the 
start of etanercept and were younger at the start of the first biological agent, and at the 
start of etanercept had higher CHAQ scores. Reasons for a switch to a second or third 
biological agent are reported in table 2. Lack of effectiveness of treatment was the most 
frequently reported reason for both switches.
114
Figure 1 (A, B) Flow-chart of switching between biological agents recorded in the Arthritis and Biologicals 
in Children Register. The recorded follow-up duration (patient-years) since start or switch are reported 
below that specific start or switch (eg, 68 patient-years of follow-up were recorded since switch to 
adalimumab in non-systemic juvenile idiopathic arthritis patients). aba=abatacept; ada=adalimumab; 
ana=anakinra; etn=etanercept; FU=follow-up; infl=infliximab.
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Table 1 Patient and disease characteristics before start etanercept
JIA patients who 
never switched 
(n=227)
Switchers to a 
second agent 
(n=80)†
Switchers to 
a third agent 
(n=22)†
Female 155 (68) 56 (70) 17 (77)
Age at onset JIA (years) 8.0 (3.9-11.4) 5.1 (2.9-11.8) 4.1 (2.9-10.9)
Disease duration before start 
etanercept (years)**
3.2 (1.5-6.7) 2.1 (1.0-4.3) 1.4 (0.9-2.8)
Age at start etanercept (years)** 13.0 (9.7-15.5) 10.2 (6.2-13.8) 8.2 (5.0-12.3)
Duration follow-up since start of 
etanercept (months)*
29.4 (16.3-51.3) 41.8 (25.6-69.2) 57.1 (35.1-94.1)
Category JIA
  Systemic-onset JIA** 27 (12) 24 (30) 11 (50)
  Polyarticular JIA RF negative 92 (41) 30 (38) 5 (23)
  Polyarticular JIA RF positive 24 (11) 5 (6) 3 (14)
  Oligoarticular JIA persistent 9 (4) 1 (1) 0 (0)
  Oligoarticular JIA extended 45 (20) 16 (20) 3 (14)
  Arthritis psoriatica 17 (8) 2 (3) 0 (0)
  Enthesitis-related arthritis 13 (6) 2 (3) 0 (0)
Medication history before etanercept
  Systemic glucocorticoids 104 (46) 50 (63) 17 (77)
  Methotrexate 202 (89) 70 (88) 19 (86)
  Other synthetic DMARD 92 (41) 32 (40) 6 (27)
Disease activity at start etanercept
  VAS physician 62 (47-72) 60 (37-75) 62 (37-79)
  CHAQ score** 1.4 (0.9-2.0) 1.9 (1.2-2.4) 2.1 (1.6-2.6)
  VAS pain patient/parent 57 (25-75) 60 (34-78) 74 (52-83)
  VAS wellbeing patient/parent 50 (27-74) 58 (35-79) 70 (50-92)
  No of joints with arthritis 8 (5-16) 10 (7-17) 11 (9-18)
  No of joints with limited motion 7 (3-13) 6 (4-12) 7 (4-11)
  ESR 18 (9-35) 19 (7-38) 23 (11-55) 
 
Numbers given are: absolute numbers (%) or median (IQR).
*p Value <0.0001 (switchers compared with patients who never switch, Mann-Whitney U test).
**p Value <0.05 adjusted for follow-up duration (switchers compared with patients who never switch, logistic regression 
analysis, p value based on Wald’s test). Because of the non-normal distribution of disease duration before the start of 
etanercept a logarithmic transformation was used.
†Patients who switched to a third agent are also represented in the switchers to a second agent patient group.
CHAQ=child health assessment questionnaire; DMARD=disease-modifying anti-rheumatic agent; ESR=erythrocyte 
sedimentation rate; JIA=juvenile idiopathic arthritis; RF=rheumatoid factor; VAS=Visual analogue scale.
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Table 2 Reasons for switching 
Switch to a second 
agent (n=80)
Switch to a third agent 
(n=22)
Ineffectiveness: primary 26 (33) 12 (55)
Partial effect / loss of response 32 (40) 3 (14)
Adverse events / intolerance 11 (14) 5 (23)
  Inflammatory Bowel Disease 5 -
  Urosepsis 1 -
   Chest pain, dyspnoea, air trapping lung 1 -
   Injection site reaction / fear of injections 1 4
  Other 3 1
Combination ineffectiveness and adverse events 1 (1) -
Uveitis 8 (10) 1 (5)
Non-compliance 2 (3) -
Unknown - 1 (5)
Most patients experienced no treatment pause between the discontinuation of a biological 
agent and introduction of another biological agent, 17 patients started the second agent 
after a median biological treatment pause of 8 months (IQR 2–32), and 12 patients started 
the third agent after a median biological treatment pause of 4 months (IQR 2-22). The 
biological treatment pause seemed mainly caused by the limited availability of other 
biological agents during the observed time period and the occurrence of SAE as a reason 
to discontinue biological treatment.
The drug survival of the first, second and third introduced biological agents is reported 
in figure 2. Eighty-four per cent (95% CI 80% to 88%) of patients who started etanercept as 
a first biological agent were, after 12 months, still on the drug, compared with 47% (95% CI 
35% to 60%) of patients who started a second biological agent and 51% (95% CI 26% to 
76%) of patients who started a third biological agent.
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Figure 2. Drug continuation of first, second and third course biologics. Kaplan–Meier estimate of overall 
drug continuation until discontinuation of the first, second and third introduced biological agent due to 
ineffectiveness, adverse events or non-compliance. Vertical lines indicate censoring (censoring is defined 
as the time a patient discontinued etanercept because of disease remission or, when still receiving the 
drug, the time of last study visit). Log-rank test (Mantel–Cox) compares the overall drug survival differences 
between the three courses of biological agents.
Table accompanying Figure 2: 
No of patients No of patients  
with events
No of patients 
censored
First course (etanercept) 307 107 200
Second course 78* 44 34
Third course 19** 9 10
 
* Two patients who used a trial drug as a second biological agent had to be excluded.
** Two patients who used a trial drug as a third biological agent had to be excluded.
118
Switching patterns 
The majority of patients with non-systemic JIA categories switched between anti-TNFα 
agents only. These patients discontinued adalimumab because of ineffectiveness or AE 
in 21 of the 42 times it was started as a second/third biological agent, and infliximab in 
nine of the 21 times it was started as a second/third biological agent. Drug survival of 
the adalimumab courses in JIA patients with non-systemic JIA categories (50% on drug 
after 12 months, 95% CI 32% to 67%) was not different compared with the infliximab 
courses (54%, 95% CI 28 to 79, log-rank p=0.50,figure 3A). Systemic JIA patients most 
often started anakinra after etanercept failure (17 times of anakinra as second/third 
biological agent). All systemic JIA patients who started adalimumab discontinued it due 
to ineffectiveness or intolerance, six of seven patients (86%) discontinued infliximab and 
11 of 17 patients (65%) anakinra. After etanercept failure, systemic JIA patients continued 
anakinra (65% on drug after 12 months, 95% CI 42 to 87) more often than a second TNFα 
antagonist (21%, 95% CI 0 to 43, log-rank p=0.006). Drug survival of anakinra as a second/
third agent was not different from drug survival of etanercept as a first agent (figure 3B). 
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Figure 3 Drug continuation of biological agents introduced in systemic juvenile idiopathic arthritis (JIA) and 
non-systemic JIA categories. Kaplan-Meier estimate of overall drug continuation until discontinuation of 
the agent due to inefficacy or adverse events. Vertical lines indicate censoring (censoring is defined as the 
time a patient discontinued etanercept because of disease remission or end of follow-up). (A) Compares 
the drug survival of etanercept (introduced as the first biological agent) with adalimumab and infliximab as 
the second/third introduced agents for patients with non-systemic JIA categories. (B) Compares the drug 
survival of etanercept (introduced as the first biological agent) with anakinra, adalimumab and infliximab 
as the second/third introduced agents for patients with systemic JIA. Log-rank test compares the drug 
survival difference between the second/third introduced biological agents (*marked categories).
Table accompanying figure 3 
No of patients No of patients 
with events
No of patients 
censored
Table accompanying Figure 3A
Etanercept (first) 256 79 177
Adalimumab (second/third) 42 21 21
Infliximab (second/third) 21 9 12
Table accompanying Figure 3B
Etanercept (first) 51 27 24
Anakinra (second/third) 17 10 7
Adalimumab or infliximab (second/third) 14 13 1
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Effectiveness of second biologic on active arthritis
Forty-six of the 58 patients who switched to a second agent due to lack of effectiveness 
had follow-up data 3 months after switch, for two patients too many variables were missing 
and two of the remaining 44 patients (5%) achieved inactive disease. Of the 43 patients 
with 15 months of follow-up, unfortunately for 14 patients too many variables were missing, 
and five of the remaining 29 patients (17%) achieved inactive disease.
Influence of reason switching
Patients who switched to a second biological agent because of primary non-response 
to treatment (n=24, two patients excluded because of inclusion in a drug trial) seemed to 
continue the second agent less often (32% on drug after 12 months, 95% CI 12% to 53%) 
than patients who switched because of partial response (50% on drug after 12 months, 
95% CI 30% to 70%) and the remaining reasons combined (61% on drug after 12 months, 
95% CI 38% to 83%).
Discontinuation of a second biological agent because of lack of effectiveness was 
associated with lack of effectiveness as a reason to switch from the first to the second 
agent (OR 8.0, 95% CI 1.7 to 37.4), but not with AE as a reason to switch from the first to 
the second biological agent (OR 0.1, 95% CI 0.0 to 1.1).
Of the eight patients who switched to a second agent because of uveitis, all switched to 
adalimumab. Median drug survival on adalimumab for these patients was 11.7 months; four 
patients (50%) discontinued adalimumab (two because of a flare of arthritis, one because of 
AE and one reason unknown).
Safety of switching
Very few patients switched because of safety issues from etanercept to the second agent 
(11 of 307 patients) and from the second to the third agent (five of 80 patients). Within 
1 year after the start of etanercept as the first biological agent, 0.23 AE/patient-year and 
0.01 SAE/patient-year (0.55 AE/patient-year of patients who switched) were reported, and 
within 1 year after the start of the second biological agent 0.32 AE/patient-year and 0.00 
SAE/patient-year, and of the third biological agent 0.36 AE/patient-year and 0.00 SAE/
patient-year.
Within the first year, 0.42 AE/patient-year during the 49 adalimumab courses were 
observed, 0.19 AE/patient-year during the 28 infliximab courses and 0.32 AE/patient-year 
during the 17 anakinra courses.
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DISCUSSION
This prospective observational study addressed the important clinical question paediatric 
rheumatologists are confronted with: ‘What to do after failing etanercept in JIA?’
In this study we show that switching to a second biological agent in JIA occurs frequently 
in daily practice and seems to be a safe option for JIA patients who fail etanercept. The 
effectiveness of a second (and third) biological agent is debatable and seems especially low 
when the first biological agent was discontinued because of primary ineffectiveness.
This is the second observational study on the effectiveness and safety of switching 
between biological agents in JIA. In the present study, most patients switched from 
etanercept to adalimumab, while in the study by Tynjala et al144 mainly a switch between 
etanercept and infliximab was described. We showed that, while JIA patients continued 
etanercept as a first biological agent more often, 47% of the switchers, who previously did 
not responded to etanercept, continued their second biological agent after 12 months of 
treatment. A lower percentage (32%) was seen for patients who discontinued etanercept 
because of primary ineffectiveness. This drug survival rate of a second biological agent 
is slightly lower than the 58% reported by Tynjala et al.144 The number of patients who 
achieved inactive disease 15 months after switch (17%) was substantially lower than the 
reported 32% in previously biologically naive JIA patients treated with etanercept.29 In 
rheumatoid arthritis (RA), a meta-analysis with over 4000 RA patients has been conducted 
and a drug continuation rate of 61.8% 1 year after the introduction of a second TNFα 
antagonist of treatment seemed higher than in JIA.162 In that study the percentage of RA 
patients achieving inactive disease was not reported, but an ACR70 response was reached 
in only 14% of patients. While a first biological agent was more effective, switching seems 
justifiable, because only very limited other therapeutic options are available after biological 
treatment.
The question remains: ‘Which patients should switch and to what type of biological agent?’ 
We have shown that, in daily practice, patients with non-systemic JIA categories mainly 
switched between TNFα inhibitors only. An important observation was that, for patients 
with non-systemic JIA categories, no differences between the effectiveness of adalimumab 
versus infliximab after etanercept failure were seen. Abatacept, even though it has been 
approved after TNFα failure, was only used in four patients, which is largely influenced by 
the limited availability of abatacept within the study period. The majority of the patients with 
systemic JIA switched between etanercept and anakinra. After etanercept failure, anakinra 
was superior compared with a second TNF-blocker. Anakinra now has a more prominent 
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place in the treatment of systemic JIA with systemic features and is often the first choice 
biological agent.161 Other IL-1 and IL-6 antagonists were, besides prescriptions in the 
presence of randomised clinical trials, not available during this study period and therefore 
were not observed in the present study.
Another observation was that patients who switched to a second biological agent with 
uveitis as the reason, all switched to adalimumab. A study by Simonini et al98 recently 
showed that adalimumab seems to be more efficacious in maintaining uveitis remission 
than infliximab. Unfortunately, the evaluation of the effectiveness on uveitis is beyond the 
scope of our register.
In this study we showed that the AE rates are comparable for each course of biological 
agents, and are also comparable for each specific biological agent. This is in contrast with 
data from Curtis et al,161 who showed a higher rate of hospitalised infections in switchers 
compared with RA patients who did not switch and a higher rate of hospitalised infections 
with infliximab use compared with the use of other available biological agents. Furthermore, 
we showed that AE as a reason to switch from a first to a second agent did not influence 
the chance of discontinuation of the second agent for AE; however, the number of patients 
with AE was small. Our finding that switching between biological agents in JIA in our study 
was not associated with an increased safety risk is reassuring.
This prospective observational study has some limitations. Because of the observational 
study design, reflecting a real-life setting, the choice of treatment is subject to the 
preferences of the treating physicians. The observed switching patterns are inevitably 
influenced by the availability of biological agents within the study period. The register 
started when etanercept became available for the treatment of JIA, and other biological 
agents were introduced later, which will have had an effect on the treatment choices of 
physicians. Furthermore, the study period is limited until the patients become 18 years of 
age. For patients followed for a longer period after the start of etanercept, we had a higher 
chance to observe a switch. The percentage of switching in this observational study is likely 
to be underreported. Therefore, together with the low number of patients per introduced 
biological agent and the uncontrolled nature of an observational study, these indirect 
comparisons between the different biological agents are difficult and should be interpreted 
with care.
Furthermore, clinicians are allowed to start or discontinue concomitant medications during 
the observed periods. The strength of this observational study is a reflection of daily clinical 
care; however, the lack of evaluation of these concomitant medications should be noted.
The switchers represent a heterogeneous patient group. The presence of systemic features, 
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uveitis and anti-drug antibodies are all important factors that influence treatment choices of 
the physicians and could affect treatment responses. In further studies these should all be 
taken into account to identify the best strategy of switching for each individual patient.
In conclusion, switching from etanercept to a second biological agent occurs frequently in 
daily practice and, as limited options are available, seems justifiable for JIA patients who 
fail etanercept. After etanercept failure, adalimumab and infliximab were equally effective 
in JIA patients with non-systemic JIA categories, while anakinra was superior to a second 
TNFα blocking agent in systemic JIA. The effectiveness of a second biological agent was 
lower than the first biological agent and seems especially low when the first agent was 
discontinued because of primary ineffectiveness. The choice of second biological agent by 
the physician mainly depends on availability of biological agents and the JIA category.
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ABSTRACT
Objective. Although the number of biologic agents available for the treatment of juvenile 
idiopathic arthritis keeps increasing, few comparative effectiveness studies have been 
performed. No head-to-head trials are available and indirect comparisons of the trials were 
limited by lack of comparability. This study attempts to assess comparative effectiveness of 
adalimumab an etanercept in three ways in an observational study.
Methods. Biologic-naïve patients starting either etanercept (n=304) or adalimumab (n=42) 
were selected from the Arthritis and Biologicals in Children register, who were included 
between 2004 and 2013. Comparative effectiveness was assessed in three analyses in the 
same dataset. A linear regression was fitted for the change in JADAS-10, with treatment 
as one of the covariates. A cox regression was fitted, also using treatment as a covariate, 
again using drug persistence as a proxy for treatment effectiveness. Lastly an attempt 
was made to construct a propensity score for the allocation of treatment, and to apply this 
propensity score in a logistic regression method with minimal disease activity as outcome 
measure
Results. In the first two methods, no significant differences were found in effectiveness 
of the two TNF-inhibitors. The third analysis could not be brought to a successful end, 
because of the lack of overlap in patient characteristics between the two treatment groups.
Conclusions. The lack of overlap in confounding factors was the most important finding 
of this study. Physicians interpreting comparative effectiveness and safety studies, but 
also investigators from other registers and observational studies should be aware of this 
problem.
128
INTRODUCTION
In the last decade the treatment of juvenile idiopathic arthritis (JIA) has greatly changed. 
One of the most important developments was the introduction of biologic treatment. 
After the approval of the first biologic agent, the TNF inhibitor etanercept in 1999, many 
new biologic agents followed. These agents also targeted TNF alpha, like adalimumab, 
or were directed at other cytokines, such as anakinra and tocilizumab. In analogy with 
developments in the treatment of rheumatoid arthritis (RA) it is to be expected that other 
agents are to follow, including the biosimilars.163 
This growth in treatment options implies a more difficult process of choosing one of these 
drugs. For regulators, patients, parents and physicians to be able to make a well informed 
choice, data on comparative effectiveness and safety are greatly needed. 
For FDA and EMA approval, new drugs need to be tested to prove their short term 
efficacy and safety in randomized controlled trials (RCTs), in which the active treatment 
is compared with a placebo. For information on comparative efficacy, ideally two active 
treatments would be compared directly in a head-to-head (non-inferiority) RCT. However, 
these trials are not likely to be performed in the future, in part because they would need a 
large number of biologic-naïve patients, which are not readily available for a rare disease 
like JIA. The relative effectiveness will therefore have to be studied in different ways, such 
as observational studies. In this study we will explore the possibility of doing so in the 
Dutch Arthritis and Biologicals in Children (ABC) register 40, by comparing etanercept and 
adalimumab, the two approved TNF-alpha inhibitors. 
The short term efficacy of these two anti-TNF agents has been established in randomized 
controlled trials. Observational studies have provided evidence that the two treatments are 
effective in controlling disease activity in patients with JIA in the long term.164 Although they 
both block TNF alpha, there are potential mechanistic differences between the two agents, 
which may explain why the effectiveness of the drugs differs between diseases (e.g. uveitis, 
psoriasis, inflammatory bowel disease and arthritis).18 The difference in effectiveness for 
arthritis is supported by the observation that many JIA patients that lack response to one, 
can still be responsive to the other TNF inhibitor.165 Because the two drugs have a different 
structure, there is a potential difference in immunogenicity, which may also influence the 
long term effectiveness of the drug.
Limited information is available on their relative effectiveness. Head-to-head trials were 
never performed and the indirect comparison of trial data was limited by lack of similarity 
of the trials and the patients investigated. The indirect comparison did not indicate a 
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significant difference in efficacy of these two TNF-inhibitors.166 Based on the available 
evidence, guidelines for the treatment of JIA make no distinction between the two.17
Hence, the relative effectiveness of the two TNF inhibitors will have to be studied in 
observational studies. A drawback of the observational study design is the lack of 
randomization. This gives rise to the possibility of confounding by indication. In an 
observational study patient or disease characteristics are able to influence the doctor’s 
choice for prescribing one or the other biologic. These same characteristics may also effect 
the treatment response. For example, a physician might be more inclined to prescribe 
adalimumab to a patient with a higher chance to develop uveitis, e.g. a patient with the 
oligoarticular JIA category. Additionally, having oligoarticular JIA might be associated with 
the response of the arthritis to the biologic treatment. In a previous study we found that 
patients in the register who were treated with adalimumab differed from patients who were 
treated with etanercept.83 To try to get round these distorting effects, the present study 
made an attempt to compare the effectiveness of the two treatments, applying various 
methods to control for confounding by indication. 
METHODS
Patients
Patients were retrieved from the Dutch Arthritis and Biologicals in Children (ABC) Register, 
a multicenter prospective cohort study that aimed to include all Dutch patients initiating 
biologic treatment.40 The ABC register contains prospectively obtained data since the 
introduction of etanercept for JIA in 1999. For the purpose of this study we selected 
biologic-naïve patients starting either etanercept or adalimumab included in the register 
between 2004 and 2013. Etanercept was available from 1999 in the Netherlands, for 
adalimumab this was the case from the end of 2008. In the early years patients with 
longstanding severe disease were included, who were less comparable to the more recently 
included patients, therefore patients from 2004 onwards were used for this analysis. To 
include a patient sample with the highest possible homogeneity with regard to patients 
characteristics in both treatment groups, we also included patients from the period before 
2008, although adalimumab was not yet readily available. This provided us with patients 
who would have been treated with adalimumab, had it been available, but who were treated 
with etanercept, because it was the only approved biologic treatment for polyarticular 
course JIA. JIA patients without active arthritis initiating biologics to treat uveitis only were 
not included in the analyses, nor were patients participating in treatment strategy trials. 
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Additionally we excluded patients with systemic JIA, because no patients with this category 
were treated with adalimumab and therefore no match could be found within this subgroup 
of patients.
Data collection
In the ABC register, patient and disease characteristics were collected at baseline. 
Thereafter, data on disease activity by means of the JIA core set is collected after 3 months 
of treatment and every following year. The variables of the JIA disease activity core set are 
the physician’s global assessment (PGA) of disease activity by visual analogue scale (VAS) 
(range 0-100 mm, 0 best score), Childhood Health Assessment Questionnaire (CHAQ) 
(range 0-3, 0 best score) by patients/parents, including global assessment of wellbeing 
by VAS, number of active and limited joints and erythrocyte sedimentation rate (ESR). 
Additionally pain is assessed by the patient/parent through VAS. Based on the variables of 
the JIA core set the juvenile arthritis disease activity score (JADAS-10) was calculated.23 
Change in JADAS-10 within 4 months after start of treatment was the outcome of interest 
in the second analysis. In the first analysis the outcome of interest was the achievement 
of minimal disease activity (MDA).167 MDA is defined as a PGA of 25 or less and no 
active joints for patients with an oligoarticular course of the disease; for patients with a 
polyarticular course it is defined as a PGA of 34 or less, a global assessment of wellbeing 
by the patient of 21 and 1 or no active joints. To apply this definition, our patients were 
divided in those with oligoarticular and those with polyarticular course JIA. Because the full 
course of the disease before start of the biologic agent was not known for all patients, we 
assigned the labels polyarticular and oligoarticular based on the number of active joints at 
start of etanercept. 
Missing data handling
At baseline 8.1% of the JIA core set variables (including VAS pain) were missing. At 
follow-up 24.6% of the core set variables were missing. Missing data were handled using 
the chained equations multiple imputation command ice in Stata. Ten imputed datasets 
were created. Adalimumab and etanercept patients were imputed together, because the 
adalimumab-treated group was too small to be imputed separately. Thus we assumed that 
the variables that were imputed were related in the same way in both groups.  
Statistical analysis
The first approach was a linear regression model of the change in JADAS-10 on possible 
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confounders which was constructed in etanercept patients. Subsequently we applied this 
model in the adalimumab patients. Thereby we predicted what the response in change 
in JADAS-10 would have been, would these patients have been treated with etanercept, 
and compared these predicted values with the observed change in JADAS-10. Potential 
confounders were identified beforehand based on pre-existing knowledge of their 
relationship with the assignment of treatment (either adalimumab or etanercept) and the 
response to treatment (baseline CHAQ score, disease duration at start of biologic).29 75 
76 83 Other baseline variables considered as possible confounders were PGA, number of 
previously used DMARDs, ANA status, number of active joints, number of limited joints, 
global assessment of wellbeing by the patient (VAS), ESR, gender, history of uveitis, JIA 
category (divided in the two categories oligo-articular and polyarticular) and age at onset. 
Secondly, a cox regression analysis was performed to estimate hazard ratios (HRs) for the 
discontinuation due to ineffectiveness or adverse events. The covariates in this model were 
the same as those included in the linear regression model, plus the covariate for biologic 
treatment. Because in this study we included patients from a period before adalimumab 
was widely available, we added year of inclusion as a covariate.
The third approach we used was a propensity score weighted logistic regression analysis 
with the outcome variable MDA. The same confounders were considered as in the other 
models. Propensity scores were constructed using the prop_sel method in Stata (developed 
by Mark Lunt at the University of Manchester, can be freely downloaded). Standardized 
differences and the expected bias of each confounder were calculated. The expected bias 
is the likely bias on the treatment effect that an existing imbalance of the confounders in the 
propensity estimate will cause. A maximum bias of 5% in either direction was considered 
acceptable in the construction of the propensity score model. 
Descriptive statistics are presented as absolute values, mean and SD or as median and IQR 
whenever appropriate. When medians were reported based on multiply imputed datasets, 
the average of the medians of all ten sets was taken. All analyses were conducted using 
Stata/SE version 12.0 and IBM SPSS Statistics 21.
RESULTS
Between 2004 and 2013 304 non-systemic JIA patients started etanercept and 42 
patients started adalimumab. Patient and disease characteristics at baseline are 
described in table 1. 
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Table 1 Patient and disease characteristics of patients treated with etanercept and adalimumab
Baseline characteristics Etanercept 
(n=304)
Adalimumab 
(n=42)
Year of start biologic treatment, median (IQR) 2008 (2007-2010) 2011 (2010-2012)
Female, n (%) 210 (69) 28 (67)
Age at onset JIA in years, median (IQR) 8.5 (3.5-12.0) 8.4 (2.3-12.2)
Age at start first biological in years, median (IQR) 12.7 (9.3-15.4) 13.0 (8.8-15.8)
JIA disease duration before start biological in years, median (IQR) 2.6 (1.4-5.7) 3.0 (0.8-6.4)
ANA positivity, n (%) (n=302/n=41) 105 (35) 22 (54)
History of uveitis, n (%) 12 (4) 21 (50)
Category JIA, n (%)
  Polyarticular RF negative 129 (42) 7 (17)
  Polyarticular RF positive 38 (13) 1 (2)
  Oligoarticular extended 76 (25) 8 (19)
  Oligoarticular persistent 16 (5) 8 (19)
  Psoriatic arthritis 23 (8) 6 (14)
  Enthesitis related arthritis 21 (7) 10 (24)
  Undifferentiated 1 (0.3) 2 (5)
Number of previously used DMARDs (including MTX), 
median (IQR)
1 (1-2) 1 (1-2)
Previous use of corticosteroids, n (%) 109 (36) 15 (36)
Disease activity parameters at baseline, median (IQR)
  PGA (0-100) (n=283/n=30) 57 (40-70) 40 (30-60)
  CHAQ total (0-3) (n=273/n=28) 1.3 (0.8-2.0) 0.8 (0.3-1.5)
  VAS pain (0-100) (n=271/n=28) 59 (30-75) 50 (21-65)
  VAS patient (0-100) (n=273/n=28) 55 (29-75) 46 (24-65)
  Active joints (n=304/n=42) 7 (4-9) 4 (2-6)
  Limited joints (n=289/n=38) 4 (2-9) 3 (2-5)
  ESR (n=299/n=39) 13 (7-29) 11 (5-24)
JADAS-10 (0-40), median (IQR) (n=256/n=24) 19 (14-23) 14 (10-17)
 
IQR=interquartile range; JIA=juvenile idiopathic arthritis; ANA=anti-nuclear antibodies; RF=rheumatoid factor; 
DMARDs=disease modifying anti-rheumatic drugs; MTX=methotrexate; PGA=global assessment of disease activity by the 
physician; CHAQ=childhood health assessment questionnaire; VAS=visual analogue scale; ESR=erythrocyte sedimentation 
rate; JADAS=juvenile arthritis disease activity score
Patients treated with adalimumab differed from patients treated with etanercept. The 
biggest differences were found in ANA status, history of uveitis and the distribution of the 
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JIA categories. Adalimumab-treated patients had more often a positive ANA, a history 
of uveitis, persistent oligoarticular, psoriatic and enthesitis related arthritis. Overall, their 
disease activity was lower than the disease activity of etanercept-treated patients. 
Linear regression approach - observed vs expected
To observe whether etanercept treatment would have been as successful as adalimumab 
treatment in the adalimumab-treated patients, a linear regression model for change in 
JADAS-10 adjusted for all prespecified confounders was fitted on the etanercept patients and 
applied to the adalimumab treated patients. The beta estimates for this multivariate model 
are displayed in Table 2. JADAS10 was significantly more likely to decrease when a patient 
had polyarticular JIA (which was to be expected, given that the joint count can decrease 
more when a patient has polyarticular course JIA than when a patient has oligoarticular 
disease). For analogous reasons, also the baseline components of JADAS-10 were significant 
predictors, except for the number of active joints. The estimated beta for the presence of a 
history of uveitis was large, however the effect was not significant, possibly because there 
were so little patients with a history of uveitis in the etanercept-treated patient group.  
Table 2 Multivariate linear regression for change in JADAS-10 in etanercept-treated patients 
 
Variable Beta 95% confidence interval p-value
Male gender 0.58 -0.96 to 2.12 0.46
Age at onset of JIA, years 0.01 0-0.17 to 0.19 0.88
Disease duration, years -0.16 -0.39 to 0.08 0.20
ANA positive 0.15 -1.35 to1.64 0.85
History of uveitis -2.45 -5.94 to 1.04 0.17
Previous use of corticosteroids -1.08 -2.50 to 0.35 0.14
Number of previously used DMARDs 0.91 -0.15 to 1.96 0.09
Polyarticular course JIA -4.19 -6.18 to -2.20 <0.001
PGA -0.07 -0.11 to -0.02 0.002
CHAQ 0.66 -0.53 to 1.85 0.27
VAS patient -0.08 -0.11 to -0.05 <0.001
Number of active joints 0.07 -0.05 to 0.19 0.23
Number of limited joints -0.10 -0.24 to 0.04 0.15
ESR -0.10 -0.14 to -0.07 <0.001
 
JIA=juvenile idiopathic arthritis, ANA=anti-nuclear antibody, DMARDs=disease modifying anti-rheumatic drugs, PGA=physician 
global assessment, CHAQ=childhood health questionnaire, VAS=visual analogue scale, ESR=erythrocyte sedimentation rate
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In etanercept-treated patients JADAS-10 decreased with a mean of -11.4 points (±7.2), 
and in adalimumab-treated patients JADAS-10 decreased with a mean of -8.3 points 
(±6.2). The predicted change in JADAS-10 in the adalimumab-treated patients did not differ 
significantly from the observed change in these patients (mean difference between the 
observed and predicted change in JADAS-10: -1.39 point(±4.9)).
Cox regression approach – hazard ratios for discontinuation
In unadjusted analyses the discontinuation rate for adalimumab-treated patients did 
not differ significantly from the discontinuation rate of etanercept-treated patients (HR 
0.94 (95% CI: 0.43 to 2.03). Adjustment for the confounders (including year of inclusion) 
changed the HR to a certain extent, however there was still no significant difference 
between etanercept and adalimumab-treated patients (HR 1.96 (95% CI: 0.64 to 4.39). The 
unadjusted survival curves are shown in figure 1. 
Fifty percent of etanercept users had discontinued treatment after 55 months, the follow-up 
of adalimumab treated patients was too short to reach the median survival.
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Figure 1 Unadjusted survival curve 
Drug continuation of etanercept and adalimumab. Kaplan–Meier estimate of overall drug continuation until 
discontinuation due to ineffectiveness, adverse events or non-compliance. Vertical lines indicate censoring 
(censoring is defined as the time a patient discontinued treatment because of disease remission or, when 
still receiving the drug, the time of last study visit).
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Propensity score approach – balancing confounders
Within a period of 4 months after starting treatment, 13% of etanercept treated patients 
achieved MDA vs. 29% of adalimumab treated patients. The initial balance of the 
prespecified confounders are shown in table 3. Significant imbalance existed in the 
variables PGA, number of active joints, number of limited joints, VAS patient, CHAQ 
score, ANA status, the number of patients with polyarticular course JIA and the number 
of patients with a history of uveitis. In table 3 both the standardized differences and 
the expected bias are given. The standardized difference is the difference between the 
groups on each variable in standard deviations. For example: the difference in means of 
CHAQ scores beteen the etanercept and adalimumab-treated groups is 0.4. Divided by 
the standard deviation of 0.7 this results in a standardized difference of 0.57. Although 
this gives us information on the differences between the groups, it does not inform us 
about the importance of this difference, i.e. the influence these differences would have on 
the achievement of MDA. The expected bias informs us about the amount of bias in the 
prediction of the achievement of MDA that we would expect if we would not balance the 
confounders. This is based on a regression on the outcome (MDA) in the etanercept-treated 
group. For example, we see in table that the adalimumab-treated group does not differ a 
lot from the etanercept-treated group in standard deviations, however the influence of this 
difference on the predicted outcome is relatively large. 
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Table 3 Initial balance of prespecified confounders 
Variable Mean in 
etanercept-
treated 
(n=304)
Mean in 
adalimumab-
treated (n=42)
Standardized 
differences
Expected 
bias (%)
Female gender 69% 67% 0.05 1.1
Age at onset of JIA 8 8.1 0.05 -0.2
Disease duration 3.9 4.2 0.08 -2.1
ANA positive 35% 52% 0.36 0.6
History of uveitis 4% 50% 1.20 74.3
Previous use of corticosteroids 36% 36% 0.003 -0.1
Number of previously used 
DMARDs
1 1 0.04 0.7
Polyarticular course JIA 74% 40% 0.72 -33.5
PGA 54 42 0.55 10.8
CHAQ 1.3 0.9 0.57 0.7
VAS patient 52 43 0.31 3.2
Number of active joints 10 6 0.47 8.3
Number of limited joints 7 4 0.31 17.7
ESR 21 17 0.21 -5.0
 
JIA=juvenile idiopathic arthritis; ANA=anti-nuclear antibodies; RF=rheumatoid factor; DMARDs=disease modifying anti-
rheumatic drugs; MTX=methotrexate; PGA=global assessment of disease activity by the physician; CHAQ=childhood 
health assessment questionnaire; VAS=visual analogue scale; ESR=erythrocyte sedimentation rate; JADAS=juvenile 
arthritis disease activity score
The next step in the analysis using propensity scores was the actual construction of 
the propensity score, in which all the confounding factors are sufficiently balanced. 
Unfortunately, convergence was not reached in the construction of the propensity score 
model, which implied that there was too little overlap between the two groups to achieve an 
appropriate balance and construct a propensity score. Therefore the analysis was stopped 
here.
DISCUSSION
In the fast changing landscape of biologic treatment for JIA, data on comparative 
effectiveness are urgently needed. Using data from the Dutch ABC Register, this study 
attempted to compare the effectiveness of etanercept and adalimumab in the treatment of 
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(non-systemic) JIA. Three methods were applied. In a cox regression, the discontinuation 
rate of etanercept and adalimumab was comparable. A linear regression fitted in 
etanercept-treated patients and applied in the adalimumab-treated patients showed a 
similar decrease in JADAS-10, implying that the arthritis in the adalimumab treated patients 
would have responded in the same way, had they been treated with etanercept. These 
results seem to indicate that there is no difference in effectiveness between etanercept and 
adalimumab for JIA. However, in our opinion, the third analysis that was performed resulted 
in the most important findings. A less frequently used technique was applied – propensity 
score matching – for the evaluation of comparative effectiveness of the two biologic agents. 
One of the advantages of using this technique is that it informs us about areas of non-
overlap in our data, which we do not recognize when we use the more popular techniques 
for controlling for confounding, such as the earlier mentioned regression methods. For the 
analysis we performed, the lack of overlap the method identified between the etanercept 
and adalimumab treated groups was a crucial problem. This minimal overlap between the 
two patient groups raises doubt as to whether it is possible to apply the other two methods. 
It may well be that the adalimumab-treated patients make up a separate patient group, 
who would not respond similarly to etanercept patients. Additionally, because adalimumab 
was a new drug, and therefore physicians were reluctant in prescribing it, the sample of 
adalimumab treated patients is much smaller than that of the etanercept treated patients. 
This limits the power for any of the analyses in detecting small differences in effectiveness.
There is no doubt that the increasing treatment possibilities are good news for patients. 
Even for the previously most refractory patients, these treatment options mean that 
inactive disease may now be an achievable goal. Moreover, a more tailored treatment may 
be possible when we know which treatment is most effective and safe for which patient. 
Unfortunately, the increase in expensive treatments may also mean that health insurance 
providers will need to decide which treatment they will reimburse. To assure the freedom 
of prescription, to assure that the right patient gets the right drug and to inform clinical 
decision making when multiple drugs are available, reliable information on comparative 
effectiveness and safety is crucial. The results of the present study show how difficult it is 
to acquire such reliable information. This realization is very important for both researchers 
and prescribing physicians. The prescribing behavior of physicians has a large influence on 
the data from observational studies and the findings of observational studies also influence 
the choice of the prescribing physician. Especially in a rare disease such as JIA, the 
evidence is often limited to small case series and open label studies rather than large and 
well-designed comparative effectiveness studies. As said before, in JIA, very little research 
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has been performed investigating comparative efficacy/effectiveness of biologic agents. No 
direct head-to-head trials were conducted, and only a few investigators made attempts to 
compare trial results indirectly.166 168 169 Head-to-head trials are not likely to be performed, 
the largest part of the evidence will have to come from observational studies. The two 
drugs in the present study have not been compared before in observational studies in JIA. 
This did happen in RA, in which it is easier to assess comparative effectiveness, not only 
because it is a more common disease, but also because RA is a much more homogeneous 
disease than JIA. Several studies assessed the comparative effectiveness of etanercept 
and adalimumab using observational data.170-174 Various methods were used to correct for 
confounders. One study used propensity score methods and also found no differences 
in effect between the two TNF-inhibitors.170 Others made use of different analyses and 
either found the two agents to be similarly effective 172 or adalimumab to be more effective 
than etanercept.171 173 174 An explanation for these inconsistent results may be found in 
differences in the populations studied and the way outcomes were measured, but possibly 
also in the way confounders were controlled for. 
The present study directs the attention to the importance of reliable comparative 
effectiveness studies, in which proper measures are taken to correct for confounding 
by indication. To reach a conclusion on the differences in effectiveness and safety large 
observational studies are needed. Extensive efforts should be made to identify the factors 
that influence the effectiveness of biologic agents and – just as important – also the 
prescribing practice of physicians treating JIA patients. A possibility of achieving the right 
balance between these possible confounders within an observational design would be to 
study these drugs in a population in which some randomness in the allocation of treatment 
consists, for instance in a country where different insurance companies reimburse only one 
of the two TNF-alpha inhibitors. It has to be kept in mind that whichever method would be 
used to control for confounding by indication, no method is able to control for unmeasured 
confounding. 
Concluding, this is the first study attempting to assess the comparative effectiveness of 
two biologic agents in JIA patients. A lack of overlap between the two treatment groups 
interfered with the analyses performed, therefore no definite conclusions could be drawn. 
Confounding by indication is an important issue that needs to be accounted for in future 
analyses of the comparative effectiveness of two biologic agents in observational studies. 
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Chapter 4. New developments in monitoring JIA 
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ABSTRACT
Objective. To evaluate the reliability of a mannequin-format patient-reported joint count in 
Juvenile Idiopathic Arthritis (JIA), and to detect changes in agreement at a second visit.
Methods. JIA patients aged 12-21 were asked to mark joints with active arthritis on a 
mannequin before their regular clinic visit. The physician then performed a joint count 
without having seen the patient’s assessment. Agreement between scores of physician and 
patient-reported joint counts was assessed using Intraclass Correlation Coefficient (ICC). 
Kappa statistics were used to assess reliability of scoring individual joints.
Results. 75 JIA patients were included. In general patients had a low number of active 
joints (median 1 joint, indicated by the physician). ICC was moderate (0.61), kappas ranged 
from 0.3-0.8. At the second visit, kappas were similar; the ICC was 0.19. When a patient 
scored 0 joints, the physician confirmed this in 93-100%. When the patient marked ≥ 1 
joints, the physician confirmed arthritis in 59-76%. Sensitivity to change was moderate.
Conclusion. Agreement between physician and patient on the number of joints with active 
arthritis was reasonable. Untrained patients tended to overestimate the presence of arthritis 
when they marked active joints on a mannequin-format joint count. When the patient 
indicated absence of arthritis, the physician usually confirmed this. As the agreement did 
not improve at follow-up, future research should focus on the possibility of achieving this 
through training. For now, the patient-reported joint count cannot replace the physicians’ 
joint count in clinical practice; it may be used in epidemiological studies with caution.
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INTRODUCTION
Juvenile idiopathic arthritis (JIA) is one of the most common chronic auto-immune diseases 
in childhood, affecting 47-87 per 100.000 children, which requires regular monitoring.80 175 
One method of monitoring is gathering information from patients themselves, through a 
patient-reported outcome (PRO) measure. PROs can be a useful tool to observe disease 
activity between clinic visits, increase patient involvement and also aid in epidemiological 
surveys. Therefore they are increasingly being developed and applied.176-178
One of these PROs is the self-reported joint count, the use of which has extensively been 
investigated in studies in patients with RA. Conclusions on agreement between patient-
reported and physician-reported joint counts are mixed. Results vary between good and 
poor to moderate agreement. A mannequin format, in which patients indicate which joints 
are inflamed on a figure, generally yields higher scores than a text format.179
Only two studies have been performed investigating self-reported joint counts in JIA, 
one using a text format and one using a mannequin format.180 181 On the text-format 
joint count agreement between physicians and patients/parents on individual joints was 
moderate, the investigators therefore concluded that this joint count could not replace 
the physician’s assessment.181 The mannequin format was used in a study investigating 
whether patients could discriminate active from inactive disease; patients seldom 
missed arthritis but frequently overestimated disease activity. The overall agreement 
and the agreement on individual joints were not described. Both these studies were of 
cross-sectional nature, only describing the first time patients were confronted with a 
joint count.
The aim of the current study was to evaluate the agreement between physician and self-
reported active joint counts by JIA patients using a mannequin and to determine whether 
the agreement between the physician and the patient changed over time.
METHODS
Data were collected prospectively at the JIA-outpatients clinic at the Erasmus MC, a 
tertiary referral center in Rotterdam, The Netherlands. All consecutive JIA patients aged 
12-21 fulfilling the ILAR criteria who visited the clinic between February 2013 to February 
2014 were invited to participate.1 The study was performed according to regulations of the 
local ethical committee. At a regular clinic visit, patients were first asked to mark the joints 
they felt to have active arthritis on a figure. Active arthritis was defined as swelling within a 
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Name: ..………………………… 
Date: …………...………………. 
Mannequin joint count: which joints are currently inflamed?
Please mark the joints where the arthritis is currently active (where there is inflammation) on 
the mannequin below. 
A joint is considered to be inflamed when at least two of the following criteria are present: 
- pain 
- swelling 
- limited motion. 
Note: if a joint is always restricted, but none of the other two features are present, you don’t 
need to mark it. 
            
 I have no complaints, none of my joints are inflamed. 
knee 
RIGHT 
SI joint (connection of pelvis to spine) 
neck 
jaw
ankle 
hip 
distal phalanx 
toes
wrist 
shoulder 
knuckle 
middle phalanx
collarbone joint 
elbow 
LEFT
Figure 1 Mannequin joint count form as filled out by the patients (translated from Dutch)
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joint, or limited range of motion accompanied by joint pain or tenderness.1 The definition of 
active arthritis was provided on the figure (figure 1). 
No additional information was given. After the patient had filled out the mannequin, the 
pediatric rheumatologist (PhvP) performed a formal joint count, without having seen the 
patient’s assessment. This practice continued during follow-up, giving patients an indirect 
feedback moment during each following visit and minimum education to see how the 
agreement would change naturally over time. The following joints were taken into account: 
temporomandibular, cervical spine, shoulder, sternoclavicular, elbow, wrist, MCP’s, PIP’s 
and DIP’s (analyzed both separately and as a unit(hand)), back, SI joints, hip, knee, ankle, 
MTP’s and phalanges of the foot (analyzed both separately and as a unit (foot)). The 
acromioclavicular and subtalar joints were not evaluated, because they were judged to be 
too difficult to assess.  
Additionally, patients were asked to fill out a Child Health Assessment Questionnaire 
(CHAQ),182 including Visual Analogue Scales (VAS, ranging from 0-100) for wellbeing and 
pain. Demographic data and data on disease history were collected from the charts. 
Statistical analysis
For both the first as the second visit, agreement was assessed in various ways. For level 
of agreement on the number of active joints a two-way random single measure absolute 
agreement ICC was used. We used the following interpretation for Cohen’s kappa and ICC: 
<0.40=poor, ≥0.40–0.60=moderate, >0.60-0.80=substantial and >0.80=good reliability.183 
Kappa statistics were used for calculating agreement on individual joints. Additionally, 
the overall agreement and the positive/negative agreement proportion per joint were 
computed.184 Overall agreement is the percentage of joints that were scored identically 
by physician and patient. The positive agreement is the number of joints that were scored 
as being active by both physician and patient, divided by the average number of joints 
scored positive. The negative agreement is the number of joints scored as inactive by both 
parties, divided by the average number of joints scored negative. Negative agreement was 
expected to be high, as most joints were expected to be scored inactive.  
We calculated that a sample size of 59 subjects with 2 observations per subject achieves 
80% power to detect an ICC of 0.6 (ρ1) when the ICC was assumed to be at least more 
than 0.35 (ρ0) using an F-test with a significance level of 0.05.185  
To evaluate whether patients could discriminate between inactive and active arthritis, taking 
the physician joint count as reference, the (positive and negative) predictive values of a 
patient scoring 0 active joints or >0 active joints were calculated. In addition, sensitivity and 
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specificity were calculated, enabling us to compare our results to previous research done 
on this subject.  
For the assessment of construct validity, Spearman’s rho correlation coefficient was 
calculated to test the correlation between VAS scores and the number of affected joints 
indicated on the two joint counts. To test the difference between the various correlation 
coefficients over time the Fisher r-to-z transformation was used. Correlation coefficients 
were interpreted as follows: ≤0.3=weak, 0.4-0.6=moderate, ≥0.7=strong. 
Absolute and proportional changes in total joint count scores between the first and 
the second visit were calculated for both the patient-reported and physician-reported 
joint counts. Consequently, sensitivity to change was assessed using two kinds of 
coefficients.186 Firstly, Pearson’s correlation coefficient was used to assess the correlation 
between absolute changes in patient and physician-reported joint counts, for the total 
group of patients. In addition the ICC of the change scores was calculated. Secondly, 
patients were divided in three groups (improved, stable and worsened), according to the 
change in the physician-reported joint counts. Standardized response means (SRM) were 
calculated for the groups that improved or worsened, based on the mean proportional 
change in the patient-reported joint counts, and its standard deviation. 
Descriptive statistics were reported as absolute number, median with IQR or mean with 
range as appropriate. Data were analyzed using the IBM SPSS statistics for windows 
package, version 21.0 (Armonk, NY: IBM Corp.). 
RESULTS
Patient characteristics
Of 80 patients who agreed to participate, only 75 could be used for the analysis of 
agreement, because in 5 patients the physician did not perform a full formal joint count. 
Characteristics of all 75 consecutive patients are shown in table 1. 
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Table 1 Patient and disease characteristics at the first visit (n=75) 
Characteristics
Age (in years), median (IQR) 16.0 (14.7-17.8)
Disease duration (in years), median (IQR) 3.7 (0.9-8.7)
Female, n (%) 54 (72)
JIA category, n (%)
  Systemic 5 (7)
  Oligoarticular persistent 17 (23)
  Oligoarticular extended 7 (9)
  Polyarticular RF+ 12 (16)
  Polyarticular RF- 18 (24)
  Psoriatic arthritis 9 (12)
  Enthesitis-related arthritis 6 (8)
  Undifferentiated arthritis 1 (1)
Laboratory blood tests, n (%)
  ANA+ 27 (36)
  HLA-B27+ 13 (17)
  RF+ 12 (16)
  CCP+ 11 (15)
History of uveitis, n (%) 11 (15)
Disease activity Variables, median (IQR)
  ESR date visit 9 (3-23)
  CHAQ date visit 0.375 (0.000-0.875)
  VAS physician 8 (0-28)
 
IQR=interquartile range; JIA=juvenile idiopathic arthritis; RF=rheumatoid factor; ESR=erythrocyte sedimentation rate; 
CHAQ=Childhood Health Assessment Questionnaire; VAS=visual analogue scale.
None of the patients refused to participate. Of 53 patients a second measurement was 
present. The inferences on the second visit are discussed in a separate paragraph below. 
Patients with a second visit did not differ from patients without a second visit with regard 
to disease activity at the first visit. Patients had a median age of 16 years (IQR 15-18) and 
an average disease duration of 3.7 years (IQR 0.9-8.7). Overall disease activity was low, 
both physician and patients indicated low disease activity on a VAS (median <20). The 
distribution of JIA categories was representative for an outpatient clinic patient population 
within these age ranges. 
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Agreement at the first measurement
The median number of active joints scored by the physician was 1 joint (IQR 0-3). The 
patients scored a median of 2 joints (IQR 1-5). The ICC was moderate with a value of 0.61 
(95% CI: 0.43-74). Adolescents (aged 12-17 years, n=44, ICC: 0.69 (95% CI: 0.48-0.83)) 
appeared to agree more with their physician than young adults (aged 18-21 years, n=31, 
ICC: 0.45 (95% CI: -0.14-0.69), although not statistically significant. Comparable estimates 
were found for patients with short disease duration (≤1 year, n=19) and patients with longer 
disease duration (n=56) with respective ICC’s of 0.69 (95% CI: 0.35-0.87, n=19) and 0.45 
(95% CI: 0.21-0.63, n=56). Agreement between patients and physicians on individual joints 
is reported in table 2, kappa values ranged from 0.3-0.7. 
Table 2 Agreement on individual joints at the first visit (n=75) 
Joint Kappa 
value
Overall 
agreement 
in %
Positive 
agreement 
in % 
Negative 
agreement 
in % 
Total no. of 
times joint 
is scored 
positive by 
physician 
(n=75) (%)
Total no. of 
times joint 
is scored 
positive by 
patients 
(n=75) (%)
Shoulder left 0.38 89 43 94 4(5) 10(13)
Shoulder right 0.28 89 33 94 5(7) 7(9)
Elbow left 0.58 93 62 96 7(9) 6(8)
Elbow right 0.64 95 67 97 5(7) 7(9)
Wrist left 0.68 89 75 93 15(20) 17(23)
Wrist right 0.65 88 73 92 17(23) 016(21)
Hand left 0.44 85 48 91 9(12) 14(19)
Hand right 0.39 81 44 92 12(16) 16(21)
Hip left 0.57 95 60 97 4(5) 6(8)
Hip right 0.57 95 60 97 4(5) 6(8)
Knee left 0.51 79 65 85 18(24) 28(37)
Knee right 0.41 75 56 82 15(20) 28(37)
Ankle left 0.47 87 55 92 9(12) 13(17)
Ankle right 0.34 88 40 93 5(7) 10(13)
Foot left 0.31 95 36 99 5(7)  6(8)
Foot right 0.47 95 50 97 4(5) 4(5)
 
Individual hand and foot joints, temporomandibular joints, cervical spine, sternoclavicular joints and the SI joints were 
omitted due to distorted or negative kappa values.
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Overall agreement was generally around 90% or higher. The agreement for the knees was 
lower; 75% for the right knee and 79% for the left knee. Differences in agreement between 
the left and right hand side occurred in other joints too. Positive agreement was generally 
poor to reasonable (33-75%, lowest scores for the shoulders) whereas negative agreement 
was excellent (82-99%, lowest scores for the knees). This last finding was expected, as 
disease activity was low and therefore most joints would be negatively scored. 
In table 3 scores are compared between patients’ and physicians’ results of the first time 
they scored the mannequin, depending on the number of active joints scored: 0, 1, 2-4, 
5-10, or more than 10 joints.
Table 3 Agreement on number of joints between physician and patient at the first visit 
Physician JC
Patient JC
0 joints 1 2-4 5-10 More than 
10 
Total JC 
patient
0 joints 18 0 0 0 0 18
1 7 7 4 0 0 18
2-4 7 5 6 1 1 20
5-10 0 2 2 3 1 8
More than 10 0 0 3 4 4 11
Total JC physician 32 14 15 8 6 75
 
Agreement is indicated by the shaded areas. JC=joint count
In all five groups patients mostly overestimated the number of active joints. 
Underestimation of the total number was less common. When over or underestimation 
occurred, this remained confined to the closest categories of number of joints. 
The presence of arthritis was indicated by 14 of 31 patients where the physician found no 
arthritis. The knees were the most marked joints in this group (n=11). The VAS pain of these 
patients was higher than VAS pain of patients who agreed with the physician on inactive 
disease (median VAS pain 18 vs 0, p=0.005, Mann-Whitney-U). Possible explanations for 
the overestimation were: residual complaints after recent arthritis/structural damage in 5 
patients, pain after high physical activity in 4 patients, enthesitis/tendinitis in 2 patients. 
Three patients had arthritis within two months after this visit, and one patient did have 
arthritis on ultrasound evaluation. In these three patients, the physician may have missed 
arthritis on examination.
Taking the physician’s joint count as a reference, the predictive value of a patient scoring 
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0 active joints was 100%. This means that when a patient scored inactive disease, the 
physician generally indicated there was no arthritis (negative predictive value). When a 
patient did score a number of active joints, only in 76% the physician agreed there was 
arthritis present (positive predictive value). Sensitivity and specificity were 100% and 
56%, respectively. Sensitivity, specificity and negative and positive predictive value for 
discriminating inactive from active disease did not change when only the most affected 
joints (shoulders, elbows, wrists, hands, hips, knees, ankles and feet) were used. 
Construct validity
We performed Spearman correlations to test the correlations between the several VAS’ 
and the joint counts. The physician-reported joint count correlated very well with the 
patient-reported joint count and the VAS physician (both a Spearman’s rho of 0.80 and 0.79 
respectively), but less well with the VAS wellbeing of the patient (Spearman’s rho of 0.61 
and 0.65). The patient-reported joint count correlated moderately with the VAS wellbeing 
(Spearman’s rho of 0.49) and with the VAS pain (Spearman’s rho of 0.64). 
Longitudinal agreement and sensitivity to change
At the second visit, the median number of active joints reported was 0 (IQR 0-3) joints for 
physicians and 2 (IQR 0-6) joints for patients. The ICC that was estimated was 0.192 (95% 
CI: -0.051 to 0.424). The confidence interval indicated a possible negative value of the 
ICC, which was caused by a large variation in between and within subject variability. The 
interpretation of this ICC can only be that there is very low agreement.187 We suspected 
this was caused by 4 subjects a with a very large discordance between physician and 
mannequin joint count. These patients all scored 30 or more active joints, while the 
physician scored 0-10 joints. The ICC with these subjects removed was still low; 0.30 (95% 
CI: 0.04-0.53). Kappa values were similar during follow-up compared to the first time of 
marking active joints on the mannequin. Negative predictive value for the second visit was 
93%, positive predictive value was 59%. Sensitivity was 96% and specificity 45%.
At the second visit, the physician indicated inactive disease in 29 patients, 16 of which did 
not agree. This is a slightly higher percentage than at the first visit. The negative predictive 
value was slightly lower than at the first visit, because1 patient indicated inactive disease 
where the physician did find arthritis on physical examination. This patient indicated to have 
no complaints. The physician joint count did indicate improvement from the previous visit, 
however the disease was not fully inactive.
At the second visit we found the patient-reported joint count to have a stronger correlation 
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(p<0.05) with VAS wellbeing (0.75) and to have a weaker correlation with physician joint 
count (0.36) compared with the first visit (0.49 and 0.8 respectively). Other correlations did 
not change significantly during follow-up. 
The absolute changes in physician and patient-reported joint counts were moderately 
correlated (Pearson’s rho: 0.436, p=0.001). The ICC for the change-scores was 0.305 (95% 
CI: 0.051-0.526). The SRM for the proportional change in patient-reported joint counts was 
moderate (0.67) in patients who worsened according to the physician. The SRM for patients 
who improved according to their physician was low (0.23). Therefore the patient-reported 
joint count appeared to be most sensitive to change for patients whose disease became 
more active over time.
DISCUSSION
This study is one of the first to investigate whether a patient-reported joint count based 
on a mannequin format can be used as a PRO in JIA. The overall agreement between the 
physician and the patient total joint count was found to be moderate (ICC 0.61) the first time 
patients filled out the mannequin. Agreement on individual joints was moderate to good, 
depending on the joint (kappa 0.3-0.7). At the second visit the kappa values stayed stable, 
however the ICC decreased during follow-up. Construct validity was high, however the 
second time patients filled in the joint count, the correlation to general wellbeing scores and 
pain was higher and the correlation to the physician joint count was lower than the first time. 
Patients tended to overestimate the presence of arthritis. A patient-reported joint count 
indicating full absence of arthritis nevertheless proved to be highly reliable. These results 
were consistent over time. Sensitivity to change over time proved moderate, and was 
highest in patients whose disease worsened.
Two other studies have investigated patient-reported joint counts in JIA patients. The first 
one tested a text-format joint count in a very large group of patients and parents of patients 
with JIA.181 In a conference abstract, it reported agreement on individual joints ranging 
from 0.15 for the shoulder to 0.69 for the cervical spine. In general, these kappa values are 
comparable to the ones found in the present study. The most frequently scored joints often 
had the highest kappa values. 
The second study investigating patient-reported joint counts in JIA used the same 
mannequin format as the present study.180 The study used this format, however it focused 
on the question whether patients could distinguish between active and inactive disease, 
and did not evaluate agreement on individual joints or total joint scores. Additionally it did 
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not focus solely on patients, but investigated patient and parent assessment. Sensitivity 
was comparable and specificity slightly lower than the specificity we found. With regard to 
the ability of patients to discriminate between inactive and active disease, the authors reach 
the same conclusion: patients did not miss arthritis, however overestimated the presence of 
it frequently. 
Overall agreement has not been investigated in studies with JIA patients. In adult RA 
patients this has been done and the ICCs of RA patients with their physicians were 
comparable to the ICC found in the present study.179 It has to be kept in mind however that 
ICCs do not generalize well from one study to another, because they are strongly influenced 
by the variance in the population it is measured in.
RA and JIA patients have been shown to overestimate their disease activity compared to 
the physician’s estimation also on other disease activity scales.188 189 The reason for this 
overestimation is not clear but it has been suggested that high functional disability and pain 
might influence this discordance.179 189 Also in this study, patients who agreed with their 
physician on the inactivity of the disease had lower pain scores than patients who indicated 
disease activity where the physician did not. There was no significant difference in CHAQ 
scores between the two groups. Patients may have difficulty distinguishing pain caused 
by active arthritis from pain as a result of other causes. Although radiological joint damage 
is relatively uncommon in the pediatric population, structural damage could be a cause of 
pain, as could muscular strain.36 190 Persistent pain and the subsequent sensitization of the 
central nervous system have been proposed to cause a lowering of the pain threshold and 
altered pain perception in JIA patients.191 192 This could be an alternative explanation for 
reported pain uncorrelated to disease activity indicated by the physician. It could also partly 
explain the high correlation between the patient-reported joint count and the VAS pain.
Before considering implementation of a patient-reported joint count, the reasons for 
overestimation should be more thoroughly investigated. The purpose of the use of a 
patient-reported joint count in clinical practice also has to be clearly defined. Armbrust et 
al. used the joint count as a general assessment of disease activity, which only makes the 
distinction between active and inactive disease. In that respect, we found that the patient-
reported joint count predicts the activity as marked on the physician joint count better than 
the VAS for general wellbeing does. If the patient-reported joint count would be used for 
this purpose, one could consider only using the most affected joints, as the discriminative 
performance did not change when only these joints were taken into account. For this 
purpose it is encouraging, that even without training, patients can generally be trusted 
when they indicate inactive disease. 
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The other option is to use the joint count not only to discriminate between active and 
inactive disease, but to actually monitor disease activity over time. The possibility to 
monitor their disease activity, may stimulate patients’ self-management and their adherence 
to therapy.193 For this purpose, it is reassuring that the sensitivity to change was highest 
in the group that worsened. In addition, although the agreement on overall and individual 
joints was only moderate, we have to keep in mind that two physicians examining the 
same patient agree to the same extent (moderately) on the presence of active or inactive 
disease.194 195 Still, ideally we would like to improve the absolute agreement between 
physician and patient, so that all changes in disease activity can be monitored accurately. 
This could be done by means of a training program. Training RA patients to examine their 
own joints had a positive effect on the reliability of patient-reported joint counts.196 
The way the mannequin should be filled out is also a question to be answered. The addition 
of a “doubt” option, did not seem to add to the discriminative power of the mannequin, but 
this may change with training.180 Also one could question whether the patient would have 
to mark every joint as the patients did in the study by Armbrust et al., as the results with 
regard to predictive value and sensitivity and specificity did not differ much from those we 
found in the current study. Only marking the active joints seems to be sufficient, and is less 
time consuming.
For the use in epidemiological surveys the agreement found seems to be acceptable, 
although one should realize that the obtained estimate of disease activity is not flawless. In 
this setting a more general indication of disease activity is sufficient, as the main objective 
is to describe disease status on a population level and no individual decisions are based on 
these data. 
For generalization of the results from the present study it has to be taken into account, that 
the JIA population in this study was 12 years and older and sampled at a tertiary referral 
clinic. Furthermore, consecutive (and therefore mostly already treated) patients visiting our 
clinic were included, resulting in a fairly homogeneous population with regard to disease 
activity, which was generally low. 
When interpreting the results from this study, it has to be kept in mind that the examination 
by the physician is not flawless either.194 195 Although imaging techniques are increasingly 
being applied in pediatric rheumatology, for most modalities no reference standards are 
available yet. So, even though it seems that ultrasound and other techniques could be of 
help in identifying subclinical arthritis, the scoring systems used still need more validation 
before they can be used extensively to guide clinical practice.197 In future studies, in 
addition to including a training program, also multiple physicians could assess the patients, 
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so that a more reliable physician joint count could be obtained.
Because they received no training, patients may have made mistakes while filling out the 
joint count. Despite the mannequin clearly stating which side was left and which was right, 
some patients might have filled in the form the wrong way round, thereby causing an overall 
lower positive agreement. In addition, patients may not have been aware of the existence of 
referred pain, and may have indicated the wrong joint to be active (for instance in the case 
of the hip-knee).
The ICC of the second measurement was much lower than the ICC of the first 
measurement. We provided an estimate for the ICC without four outliers, because the 
ICC that was estimated for the whole group was unreliable. For an unknown reason at 
the second measurement there were more outlying values, causing the within-subject 
variability to be disproportionate to the between-subject variability. The correlation between 
the physician joint count and the patient-reported joint count also changed. The patient-
reported joint count correlated more with the VAS pain. Apparently these patients were 
more likely to fill out the mannequin, marking the joints with pain instead of those with 
active arthritis.
In conclusion, agreement between physician and patient-reported joint counts was 
moderate. Especially a joint count of zero by the patient was predictive of the joint count 
of the physician. This PRO can therefore not fully replace the physician’s joint count at a 
regular clinical visit.
The mannequin joint count could be used to aid in epidemiological surveys, as it gives a 
reasonable estimate of the true number of active joints. Before being implemented in a 
clinical setting, more research is needed to determine whether agreement can be improved 
by training and whether the patient-reported joint count is then also better able to detect 
changes over time.
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ABSTRACT 
Introduction. Chronic inflammation combined with glucocorticoid treatment and 
immobilization puts juvenile idiopathic arthritis (JIA) patients at risk of impaired growth and 
reduced bone mineral density (BMD). Conventional methods for evaluating bone age and 
BMD are time-consuming or come with additional costs and radiation exposure. In addition, 
an automated measurement of bone age and BMD is likely to be more consistent than 
visual evaluation. In this study, we aimed to evaluate the feasibility of an automated method 
for determination of bone age and (cortical) bone mineral density (cBMD) in severely 
affected JIA patients. A secondary objective was to describe bone age and cBMD in this 
specific JIA population eligible for biologic treatment.
Methods. In total, 69 patients with standard hand radiographs at the start of etanercept 
treatment and of calendar age within the reliability ranges (2.5 to 17 years for boys and 
2 to 15 years for girls) were extracted from the Dutch Arthritis and Biologicals in Children 
register. Radiographs were analyzed using the BoneXpert method, thus automatically 
determining bone age and cBMD expressed as bone health index (BHI). Agreement between 
measurements of the left- and right-hand radiographs and a repeated measurement of the 
left hand were assessed with the intraclass correlation coefficient (ICC). Regression analysis 
was used to identify variables associated with Z-scores of bone age and BHI.
Results. The BoneXpert method was reliable in the evaluation of radiographs of 67 
patients (radiographs of 2 patients were rejected because of poor image quality). 
Agreement between left- and right-hand radiographs (ICC = 0.838 to 0.996) and 
repeated measurements (ICC = 0.999 to 1.000) was good. Mean Z-scores of bone 
age (−0.36, P = 0.051) and BHI (−0.85, P < 0.001) were lower compared to the healthy 
population. Glucocorticoid use was associated with delayed bone age (0.79 standard 
deviation (SD), P = 0.028), and male gender was associated with a lower Z-score of BHI 
(0.65 SD, P = 0.021).
Conclusions. BoneXpert is an easy-to-use method for assessing bone age and cBMD in 
patients with JIA, provided that radiographs are of reasonable quality and patients’ bone 
age lies within the age ranges of the program. The population investigated had delayed 
bone maturation and lower cBMD than healthy children.
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INTRODUCTION
Chronic inflammatory diseases such as juvenile idiopathic arthritis (JIA) can influence bone 
development. Continuous exposure to inflammatory cytokines, together with glucocorticoid 
therapy, affects bone formation. This combined with decreased physical activity and 
pubertal delay puts JIA patients at risk of impaired growth and reduced bone mineral 
density (BMD).198 199 The pediatric rheumatologist needs to be aware of both the bone age 
and the BMD of JIA patients in order to take this into account in choosing the best therapy.
The assessment of bone age is usually made using the Greulich and Pyle atlas.200 Dual-
energy X-ray densitometry (DXA) is the most commonly used method of assessing BMD.201 
Recently, BoneXpert was developed, bringing back the use of radiogrammetry, one of 
the oldest methods for assessing BMD.202 This new digital X-ray radiogrammetry (DXR) 
method combines the assessment of bone age with a radiogrammetric measurement of 
(cortical) BMD (cBMD) of the second to fourth metacarpal joints. The cBMD is expressed 
by BoneXpert as a Bone Health Index (BHI), in which cBMD is corrected for size. The 
BoneXpert method makes use of conventional radiographs of the hand, thereby making 
it attractive for pediatric use because of its simple application, relatively low costs203 and 
lower effective radiation dose compared with other methods. Normative data are available 
because the method was validated in a healthy pediatric population.204 205 The application 
has not been tested in JIA patients, in whom long-standing inflammation of the wrist can 
lead to growth abnormalities and destruction of the bone, thereby possibly complicating the 
assessment of bone age and bone health. Utilization of the Dutch Arthritis and Biologicals 
in Children (ABC) register provides a unique way to evaluate this method in a severely 
affected JIA population eligible for biologic treatment. Our objective in this study was to 
evaluate the feasibility of an automated method for the determination of bone age and 
cBMD in severely affected JIA patients. A secondary objective was to describe bone age 
and cBMD in this specific JIA population eligible for biologic therapy.
METHODS
Patient selection
Patients from two centers participating in the Dutch ABC register who were prospectively 
enrolled between 1999 and 2012 were eligible for this study. Biologic-naïve patients were 
selected, starting etanercept, of whom a standard radiograph of both hands and wrist in the 
posteroanterior view was made at the start of treatment (that is, 1 year before to 3 months 
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after starting etanercept). The participants’ calendar age had to be within the reliability 
range of the BoneXpert method (that is, 2.5 to 17 years for boys and 2 to 15 years for girls). 
Ultimately, the radiographs of 69 patients were eligible for automatic analysis by BoneXpert. 
A flowchart of the patient selection is provided in Additional file 1.
Clinical data collection
The ABC register, a multicenter, prospective, observational study, aimed to include all 
children diagnosed with JIA in whom biologic treatment was being initiated. Informed 
consent was obtained from all patients older than 12 years of age, in addition to the parents 
or guardians of all patients younger than 16 years of age. The study protocol was centrally 
approved by the Medical Ethics Committee of the Erasmus MC, and local permission was 
obtained from the ethical bodies in the two other participating hospitals (Academic Medical 
Center and Reade). From the ABC register, patient and disease characteristics were collected 
at baseline, including data on disease activity from the following sources: physician’s global 
assessment of disease activity on a visual analogue scale (VAS) (range from 0 to 10 cm, with 
0 being the best score); Childhood Health Assessment Questionnaire (CHAQ) (range from 0 to 
3, with 0 being the best score) by patients and/or their parents, including global assessment 
of well-being and pain on a VAS (range from 0 to 10 cm, with 0 being the best score); number 
of joints with active arthritis and joints with limited motion; and erythrocyte sedimentation rate 
(ESR). Using these variables, the Juvenile Arthritis Disease Activity Score in 10 active joints 
(JADAS-10) was calculated. The scale from 0 to 40 represents the simple linear sum of the 
scores of the physician and parent and/or patient global assessment, an active joint count 
(up to 10 joints) and a normalized value of ESR to a 0 to 10 scale.23 
Image analysis
The stand-alone Windows product of BoneXpert (BoneXpert Version 2.1.0.12; Visiana, Holte, 
Denmark) was used to analyze the hand radiographs. BoneXpert automatically generates 
the following outcome variables: (calendar) age, bone age based on Greulich and Pyle, 
Z-scores of bone age (compared with a healthy reference population),206 BHI and Z-scores 
of BHI.202 BHI is based on the cortical thickness (T) of the three middle metacarpals. In 
the construction of BHI, metacarpal width (W) and length (L) are also incorporated to 
compensate for the high variation in stature of growing children, as expressed in the 
following formula:202
BHI = π T (1 − T/W) / (LW)0.33
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The radiographs included the complete hand and wrist joints of both the left and right 
sides. All images were collected as a DICOM files from three different centers. If the 
radiographs were available only on conventional films, they were digitized with a Sierra 
Plus scanner (VIDAR Systems, Herndon, VA, USA) and converted to a 300-dpi DICOM 
file. During the analytical process in BoneXpert, possible error messages were noted. The 
left-hand radiograph was uploaded and analyzed in BoneXpert a second time in order to be 
able to determine its test–retest reliability.
Statistical analysis
Descriptive statistics are reported in terms of absolute numbers, median and interquartile 
range (IQR) or mean and standard deviation (SD). The single measure intraclass correlation 
coefficient (ICC) and Bland-Altman plots were used to determine the agreement of the 
outcome variables of the BoneXpert method.
To determine whether the Z-score of bone age and the Z-score of BHI were different from 
those in the healthy population, a one sample t-test was used. Univariate linear regression 
analysis was performed to identify variables associated with the Z-score of bone age and 
the Z-score of BHI. Because of the small sample size, only a limited number of variables 
could be tested. The prespecified variables entered into the univariate model were age, sex, 
JADAS-10, disease duration and use of systemic glucocorticoids, defined as “ever use” or 
“never use”. All analyses were performed with SPSS version 20 software (SPSS, Chicago, 
IL, USA).
RESULTS
Feasibility
A standard hand radiograph of both hands was available for 69 patients starting etanercept 
treatment. The calculations of bone age and BMD by BoneXpert took a few seconds. 
BoneXpert rejected the radiographs of two patients because of poor image quality, resulting 
in available BoneXpert outcomes of 67 patients. In three patients, an error message 
indicating uncertainty of bone age was given by BoneXpert; these patients had calendar 
ages within the BoneXpert age ranges (2.5 to 17 years for boys and 2 to 15 years for girls), 
but their bone age came out of the analysis to be outside these age ranges, resulting in an 
error message. However, BoneXpert produced all outcome variables in these three patients, 
except for a missing Z-score of BHI in one patient.
The ICC of the agreement of all outcome variables between the left and right hand 
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radiographs varied from 0.838 to 0.996. Bland-Altman plots of the agreement between 
left and right hand radiographs are provided in Additional file 2. The ICC of the agreement 
of repeated measurements of all left-hand radiographs on Z-scores of bone age and BHI 
varied from 0.999 to 1.000.
Patient and disease characteristics
Patient and disease characteristics of the 67 patients who could be evaluated with 
BoneXpert are presented in Table 1. Disease activity of these patients was moderate to 
severe at the time the hand radiographs were made (mean JADAS-10 score = 21 ± 5).
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Table 1 Patient and disease characteristics at start etanercept 
Baseline characteristics n=67
Female, n (%) 36 (54)
Age at onset JIA in years, mean (±SD) 8.5 (± 3.8)
Age at start etanercept, mean (±SD) 11.0 (± 3.1)
JIA disease duration before start etanercept in years, median (IQR) 1.8 (1.1-3.8)
ANA positive, n (%) 14 (21)
Category JIA, n (%)
  Systemic JIA 4 (6)
  Polyarticular RF negative 27 (40)
  Polyarticular RF positive 9 (13)
  Oligoarticular extended 18 (27)
  Psoriatic arthritis 5 (8)
  Enthesitis related arthritis 4 (6)
Previously used medications, n (%)
  Systemic prednisone 32 (48)
  Methotrexate 66 (99)
  DMARD other than MTX 14 (21)
Concomitant co-medication at start biological, n (%)
  Systemic prednisone 26 (39)
  Methotrexate 64 (96)
  DMARD other than MTX 2 (3)
Disease activity parameters at baseline, median (IQR)
  VAS physician (0-10 cm; 0 best score) 6.5 (5.0-7.4)
  CHAQ total (0-3; 0 best score) 1.50 (0.90-2.10)
  VAS pain (0-10 cm; 0 best score) 6.3 (2.4-7.7)
  VAS wellbeing (0-10 cm; 0 best score) 6.1 (3.2-7.4)
  Active joints 11 (7-18)
  Limited joints 6 (3-13)
  ESR 11 (5-29)
JADAS-10 (0-40), mean (±SD) 21 (± 5)
Ever hand or wrist involvement, n (%) 64 (96)
Z-score of BA, mean (±SD) -0.36 (± 1.44)
Z-score of BHI, mean (±SD) -0.85 (± 1.15)*
 
* significantly different from 0 at the p < 0.05 level.
JIA=juvenile idiopathic arthritis; ANA=anti-nuclear antibodies; RF=Rheumatoid Factor; MTX=methotrexate; 
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DMARD=disease modifying anti-rheumatic drug; VAS=visual analogue scale; CHAQ=child health assessment 
questionnaire; ESR=erythrocyte sedimentation rate; JADAS=juvenile arthritis disease activity score; BA=Bone Age; 
BHI=Bone Health Index; Z-score=standard deviation score compared with healthy population.
Bone maturation was delayed compared with the normal population, but not significantly 
(mean Z-score of bone age = −0.36 (±1.44), P = 0.051). Bone maturation was greatly 
impaired (below −2 standard deviations (SD)) in eight patients, and three patients had highly 
accelerated bone maturation (above +2 SD). The mean Z-score of bone age was strongly 
influenced by one patient with a very high bone age (+5 SD), who had long-standing severe 
polyarticular enthesitis-related arthritis. When this patient was left out of the analysis, the 
mean bone maturation of the remaining patients was significantly delayed (mean Z-score of 
bone age = −0.45 (±1.28), P = 0.008). Compared with the normal population, the cBMD was 
lower (mean Z-score of BHI = −0.85 (±1.15), P < 0.001). Ten patients had a Z-score of BHI 
less than −2 SD.
Regression analysis
A univariate linear regression analysis of bone age and BHI was performed to investigate 
which variables were associated with the Z-score of bone age and the Z-score of BHI 
(Tables 2 and 3). Glucocorticoid use was associated with a lower Z-score of bone age (0.79 
SD, P = 0.028). Only male gender was significantly associated with the Z-score of BHI; 
being a boy lowered the Z-score of BHI of 0.65 points (P = 0.021).
Table 2 Univariate regression coefficients of baseline variables with the Z-score of bone age 
Baseline variable Estimated beta 95% CI p-value
Age 0.024 -0.116 – 0.164 0.736
Male gender -0.190 -0.921 – 0.541 0.605
Disease duration -0-030 -0.184 – 0.1234 0.694
CHAQ -0.021 -0.577 – 0.534 0.940
JADAS-10 0.008 -0.065 – 0.081 0.830
Ever use of systemic glucocorticoids -0.790 -1.492 – -0.088 0.028
 
CHAQ=child health assessment questionnaire; JADAS=juvenile arthritis disease activity score; BHI=Bone Health Index; 
Z-score=standard deviation score compared with healthy population.
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Table 3 Univariate regression coefficients of baseline variables with the Z-score of BHI 
Baseline variable Estimated beta 95% CI p-value
Age 0.067 -0.024 – 0.159 0.147
Male gender -0.649 -1.197 – -0.102 0.021
Disease duration 0.040 -0.080 – 0.160 0.505
CHAQ 0.008 -0.420 – 0.436 0.971
JADAS-10 -0.036 -0.094 – 0.023 0.224
Ever use of systemic glucocorticoids -0.340 -0.904 – 0.224 0.233
 
CHAQ=child health assessment questionnaire; JADAS=juvenile arthritis disease activity score; BHI=Bone Health Index; 
Z-score=standard deviation score compared with healthy population. 
DISCUSSION
Application of the BoneXpert automated method for assessing bone age and cBMD in 
JIA patients proved to be feasible. Its use was easy and fast, and the program rejected 
few radiographs. The Z-scores of bone age and BHI were found to be impaired in the 
population of JIA patients evaluated in this study compared with a healthy population.
In addition to its validation in a healthy pediatric population,204 205 bone age measurement 
using BoneXpert has been evaluated in pediatric patients of short stature, children with 
precocious puberty and patients with congenital adrenal hyperplasia.207-209 In these patient 
groups, in whom bone maturation is likely to be affected, the BoneXpert bone measurement 
method proved feasible. We had anticipated a higher number of rejections by the BoneXpert 
program relating to growth abnormalities, periarticular abnormalities and deviation of bone 
age commonly found in severely affected JIA patients.190 210-212 Unexpectedly, BoneXpert 
rejected no radiographs because of these abnormalities. Besides the two rejections due to 
poor image quality, only one radiograph with extremely accelerated bone maturation resulted 
in absence of a Z-score of BHI. The low rejection rate is advantageous; however, one has to 
take into account that patients outside the age ranges of the program had to be excluded, 
who were composed mostly of older patients (older than 15 years of age for girls and older 
than age 17 years for boys). For follow-up of patients, it would be useful if a BHI reference 
existed for children who have reached skeletal maturity. Besides a low rejection rate, the 
method also showed a very good agreement between left- and right-hand assessment 
and two repeated measurements of the left-hand radiograph. The excellent agreement of 
the repeated measurement of one radiograph is to be expected, whereas BoneXpert is 
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an automated computer technique. Other methods used to determine reliability, such as 
analysis of two radiographs of the same hand of the same patient at one time point, could 
not be performed, because these radiographs were not available. Bone maturation and 
cBMD were found to be impaired, as was expected for this group of JIA patients.198 199 210 A 
regression analysis showed that delayed bone age was associated with glucocorticoid use 
and that lower BHI was associated with male gender. The association between delayed bone 
age and glucocorticoid use was not unexpected, as numerous studies have shown that 
glucocorticoid use may slow longitudinal bone growth and growth plate senescence.152 213 In 
other earlier studies, not only bone age but also impaired BMD has been associated with the 
use of glucocorticoids.199 214 215 In the present study, this was not the case; the only variable 
in the regression analysis significantly associated with cBMD was male gender. The lack of 
association between glucocorticoid use and cBMD could be due to the broad definition of 
glucocorticoid use (that is, cumulative dose was not taken into account) and the relatively 
small size of our study population. On the other hand, several randomized trials in adults with 
rheumatoid arthritis have shown that glucocorticoids can decelerate the loss of hand BMD.216 
217 Although rheumatoid arthritis and JIA are two different entities, a similar protective effect of 
glucocorticoids on hand BMD may have played a role in our population. The association with 
male gender is less easy to interpret. It was previously shown that differences exist between 
healthy boys and girls in BMD of the forearm, with boys having higher BMD of the forearm 
than girls.218 This difference is not associated with body mass index, but is likely to be 
associated with other factors. The same group also found an association between physical 
activity and BMD of the forearm, combined with the finding that boys are more physically 
active than girls.219 The difference in BHI between boys and girls in the current studies might 
therefore be explained by low physical activity due to disease activity and by boys being 
relatively less physically active compared to their healthy peers than girls. The link between 
physical activity and lower cortical thickness of the forearm was also hinted at in a study in 
pediatric Crohn’s disease patients. In that study, a lower cortical thickness was also found 
in boys, which improved with treatment, possibly because patients also increased their daily 
physical activities with their response to treatment.220 
The BoneXpert method is used to measure bone age and BHI. With respect to bone age, 
the method can be considered feasible for future use in multicenter or longitudinal follow-
up studies in JIA patients, because of its easy use, high precision and small differences 
between left- and right-hand radiographs.204 Besides its application in research, the 
BoneXpert method can also potentially be of use in clinical practice. The automatic 
determination of bone age and cBMD is less costly than other methods and is time-saving 
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for both pediatric rheumatologists and radiologists. Moreover, only one hand—either right 
or left—needs to be analyzed, which increases the feasibility of use in daily practice (unless 
there is an extreme clinical discrepancy between left and right).
The other major outcome variable, the BHI, needs more validation studies before it can be 
used in research and clinical practice. The DXR method for the assessment of cBMD, used 
by BoneXpert, has been compared to DXA in several patient groups, including patients with 
inflammatory bowel disease.221 In these patients, the correlation between DXR and DXA 
was found to be moderate to good. In JIA patients, however, cBMD of the hand may be 
influenced by local inflammation, possibly resulting in a lower correlation with generalized 
BMD, as shown in adult patients with rheumatoid arthritis.222 If BHI can be used as a proxy 
for generalized BMD in JIA patients, further validation in this population is needed, including 
a comparison with other BMD measurement techniques. This is complicated by the fact 
that there are different methods used to determine BMD without consensus on the gold 
standard, although DXA is the most widely utilized technique.
Limitations
This study is limited by its observational design and the very specific population derived from 
the ABC register. These factors introduce a selection bias, which limits generalization to the 
full JIA population. However, patients included in the ABC register are considered to be the 
most severely affected patients because of their eligibility for biologic treatment; therefore, 
these patients are most likely to have structural bone damage. It can be assumed that if the 
BoneXpert method can be applied in these patients, it can be used in all JIA patients. Most 
radiographs used in this study were digital; however, some conventional radiographs were 
included. BoneXpert works less well with these digitized images, as demonstrated by the two 
radiographs that were rejected by the program. Given the widespread use of digital radiology 
throughout Europe, this will not be a problem in future studies.
CONCLUSIONS
To our knowledge, this study is the first in which the BoneXpert automated determination 
of bone age and cBMD has been evaluated in JIA patients. The method proved feasible 
and easy to use, even in severely affected JIA patients, provided that radiographs were 
of reasonable quality and patients were within the age ranges of the BoneXpert program. 
This method can be implemented in clinical practice for the determination of bone age 
in JIA patients. It needs further validation for the determination of bone health, including 
comparison with existing methods for the determination of BMD.
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ABSTRACT
Objectives. Juvenile idiopathic arthritis (JIA) affects bone mineral density (BMD). Dual-
energy X-ray absorptiometry (DXA) is the most widely used technique to determine BMD. 
BoneXpert is a new and feasible method for automatic determination of cortical BMD on 
hand radiographs. This study aimed to compare BoneXpert and DXA in the assessment of 
BMD in JIA patients. 
Methods. Thirty-five JIA patients with available DXA and hand radiograph within the same 
time period were included from the Dutch Arthritis and Biologicals in Children register. 
Outcome measures for BMD were Bone Health Index from BoneXpert and BMD total 
body, BMD lumbar spine and Bone Mineral Apparent Density from DXA. All measures were 
transformed to Z-scores. Correlations were assessed with Pearson correlation coefficients. 
Results. Median age of the patients (60% female) was 11.7 years. Pearson correlation 
coefficient was significant for the absolute scores: 0.568-0.770 (p<0.001). No significant 
correlation was found between the Z-scores of DXA and BoneXpert. 
Conclusions. The BMD assessment from the BoneXpert method was correlated to DXA 
measures in a cohort of JIA patients, although only in absolute scores. Future steps for 
implementation of BoneXpert in clinical practice include evaluation of responsiveness to 
change, predictive value and comparison with other imaging techniques. 
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INTRODUCTION
Juvenile idiopathic arthritis (JIA) is an umbrella term that encompasses all forms of arthritis 
of unknown aetiology that begin before the age of 16 years and persist for more than 6 
weeks.1 Chronic inflammatory activity in JIA affects the bone, possibly resulting in growth 
abnormalities and decreased bone mineral density (BMD). Low physical activity, chronic 
exposure to inflammatory cytokines and glucocorticoid therapy all result in a high risk for 
osteoporosis. Monitoring the bone status of JIA patients is therefore important for the 
prevention of fractures and osteoporosis at later age.199 The finding of impaired bone status 
can lead to preventive actions (e.g. calcium or vitamin D suppletion, physical therapy) or 
treatment with bisphosphonates in the more severe cases.223
The most widely used technique for the assessment of bone mineral density in paediatric 
patients is dual–energy X-ray absorptiometry (DXA).201 Recently however an automated 
method for the evaluation of bone age and BMD has become available, which makes use 
of hand radiographs.202 This BoneXpert method is based on digital X-ray radiogrammetry 
(DXR) and adjusts radiogrammetric measurement of cortical BMD for the automated 
determined bone age. Advantages of the BoneXpert method include the availability of 
normative data, low costs, and low effective radiation dose.205 Additionally, the method 
proved to be easy-to-use and feasible in the JIA population.224 Besides a study in children 
with inflammatory bowel disease (IBD) showing moderate correlations between DXR and 
DXA, a comparison of DXR with DXA has never been performed in paediatric populations.221 
To be able to use this new method in clinical practice, its place in the framework of existing 
techniques for the assessment of BMD has to be determined. Therefore the aim of this 
study was to compare BoneXpert and DXA in the assessment of BMD in JIA patients. 
MATERIALS AND METHODS
Patients
Patients were sampled from the Dutch Arthritis and Biologicals in Children (ABC) register. 
We selected patients included in the ABC register between 2003 and 2012, who were 
treated in the Erasmus MC Sophia Children’s Hospital. These patients were evaluated for 
BMD by DXA and had conventional radiographs from their hands taken within the same five 
month period (preferably as close as possible). Patients had to be older than 4 years (the 
lower limit of Z-scores available for BMD measures) and younger than the upper limits of 
the reliability range of the BoneXpert method (i.e. 17 years for boys and 15 years for girls). 
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Clinical data collection
The ABC register aimed to prospectively include all Dutch JIA patients that started 
treatment with biologic agents since 1999, when the first biologic (etanercept) was 
approved for the treatment of JIA. The study protocol was approved by the Medical Ethics 
Committee at Erasmus MC in Rotterdam. Informed consent was obtained from all parents 
and from patients older than 12 years of age. In the ABC register, demographic data and 
disease characteristics are collected, including longitudinal data on medication use and 
disease activity.40
BoneXpert
Radiographs of the complete left and right hand and wrists were analysed using the 
standalone Windows product of BoneXpert (BoneXpert, Version 2.1.0.12, Visiana, Holte, 
Denmark). The BoneXpert outcome variable of interest was the Bone Health index 
(BHI).202 BHI is based on the cortical thickness (T) of the three middle metacarpals. In 
the construction of BHI, also metacarpal width (W) and length (L) are incorporated to 
compensate for the high variation in stature of growing children, as expressed in the 
following formula: BHI=π T (1 − T/W) / (LW)0.33.
The BoneXpert method also automatically compares BHI to a Caucasian reference 
population with the same sex and bone age, and expresses it as a Z-score. Additionally 
the bone age (based on Greulich and Pyle) and the Z-score of bone age were measured.202 
205 The mean BHI of the right and left hand was analysed, unless only one hand 
radiograph was available (6 cases). The agreement between right and left hand BoneXpert 
measurement in JIA patients is very good.224
DXA
A DXA scan (Lunar Prodigy, GE, USA) was used to automatically measure BMD of the 
total body (BMDTB) and the lumbar spine (BMDLS), expressed in g/cm
2. DXA measures 
areal BMD, based on the density of the cortical and the trabecular bone combined, 
in contrast to BoneXpert, which only measures BMD of the cortical bone. The Bone 
Mineral Apparent Density (BMAD) of the lumbar spine was calculated according to the 
following formula: BMD of L2-L4 × [4 / (π × width)], expressed in g/cm3, in which width 
is the average width of L2-L4.225 BMAD is used to correct for differences in size of the 
vertebral bodies. An experience reader assessed the width of the lumbar vertebral 
bodies on the scans. When there was doubt about the width of lumbar vertebral bodies, 
another reader was consulted and consensus was reached. BMDLS, BMDTB and BMAD 
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were compared to a Caucasian reference population from Rotterdam and expressed as 
Z-scores.226 
Statistical analysis
Correlations between BMD measurements by DXA and BoneXpert were assessed with 
Pearson correlation coefficients. To determine whether the BMD measurements differed 
significantly from the reference population, one sample t-tests were used. A p-value of 
<0.05 was considered significant. Linear regression was used to investigate whether the 
relationship between DXA and BoneXpert measurements was influenced by body mass 
index (BMI), bone age or corticosteroid use (defined as ever versus never use). With DXA 
Z-scores as a reference, sensitivity, specificity and predictive values were calculated to 
describe discriminative properties of BoneXpert in distinguishing impaired (<-2SD) from 
normal bone status. Descriptive statistics are reported as absolute values, mean with 
standard deviation or median with interquartile range. For all analyses IBM SPSS Statistics 
for Windows version 21.0 was used (Armonk, NY: IBM Corp.). 
RESULTS
Patient characteristics
Patient and disease characteristics of the patients included in this study are shown in 
Table 1. The systemic JIA category is highly represented in our patient sample (31%). 
Systemic JIA patients are often treated with high dose systemic corticosteroids, are 
therefore more likely to develop impaired BMD and often had a DXA scan. Mean BMD 
measurements by both DXA and BoneXpert were significantly impaired compared to the 
normal population.
Table 1 Patient characteristics 
Characteristic n=35
Female gender, n (%) 21 (60)
BMI in kg/m2, mean (SD) 19.2 (±3.9)
Age at onset of JIA in years, median (IQR) 6.0 (3.4-9.8)
JIA category, n (%)
  Systemic JIA 11 (31)
  Polyarticular RF positive JIA 3 (9)
  Polyarticular RF negative JIA 11 (31)
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  Oligoarticular extended JIA 7 (20)
  Psoriatic JIA 3 (9)
Wrist and/or hand involvement, n (%) 33 (94)
Ever use of corticosteroids, n (%) 30 (86)
Disease duration at radiograph in years, median (IQR) 4.1 (1.8-8.0)
Age at radiograph in years, median (IQR) 11.7 (9.3-14.1)
Z-score bone age in years, mean (SD) -0.4 (±1.5)
Z-score BMDTB, mean (SD) -0.7 (±1.3)**
Z-score BMDLS, mean (SD) -0.7 (±1.1)**
Z-score BMAD, mean (SD) -0.4 (±1.1)*
Z-score BHI, mean (SD) -1.1 (±1.2)**
Time between hand radiograph and DXA in months, median (IQR) 0.1 (0.0-0.8)
 
IQR=interquartile range; JIA=juvenile idiopathic arthritis; BMDTB=total body bone mineral density; BMDLS=lumbar 
spine bone mineral density; BMAD=bone mineral apparent density; BHI=bone health index; DXA=dual-energy X-ray 
absorptiometry
* p-value <0.05 on one sample t-test with test value 0 
** p-value <0.01 on one sample t-test with test value 0 
 
Correlation between DXA and BoneXpert 
Pearson correlation coefficients were calculated between absolute values and Z-scores 
of BHI and the BMD measurements by DXA. BHI was significantly correlated to all DXA 
measurements. The Pearson correlation coefficient was 0.568 (p<0.001) for BMAD vs 
BHI, 0.665 (p<0.001) for BMDTB vs BHI, and 0.770 (p<0.001) for BMDLS vs BHI. Correlation 
coefficients were lower and not significant for Z-scores of BHI and DXA measurements. 
The Pearson correlation coefficients for DXA measurements with Z-score BHI were: 0.263 
(p=0.127) for Z-score BMAD, 0.137 (p=0.433) for Z-score BMDTB, 0.247 (p=0.153) for 
Z-score BMDLS. The correlations between the BoneXpert and DXA for both the absolute 
values and Z-scores are shown in Figure 1. In a multivariate linear regression, the 
relationship between Z-score BMAD and Z-score BHI was not significantly influenced by 
BMI, bone age or corticosteroid use (ever versus never use).
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Figure 1 Correlation between BoneXpert  
and DXA measures for BMD for both 
absolute scores (a-c) and Z-scores (d-f) in 
35 JIA patients
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Agreement between DXA and BoneXpert
For treatment purposes it is most important to identify patients deviating more than 2 
standard deviations (SD) from the normal population. We categorized patients according 
to this criterion and compared how patients were classified according to DXA (BMAD) and 
BoneXpert. The results are shown in Table 2. According to DXA (BMAD), 5 patients had 
severely impaired BMD (14%) and according to BoneXpert, BMD was severely impaired in 8 
patients (23%). Taking DXA (BMAD) as a reference, BoneXpert had a sensitivity of 40% and 
a specificity of 80%. A positive test for impaired BMD on BoneXpert resulted in a positive 
test on DXA in 25% of cases. The negative predictive value was much higher (90%).
Table 2 Classification of BoneXpert and DXA (BMAD) of patients with impaired bone status (scoring ≤-2SD) 
on either method 
BMAD impaired BMAD not impaired Total
BHI impaired 2 6 8
BHI not impaired 3 24 27
Total 5 30 35
 
BHI=bone health index; BMAD=bone mineral apparent density
 
DISCUSSION
In this study we compared DXA and BoneXpert for the assessment of BMD in JIA patients. Hand 
BMD measured by BoneXpert and BMD of the lumbar spine measured by DXA correlated well 
on absolute scores. However, to properly interpret the values found by both BoneXpert and DXA 
in this paediatric population, one needs to calculate Z-scores, in which the values are compared 
to a reference population matched on sex and (bone) age. The Z-scores derived from DXA and 
BoneXpert measurements did not show any significant correlation. 
BoneXpert is a new method, which has the advantage of calculating a Z-score of the BHI based 
on a reference population matched for sex and bone age. It has never before been compared 
to DXA measurements in a JIA population. In previous studies however, the DXR method, 
which BoneXpert applies to derive the BHI, has been compared to DXA. These studies found 
moderate to good correlations for the absolute values derived from DXA and DXR in both adult 
and paediatric populations (Table 3).221 222 227-232 Only one study also compared Z-scores of DXR 
and DXA (BMDLS) based on a sex and age matched population in 26 children with IBD. This 
correlation was lower than those found for the absolute values, but still moderate (r=0.58).221
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Table 3  Studies reporting on the correlation between the DXR BMD and a DXA BMD measurement.  
Author (year) Disease n DXA variable Correlation 
coefficient
p-value
Adults 
Bottcher (2004)222 RA 106 BMDLS r=0.45 <0.01
Desai (2010)227 RA 138 BMDLS β=0.45 0.004
Forsblad-d’Elia (2011)228 RA 75 BMDLS r=0.52 <0.001
Özçakar (2005)229 HIV 27 BMDLS r=0.60 <0.01
Rosholm (2001)230 Healthy 416 BMDLS r=0.62 <0.0001
Ward (2003)232 Various 154 BMDLS r=0.56 <0.001
Children
van Rijn (2006)231 ALL 41 BMDLS r=0.760-0.853 <0.01
BMDTB r=0.806-0.878 <0.01
BMAD r=0.666-0.682 <0.01
GHD 26 BMDLS r=0.760-0.779 <0.01
BMDTB r=0.734-0.760 <0.01
BMAD r=0.301-0.414 >0.01
Mentzel (2006)221 IBD 26 BMDLS r=0.78 <0.01
Z-score 
BMDLS†
r=0.58 <0.01
 
† correlation with Z-score DXR-BMD. DXR BMD=digital x-ray radiogrammetry bone mineral density; DXA BMD=dual 
energy x-ray absorptiometry bone mineral density; r=correlation coefficient; β=beta coefficient; RA=rheumatoid arthritis; 
BMDLS=bone mineral density lumbar spine; BMDTB=bone mineral density total body; BMAD=bone mineral apparent 
density; HIV=human immunodeficiency virus; ALL=acute lymphoblastic leukaemia; GHD=growth hormone deficiency. 
There may be several explanations for the lack of correlation between the Z-scores derived 
from DXA and BoneXpert. Firstly, the Z-scores of both measurements are based on different 
reference populations. The BMAD Z-score derived from DXA, which is first corrected for 
vertebral size, is sex and age specific. The BHI Z-score derived from BoneXpert is based 
on a reference population which is sex specific, but instead of age uses bone age to match 
patients on. The bone age of our cohort was impaired, which may result in difference in 
these two Z-scores. Another difficulty may lie in the components of the bone on which 
the two modalities base their BMD measurement. DXA determines BMD based on a 
measurement of trabecular and cortical bone, whilst the BoneXpert measurement is based 
on only cortical bone. Trabecular and cortical bone respond differently to stimuli like chronic 
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inflammation, glucocorticoid treatment and low physical activity.233 234 Secondly, there is 
a difference in location for the BMD measurement, as BoneXpert uses the hand and DXA 
uses the lumbar spine. This is important, because like in RA, BMD in JIA may be affected in 
two ways.235 236 There may be generalized bone loss due to systemic influences of chronic 
inflammation and glucocorticoid use. Additionally, there may be a periarticular effect of 
local inflammation, functional disability and medication use. In the present study, we could 
not investigate the effects of local inflammation (arthritis of the wrist) and corticosteroid use, 
because the majority of our patients were exposed to both risk factors. 
Aside from the discussion on the comparability of DXA and BoneXpert, an important 
point of debate is whether DXA is the best technique to assess BMD, especially in the 
paediatric population. First of all, variations in body composition, which occur commonly 
in the growing child, cause inaccuracies in BMD measurement by DXA.237 238 Secondly, 
although the BMAD tries to correct for variations in vertebral body size by taking the 
width of the vertebrae into account, it remains an estimation based on a two-dimensional 
measurement and does not fully capture true volumetric BMD.239 This may especially cause 
imprecise estimates of BMD in a paediatric population like the JIA cohort in the present 
study, in which patients may have variations in vertebral body size due to physiological and 
pathological changes (e.g. growth and impaired bone maturation).
A method that does measure true volumetric BMD is (peripheral) quantitative computed 
tomography ((p)QCT). It is considered to be superior to DXA in its accuracy for BMD 
measurement.201 240 Absolute scores and Z-scores of DXA and pQCT were weak to 
moderately correlated in children with JIA.241-243 In light of these correlations, it is hard to 
appreciate the place of BoneXpert in the spectrum of BMD assessment techniques. A 
comparison of BoneXpert to pQCT for the assessment of both generalized and periarticular 
bone loss would therefore be worthwhile. Disadvantages of (p)QCT include its high 
radiation exposure, costs and availability, which make its use in children less desirable. 
In the current study only DXA measurements were available for comparison with BoneXpert. 
Taking DXA as a reference standard, BoneXpert did not identify patients with clinically 
important deviations in BMD incorrectly. It did miss some patients with an impaired bone 
status according to DXA. However, to truly evaluate misclassification of clinically relevant 
impaired bone status, clinical factors like the fracture status would also have to be taken 
into account. Overall, measuring BMD by any method preferably serves as a tool to 
determine whether further assessment of risk factors for impaired bone status (e.g. vitamin 
D levels, calcium intake or physical activity) is warranted. 
This is the first study to compare DXA and BoneXpert for the assessment of BMD in JIA 
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patients. It was limited by the small sample size, and the cross sectional nature of the data. 
In conclusion, the BoneXpert method was correlated to DXA, although only in absolute 
scores. The use of BoneXpert for the assessment of BMD in JIA patients is hampered by the 
complicated concept of measuring bone status in children in general and effects of chronic 
inflammation and medication use on different modes of BMD in JIA patients specifically. 
Future practical steps to be taken for the implementation of BoneXpert in clinical practice 
include the evaluation of its responsiveness to change and predictive value for clinically 
relevant impaired bone status. Additionally, if possible, BoneXpert should be compared with 
(p)QCT, to elucidate on its role in identifying both generalized and periarticular BMD.
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ABSTRACT
Objectives. Approximately 30% of juvenile idiopathic arthritis (JIA) patients fail to respond 
to anti-TNF treatment. When clinical remission is induced, some patients relapse after 
treatment has been stopped. We tested the predictive value of MRP8/14 serum levels to 
identify responders to treatment and relapse after discontinuation of therapy.
Methods. Samples from 88 non-systemic JIA patients who started and 26 patients who 
discontinued TNF-blockers were analysed. MRP8/14 serum levels were measured by an 
in-house MRP8/14 ELISA and by Bühlmann MRP8/14 Calprotectin ELISA at start of anti-
TNF treatment, within 6 months after start and at time of discontinuation of etanercept in 
clinical remission. Patients were categorized into responders (ACRpedi≥50 and/or inactive 
disease) and non-responders (ACRpedi<50) within six months after start, response was 
evaluated by change in JADAS-10. Disease activity was assessed within six months after 
discontinuation.
Results. Baseline MRP8/14 levels were higher in responders (median MRP8/14 of 1466 
ng/ml (IQR 1045-3170)) compared to non-responders (median MRP8/14 of 812 (IQR 
570-1178), p<0.001). Levels rapidly decreased after start of treatment only in responders 
(p<0.001). JADAS-10 disease activity was significantly correlated to MRP8/14 levels 
(Spearman’s rho: 0.4, p=0.03). Patients who flared within 6 months after treatment 
discontinuation had higher MRP8/14 levels (p=0.031, median 1025 ng/ml (IQR 588-1288 
ng/ml)) compared to patients with stable remission (505 ng/ml (IQR 346-778 ng/ml)). Data 
were confirmed by the Bühlmann ELISA with high reproducibility but different overall levels.
Conclusions. High levels of baseline MRP8/14 are associated with a good response 
to anti-TNF treatment, whereas elevated MRP8/14 levels at time of discontinuation of 
etanercept are associated with a higher chance to flare.
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INTRODUCTION
Addition of biologic agents for treatment of juvenile idiopathic arthritis (JIA) has brought 
the treatment goal of inactive disease into reach even for JIA patients not responding to 
conventional disease modifying anti-rheumatic drugs (DMARDs). However, for unknown reasons, 
this treatment goal is still not achieved in 30-40% of patients treated with a biologic agent.25 39 
49 Several clinical parameters have been found to be associated with response to etanercept 
(a TNF-alpha inhibitor and the first biologic to be approved for the treatment of JIA).29 244 These 
include patient characteristics, such as age and gender, as well as characteristics of the 
disease, such as the number of active joints, the extent of disability and the disease duration. 
However, these clinical characteristics in themselves are not sufficient to guide treatment 
decisions. A more tailored approach to drug choice, based upon use of validated biomarkers in 
combination with clinical parameters, could facilitate early remission induction for more children. 
Measurement of serum inflammatory proteins before starting treatment with a biologic agent 
may be valuable to separate children with a high chance of good response from poor- or non-
responders. In addition, biomarkers could be of help in identifying patients in clinical remission 
who can successfully discontinue treatment. The myeloid related protein (MRP) complex 8/14 
(S100A8/9, also known as calprotectin) is released from activated monocytes and phagocytes. 
MRP8/14 is a ligand to Toll-like receptor 4 (TLR-4), has a proinflammatory effect on phagocytes 
and endothelial cells245 and is an important factor in mediating osteoclastic bone destruction in 
experimental arthritis.246 MRP8/14 serum level correlates with disease activity in JIA patients247, 
can be used to identify subclinical disease activity, and is associated with flares in JIA patients 
who were in clinical remission on MTX.248 249 In addition, this biomarker correlates closely to the 
response to treatment in patients with systemic JIA33 and is able to predict a good response to 
MTX in a subset of non-systemic JIA patients.250 
Whether MRP8/14 is also associated with response to TNF-alpha inhibitors in non-systemic 
JIA patients or can predict flares after discontinuation of etanercept after successful treatment, 
when clinical remission is achieved, is unknown. Therefore, in the present study we prospectively 
evaluated the relationship between the clinical course of JIA after start of anti-TNF treatment and 
after discontinuation of etanercept and the corresponding serum levels of MRP8/14.
PATIENTS AND METHODS
Study population
Serum samples were included from non-systemic biologic naive JIA patients starting either 
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etanercept or adalimumab included in the Dutch Arthritis and Biologicals in Children (ABC) 
Register (n=68), German Registry for Biologics in Paediatric Rheumatology (BIKER) (n=12) 
or Childhood Arthritis Response to Medication Study (CHARMS) from the United Kingdom 
(n=8). Additionally, samples at discontinuation of etanercept in remission were collected 
(26 patients (ABC register (n=8), BIKER register (n=18)). Patients fulfilled the  International 
League of Associations for Rheumatology (ILAR) criteria for the diagnosis of juvenile 
idiopathic arthritis.1 Patients diagnosed with systemic JIA were described elsewhere.33
The ABC register is a multicentre prospective observational study that aimed to include 
all JIA patients in the Netherlands who initiated biologic agents. The study protocol 
was approved by the Medical Ethics Committee at Erasmus MC Rotterdam and by all 
participating hospitals.25 The German BIKER register was founded with the same objective, 
after approval by the ethics committee of the University Halle.49 The CHARMS study 
included JIA patients at the start of treatment with new disease-modifying medication for 
active arthritis.250 In all three studies patient and disease characteristics were recorded 
at start of biologic treatment. Changes in disease activity, medication use and adverse 
events were thereafter prospectively followed up. These included the JIA core set variables: 
physician’s global assessment of disease activity on a visual analogue scale (VAS) (range 
0-10 cm, 0 best score), Childhood Health Assessment Questionnaire (CHAQ) (range 0-3, 0 
best score) by patients/parents, the global assessment of wellbeing VAS, number of joints 
with active arthritis and joints with limited motion and erythrocyte sedimentation rate (ESR). 
Additionally, pain was assessed using a VAS.
Response to treatment, inactive disease and flare
The effect of treatment was assessed using the ACRpedi 30, 50 and 70 response criteria.44 
A modified definition for inactive disease was used and defined as no active arthritis, no 
systemic features, no uveitis, normal ESR (≤20 mm/h), and physician’s global assessment 
of disease activity indicating no disease activity (defined as a score ≤10 mm).123 Patients 
were divided into responders (who achieved ACRpedi50, ACRpedi70 or inactive disease) 
and non-responders (patients with no response or an ACRpedi30 response) within 6 
months after start of treatment. Additionally, response to treatment was evaluated using 
the change on the continuous JADAS-10 score, a composite score based on four of the 
disease activity variables.23  
Patients who discontinued treatment were all in remission on medication (defined as a 
period of ≥ 6 months of continuous inactive disease).45 For the evaluation of the association 
between MRP 8/14 levels at discontinuation and flaring after discontinuation, we defined 
188
flare based on a combination of previously proposed flare definitions.128 251 A flare was 
defined as having at least three of the following: a physician or patient VAS ≥ 20 mm, ≥ 1 
active joints, any worsening on the CHAQ and ≥30% worsening on ESR and limited joints.
Determination of MRP8/14 serum levels
Serum levels of MRP8/14 complexes were determined by enzyme-linked immunosorbent 
assay (ELISA) system. For comparison with earlier studies, internal control sera were used 
as a reference in all ELISA studies. Additionally, the MRP8/14 levels were measured using 
the commercially available Bühlmann MRP8/14 Calprotectin ELISA (Bühlmann Laboratories) 
to investigate interassay variation. The readers of the assay were blinded for diagnosis and 
disease activity of the patients. Treating physicians were blinded for the MRP8/14 serum 
levels.
Statistical analysis
Descriptive statistics are presented as absolute frequencies, as median values and 
interquartile range (IQR) or as mean and standard deviation (SD) wherever appropriate. To 
compare categorical characteristics of responders with those of non-responders a chi-
square test was used. The Mann-Whitney U test was used for comparison of continuous 
variables. Correlations between the serum level of MRP8/14 and clinical variables were 
assessed using Spearman’s correlation coefficient. The correlation between the in-house 
ELISA and the Bühlmann ELISA was assessed using Pearson’s correlation coefficient. The 
Wilcoxon signed rank test was used to analyse differences in MRP8/14 levels at paired time 
points. Receiver operator characteristic (ROC) analyses were performed to determine the 
optimal cut-off point in MRP8/14 levels for both assays separately to predict response to 
treatment and flare within 6 months after treatment discontinuation. The cut-off value was 
determined using the Youden index,252 if multiple values were available with a high Youden 
index, the cut-off value with the highest specificity was chosen.
To assess the association between treatment response and baseline MRP8/14 levels as 
determined by both ELISA methods, univariable logistic regression models were fitted. To 
evaluate the relationship between change in disease activity and baseline MRP8/14 serum 
levels a linear regression model was fitted for change in JADAS-10. Change in JADAS-10 
was defined as the difference between the baseline and the follow-up JADAS-10. 
Multivariable linear models were fitted for change in JADAS-10 to correct for other possible 
predictor variables and to assess additional value of MRP8/14 in predicting clinical 
response. These variables were specified beforehand based on pre-existing knowledge of 
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their relationship with serum-levels of MRP8/14 and/or the response to treatment (age at 
onset of JIA, baseline JADAS-10, number of previously used DMARDs, gender, baseline 
CHAQ score, ESR). Additionally, disease duration at baseline was considered as a possible 
predictor and added to the multivariable models.76 Missing data were handled using 
the chained equations multiple imputation command ice in Stata. Ten imputed datasets 
were created. Adalimumab and etanercept patients were compared and due to identical 
characteristics imputed together. Of the baseline JIA core-set variables (including VAS pain) 
3.6% was missing (median of 0 missing values per patient (range 0-3). At the last available 
follow-up within six months of treatment 9.3% of the JIA core set variables were missing 
(including VAS pain, median of 0 missing values per patient (range 0-7)). Analyses were 
performed with IBM SPSS Statistics for Windows Version 21.0, Stata/SE version 13.0 and 
Prism (v5, Graphpad).
RESULTS
Baseline characteristics
Baseline serum samples were available from 88 non-systemic JIA patients and of these 
81 were available to perform both in-house and commercial ELISA. The characteristics of 
both the patients who started TNF-inhibitors and those who discontinued etanercept are 
summarized in table 1 in the supplementary files. Median MRP8/14 (ng/ml) in patients who 
started TNF-inhibiting treatment was 1289 (IQR 795-2809). 
MRP8/14 serum levels were significantly correlated to ESR at baseline (Spearman’s rho 
0.440, p<0.001). The presence of rheumatoid factor, CHAQ at baseline, number of active 
joints and disease activity expressed as JADAS-10 were not correlated with MRP8/14 
levels.
Clinical response to treatment
A total of 25% of patients (n=22) did not achieve an ACRpedi50 response or higher and 
were therefore considered non-responders to treatment. The remaining 66 patients were 
responders. Of these 66 patients, 46 achieved ACRpedi70, and 31 patients reached a state 
of inactive disease according to the Wallace criteria. Mean JADAS-10 score at the last 
available follow-up within 6 months was 5.7 (±5.4). 
Baseline characteristics of responders and non-responders are shown in Table 1. No 
significant differences were found between responders and non-responders.
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Table 1 Differences in baseline characteristics between responders and non-responders 
Baseline characteristic Responders 
(n=66)
Non-responders 
(n=22)
Female gender, n (%) 48 (73) 18 (82)
Age at onset of JIA in years, median (IQR) 10.0 (4.2-12.3) 9.4 (3.5-13.7)
Disease duration in years, median (IQR) 2.4 (1.1-4.9) 2.3 (0.8-7.7)
JADAS-10, median (IQR) 20 (14-21) 17 (11-22)
CHAQ score, median (IQR) 1.5 (0.7-2.2) 1.3 (0.6-2.0)
Number of active joints, median (IQR) 11 (5-18) 8 (2-16)
ESR in mm/h, median (IQR) 16 (9-28) 12 (7-18)
Number of previously used DMARDs, median (IQR) 1 (1-2) 1 (1-2)
 
IQR=interquartile range; ESR=erythrocyte sedimentation rate; CHAQ=Child Health Assessment Questionnaire; 
DMARDs=Disease Modifying Anti-Rheumatic Drugs
MRP8/14 serum levels and response to treatment
Baseline MRP8/14 serum levels were higher in responders (median MRP8/14 of 1466 ng/ml 
(IQR 1045-3170)) compared to non-responders (median MRP8/14 of 812 (IQR 570-1178), 
p<0.001) (Figure 1). In a univariable logistic regression this resulted in an OR of 1.5 (95% 
CI: 1.1-2.1) for achieving at least an ACRpedi 50 response per 500 units of MRP (ng/ml). 
Baseline MRP8/14 was weakly but significantly correlated with change in JADAS-10 score 
over three months of treatment (Spearman’s rho 0.361, p=0.001).
Figure 1 Difference in MRP8/14 between non-responders and responders
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Use of MRP8/14 as a prognostic marker for response to treatment
Based on ROC analysis, cut off values were identified for the prediction of response to 
treatment (ACR pedi50 or higher). Sensitivity, specificity and likelihood ratios are given in 
table 2. 
Table 2 Sensitivity, specificity and likelihood ratios for the determined cut-off value of MRP8/14 predicting 
response to anti-TNF treatment 
Accuracy measure
Cut-off level MRP8/14 (ng/ml) 1193
Sensitivity 66%
Specificity 81%
Positive likelihood ratio 3.4
Negative likelihood ratio 0.4
Youden index 0.47
AUC 0.76
 
AUC=area under the curve
Added value of MRP8/14 in prediction of response
Baseline MRP8/14 serum levels were significantly associated with change in JADAS-10 in 
a linear regression analysis (β=0.636 per 500 unit increase in ng/ml, 95% CI 0.254 to 1.018, 
p=0.001). Since other factors can also be associated with treatment effect we constructed 
a multivariable linear regression model with these known factors and subsequently 
added MRP8/14 to the model. In this multivariable model MRP8/14 was still significantly 
associated with the change in JADAS-10 (corrected β=0.472 per 500 units increase in ng/
ml, 95% CI 0.161 to 0.782, p<0.001). The only other variable significantly associated with 
the change in JADAS-10 was the baseline JADAS-10 (corrected β=0.678, 95% CI 0.434 
to 0.921, p<0.001). The variables in the model without MRP8/14 serum levels explained 
50% of the variance in the change in JADAS-10 over three months of treatment (R2=0.50). 
Adding MRP8/14 to this model resulted in a slightly better predictive model, with an R2 of 
0.54 (p=0.004). 
Change in MRP8/14 levels after treatment
For 43 patients, a follow-up measurement within five months after start of anti-TNF 
treatment was available, and 14 of these could be categorized as being non-responders. 
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Treatment with etanercept lowered MRP8/14 serum levels significantly only in responders 
(p<0.001) (Figure 2A), but not in non-responders (Figure 2B). Change in MRP was 
significantly correlated to change in JADAS10 (Spearman’s rho: 0.421, p=0.006)."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Association of MRP8/14 level and flare after etanercept withdrawal after successful 
treatment
Patients who flared within 6 months (n=12) after the discontinuation of etanercept had 
higher MRP levels at discontinuation than patients who did not flare (n=14) (p=0.031, 
median 1025 ng/ml (IQR 588-1288 ng/ml) vs. 505 ng/ml (IQR 346-778 ng/ml) figure 3). 
The cut-off for the prediction of a flare after etanercept withdrawal and the prognostic 
accuracy are reported in table 3. 
Table 3 Sensitivity, specificity and likelihood ratios for the determined cut-off value of MRP8/14 predicting a 
flare within 6 months 
Accuracy measure
Cut-off level MRP8/14 (ng/ml) 720
Sensitivity 75%
Specificity 79%
Positive likelihood ratio 3.5
Negative likelihood ratio 0.5
Youden index 0.54
AUC (95% CI) 0.75 (0.55 to 0.95)
 
AUC=area under the curve
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Figure 3A Differences in MRP8/14 between patients with persistent remission and patients who 
flared after discontinuation of etanercept, median (range)
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Validation for routine use by commercial ELISA
Commercial MRP8/14 ELISAs are available but not validated for use as monitoring tool 
of anti-TNF therapy. Therefore, we aimed to validate our findings with the commercial 
Bühlmann MRP8/14 Calprotectin ELISA to make MRP8/14 as marker for anti-TNF therapy 
widely available. The measurements by the in-house ELISA correlated very well with 
those from the Bühlmann ELISA (Pearson’s rho 0.902, p<0.001). Although MRP8/14 levels 
appeared to be 3-4 fold higher when they were measured with the Bühlmann ELISA, the 
associations between MRP8/14 and response, on both the achievement of ACRpedi 50 or 
higher and on the change in JADAS-10 were comparable.  
For predicting response to anti-TNF treatment, the in-house ELISA and the Bühlmann 
ELISA had the same accuracy. The two methods differed to some extent with regard to 
their accuracy for predicting a flare/ persistent remission after discontinuation of etanercept 
in remission. Using the cut-off values we found, a prediction of a flare by the in-house 
ELISA was marginally more accurate than by the Bühlmann ELISA. The Bühlmann ELISA 
had higher sensitivity and lower negative LR and was therefore better at predicting 
persistent remission in the first 6 months after discontinuation. The exact results for the 
Bühlmann ELISA can be found in the supplementary files.
DISCUSSION
In this study we show that MRP8/14 can predict response to anti-TNF treatment, although 
it has little additive value to other clinical factors. Patients who responded to anti-TNF 
treatment had higher levels of MRP8/14 at start of that treatment than patients who did 
not respond. Disease activity declined more in patients with higher levels of MRP8/14. 
In responders, these levels decreased after initiation of treatment, in non-responders 
MRP8/14 levels were constant. When the disease had become inactive and treatment 
with etanercept could be stopped, MRP8/14 levels appeared to be higher for patients in 
whom the disease flared than for patients who did not experience a flare. The prognostic 
accuracy of the two ELISAs differed slightly. The in-house experimental ELISA performed 
better on predicting response to treatment and occurrence of flares, while the commercial 
Bühlmann ELISA predicted non-response and persistent remission after discontinuation 
more accurately.
In recent years, MRP8/14 has been widely studied as a potential predictor of disease 
activity and response to treatment in rheumatic and other inflammatory diseases. In 
rheumatoid arthritis (RA), MRP8/14 could be used as a predictor for response to biologic 
treatment.253 In JIA in particular, MRP8/14 levels are highly predictive of disease activity 
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and of disease flares in systemic JIA.33 Also in enthesitis related arthritis, a relationship with 
disease activity exists.254 In a more heterogeneous group of JIA patients, MRP8/14 levels 
have been shown to predict response to MTX treatment.250 The univariable odds ratio for 
achieving an ACRpedi50 response or higher following MTX treatment 250 is comparable to 
the odds ratio found in the present study following anti-TNF treatment. Using the same 
ELISA to measure MRP8/14 levels, the average serum levels of MRP8/14 in that study were 
higher than in our patients, as were the cut-off points specified. Patients in the present 
study mostly had MRP8/14 levels comparable to the patients who did not respond to MTX 
treatment.250 This is not surprising as failure of MTX treatment is an eligibility criterion for 
treatment with biologic agents. Therefore there may be a possibility of using MRP8/14 
levels to decide which patient is more likely to respond to MTX and which patient may be 
better off with biologic treatment right away. Unfortunately we did not have MRP8/14 serum 
levels of our patients at the start of MTX treatment. 
Well-established experimental ELISA protocols exist for MRP8/14, however these are not 
available for use in routine laboratories. We have already demonstrated good performance 
of the commercially available Bühlmann ELISA kit designed for analysing patient serum 
samples and the necessity for serial dilution of individual sera to obtain reliable results 
in the range of MRP8/14 concentrations found during different disease levels of JIA.255 
In addition, the level of MRP8/14 concentrations analysed with the two assays varied 
substantially. Therefore, a direct comparison of the results obtained with one ELISA with a 
result from a different assay should not be made. Both methods were equally accurate in 
predicting response to treatment. We found slight differences in prognostic performance for 
predicting a flare after discontinuation of teatment in remission, the in-house ELISA being 
more accurate in predicting a flare and the commercially available Bühlmann ELISA being 
more accurate in predicting persistent remission.
For a biomarker to be used in informing therapeutic choice, it will have to fulfil certain 
requirements. It has to be able to predict a certain outcome and this predictive value 
has to be validated. It has to have additional value on top of other known predictors. 
Additionally the prediction should have therapeutical consequences. MRP8/14 has shown 
to be predictive of response to treatment, in both the current as well as previous studies 
in JIA. Its value added to other predictors however is small. Some of the responders and 
non-responders to treatment had comparable MRP8/14 serum levels, and sensitivity and 
specificity were not optimal for any cut-off value, which is in line with the results found in 
the study by Montcrieffe et al.250 Because prediction is not perfect, therapeutic decisions 
cannot only be based on MRP8/14 levels. However, it is unlikely that a single biomarker 
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will ever be able to perfectly predict response in the heterogeneous pool of JIA patients. 
MRP8/14 has the advantage that it is a relatively stable protein and easily measurable in 
serum, in contrast to for instance cytokines such as TNF or IL-1beta. Therefore, MRP8/14 
could play a supporting role in response prediction models for response to treatment 
including clinical as well as laboratory measures, which are under investigation for both JIA 
and RA.29 256-260 More importantly, MRP8/14 might be used to objectively monitor disease 
activity as it has shown to decrease together with disease activity and might be useful as 
an early marker of response in clinical trials.
For prediction of flares after discontinuation of treatment, MRP8/14 can be used as a 
prediction tool. MRP8/14 serum levels have already been shown to be predictive of flares 
after the discontinuation of MTX in JIA patients.249 We show that this is true to the same 
extent for stopping etanercept in non-systemic JIA patients after inactive disease has 
been achieved. Additionally, we found cut-off values comparable to the earlier specified 
cut-off value for the in-house ELISA, giving an even higher sensitivity and specificity than 
described in the other cohort.249 255 The likelihood ratios indicated that this marker could 
be of value in predicting the likelihood of a flare after stopping of therapy. Still, the cut-
off values did not perfectly predict flare or persistent remission after discontinuation. For 
clinical practice this means that we have to keep searching for additional features that will 
provide such a perfect prediction.
In conclusion, serum levels of MRP8/14 are associated with response to treatment with 
etanercept in non-systemic JIA patients. They could be a useful addition to response 
prediction models in combination with other factors associated with response. MRP8/14 
serum levels decrease together with disease activity in responders to etanercept. MRP8/14 
serum levels can very well be used to predict flares in patients in clinical remission after 
cessation of etanercept. They can also be determined using a commercially available ELISA 
kit when the specific prognostic performance of this kit is kept in mind.
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SUPPLEMENTARY FILE – TABLE 1A AND TABLE 1B PATIENT CHARACTERISTICS
 
Table 1A Characteristics of patients who started anti-TNF treatment  
Baseline characteristics N=88
Female, n (%) 66 (75)
Age at onset JIA in years, median (IQR) 10.0 (3.9-12.3)
Age at start first biological in years, median (IQR) 12.8 (9.9-15.6)
JIA disease duration before start biological in years, median (IQR) 2.3 (0.9-6.0)
ANA positive, n/N (%) 25/76 (33)
RF positive, n/N (%) 13/80 (16)
Category JIA, n (%)
  Polyarticular RF negative 33 (3.8)
  Polyarticular RF positive 13 (15)
  Oligoarticular extended 24 (27)
  Oligoarticular persistent 5 (6)
  Psoriatic arthritis 9 (10)
  Enthesitis related arthritis 4 (5)
Previously used medications, n (%)
  Systemic prednisone 42 (48)
  Methotrexate 85 (97)
  DMARD other than MTX 26 (30)
Biological started, n (%)
  Etanercept 81 (92)
  Adalimumab 7 (8)
Concomitant co-medication at start biological, n (%)
  Systemic prednisone 25 (28)
  Methotrexate 74 (84)
  DMARD other than MTX 3 (3)
Disease activity parameters at baseline, median (IQR)
  VAS physician (0-100) 54 (30-68)
  CHAQ total (0-3) 1.50 (0.75-2.1)
  VAS pain (0-100) 56 (25-72)
  VAS wellbeing (0-100) 53 (25-70)
  Active joints 10 (5-17)
  Limited joints 6 (2-14)
  ESR 13 (8-27)
JADAS-10 (0-40), mean (SD) 18 (7)
MRP8/14 measured by in-house ELISA (ng/ml), median (IQR) 1289 (795-2809)
MRP8/14 measured by Bühlmann ELISA (ng/ml), median (IQR) 4763 (2795-8701)
 
JIA=juvenile idiopathic arthritis, IQR=interquartile range, ANA=anti-nuclear antibodies, RF=rheumatoid factor, 
DMARD=disease modifying anti-rheumatic drug, MTX=methotrexate, VAS=visual analogue scale, CHAQ=childhood health 
assessment questionnaire, ESR=erythrocyte sedimentation rate, JADAS=juvenile arthritis disease activity score
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Table 1B Characteristics of patients discontinuing etanercept in clinical remission 
Baseline characteristics Flare (n=12)
Female, n (%) 9 (75)
Category JIA, n (%)
  Polyarticular RF negative 6 (50)
  Polyarticular RF positive -
  Oligoarticular extended -
  Oligoarticular persistent 3 (25)
  Psoriatic arthritis 1 (8)
  Enthesitis related arthritis 2 (17)
MTX treatment at time of discontinuation, n (%) 5 (42)
MRP8/14 measured by in-house ELISA (ng/ml), median (IQR) 1025 (588-1288)
MRP8/14 measured by Bühlmann ELISA (ng/ml), median (IQR) 3835 (2146-4806)
 
JIA=juvenile idiopathic arthritis, IQR=interquartile range, RF=rheumatoid factor, MTX=methotrexate, MRP=myeloid related 
protein
SUPPLEMENTARY FILE - RESULTS OF BÜHLMANN ELISA
MRP8/14 levels at baseline and response to treatment
MRP8/14 serum levels were significantly correlated to ESR at baseline (Spearman’s 
rho 0.361, p=0.001 (Bühlmann ELISA)). Baseline MRP8/14 serum levels were higher 
in responders (median in responders was 5556 (IQR 3092-10008)) compared to non-
responders (median 2504 (IQR 1292-3950), p<0.001)) (Figure 1).
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"!Figure 1 Differences in MRP8/14 between non-responders and responders, Bühlmann ELISA
199
In a univariable logistic regression this resulted in an OR of 1.2 (95% CI: 1.0-1.3) for 
achieving at least an ACRpedi 50 response per 500 units of MRP (ng/ml) for the Bühlmann 
ELISA measurements.
Prediction of response corrected for other variables
Baseline MRP8/14 serum levels were significantly associated with change in JADAS-10 in 
a univariable linear regression analysis (β=0.245, 95% CI 0.116 to 0.375, p<0.001 for the 
Bühlmann ELISA). IN the corrected multivariable analysis the corrected β was 0.197 per 500 
units increase in ng/ml, 95% CI 0.087 to 0.306, p<0.001. The change in explained variance 
was identical: 4%.
Use of MRP8/14 as a prognostic marker for response to treatment
The in-house ELISA and the Bühlmann ELISA had the same accuracy for predicting 
response to anti-TNF treatment, the accuracy of the Bühlmann ELISA is shown in table 2. 
Table 2 Sensitivity, specificity and likelihood ratios for the determined cut-off value of MRP8/14 predicting 
response to anti-TNF treatment, Bühlmann ELISA 
Accuracy measure Bühlmann ELISA
Cut-off level MRP8/14 (ng/ml) 4387
Sensitivity 67%
Specificity 81%
Positive likelihood ratio 3.4
Negative likelihood ratio 0.4
Youden index 0.47
AUC 0.77
 
AUC=area under the curve
Change in MRP8/14 levels after treatment
Of 34 patients, enough serum was available to determine MRP in the follow-up sample. 
Of these patients 11 could be categorized as non-responders. Treatment with etanercept 
lowered MRP8/14 serum levels significantly only in responders (p<0.001 for both ELISAs) 
(Figure 2A), but not in non-responders (Figure 2B)). Change in MRP was significantly 
correlated to change in JADAS10 (Spearman’s rho: 0.581, p=0.001 (Bühlmann ELISA)).
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Association of MRP8/14 level and flare after etanercept withdrawal after successful 
treatment
Patients who flared within 6 months (n=12) after the discontinuation of etanercept had 
higher MRP levels at discontinuation than patients who did not flare (n=14) (p=0.013, 
median 3835 (IQR 2146-4806) vs. 1415 (IQR 1099-863) (Bühlmann ELISA), figure 3).
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Figure 2A Change in MRP8/14 in non-responders, Bühlmann ELISA
Figure 2B Change in MRP8/14 in responders, Bühlmann ELISA
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Cut-off for the prediction of a flare after etanercept withdrawal plus their prognostic 
accuracy are given in table 3. 
Table 3 Sensitivity, specificity and likelihood ratios for the determined cut-off value of MRP8/14 predicting a 
flare within 6 months 
Accuracy measure Bühlmann ELISA
Cut-off level MRP8/14 (ng/ml) 2045
Sensitivity 83%
Specificity 71%
Positive likelihood ratio 2.9
Negative likelihood ratio 0.2
Youden index 0.55
AUC (95% CI) 0.79 (0.61 to 0.96)
 
AUC=area under the curve
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LETTER
In juvenile idiopathic arthritis (JIA) patients there is a lack of markers that predict severe 
disease. Although anticitrullinated protein antibodies (ACPA) have contributed substantially 
to the understanding of rheumatoid arthritis (RA),261 their detection in JIA has not been 
equally useful as incidence rates in JIA patients are low 262 and merely confined to the 
polyarticular immunoglobulin (Ig)M-rheumatoid factor (RF)-positive category resembling 
RA. Recently, anticarbamylated protein (anti-CarP) antibodies were detected in 45% of RA 
patients and importantly also in 16%–20% ACPA-negative patients.263-265 Within the ACPA-
negative patients, anti-CarP antibodies were associated with more severe radiographic 
progression.263 Since most JIA patients are ACPA-negative, we investigated whether anti-
CarP antibodies are present in the sera of JIA patients and how they are related to ACPA 
and IgM-RF.
JIA patients from three Dutch sources were included: the BeSt for Kids trial (NTR 1574, a 
treatment strategy study) (n=33), a previously described cohort 266(n=48) and the Arthritis 
and Biologicals in Children (ABC) register 29(n=153). Healthy controls (n=107) (mean age 
(range) 11 (2–20)) are stem-cell graft donors. Written informed consent was obtained from 
all patients and controls. Blood collection and storage are comparable among different 
cohorts. Cross-sectionally obtained sera from 234 JIA patients at variable time points in 
disease course were analysed. All International League against Rheumatism JIA categories 
were included1 with polyarticular JIA over-represented. Median disease duration at the time 
of serum collection was 2.3 years (IQR 0.7–6.8) (table 1). Patients’ disease characteristics 
were collected from patient files. Anti-CarP antibodies and ACPA were measured by ELISA 
as described previously.263 
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Table 1 Disease characteristics of 234 JIA patients 
Characteristics Number
Gender m/f (%f) 76/158 (67.5%)
Median age (years) (IQR) 12.1 (8.4–16.2)
Median disease duration (IQR) 2.3 (0.7–6.8)
Median age at JIA onset (IQR) 8.8 (3.4–12.4)
ANA-positive at disease onset 64 (27.4%)
Systemic JIA 35 (15.0%)
Polyarticular JIA RF-negative 90 (38.5%)
Polyarticular JIA RF-positive 19 (8.1%)
Oligo-articular JIA extended 41 (17.5%)
Oligo-articular JIA persistent 18 (7.7%)
Juvenile psoriatic arthritis 24 (10.3%)
Enthesitis-related arthritis 5 (2.1%)
Undifferentiated 2 (0.8%)
 
ANA=anti-nuclear antibodies; RF=rheumatoid factor.
We observed that 8.1% (19/234) of the JIA patients were positive for anti-Ca-FCS 
antibodies versus 4.7% (5/107) of controls (p=0.20); 13.2% (31/234) of patients versus 
2.8% (3/107) of controls were positive for anti-Ca-Fib antibodies (p=0.003); 16.7% (39/234) 
of patients versus 8/107 (7.5%) of controls were positive for at least one anti-CarP antibody 
(p=0.028); and 11/234 (4.7%) versus 0 of controls (p=0.017) were positive for both anti-
CarP reactivities. Both anti-Ca-FCS and anti-Ca-Fib antibodies were predominantly present 
in polyarticular IgM-RF-positive patients compared with other JIA categories (p<0.0001) 
(figure 1). Additionally, 53% (8/15) of ACPA-positive patients and 42.1% (8/19) of IgM-
RF-positive patients were also positive for anti-CarP antibodies. Importantly, anti-CarP 
antibodies were also found in ACPA and IgM-RF-negative patients as 57.9% (11/19) of anti-
CarP-positive patients were negative for ACPA and 27.3% (3/11) were negative for IgM-RF. 
In total, nine JIA patients were positive for IgM-RF, ACPA and anti-CarP (Ca-FCS and/or 
Ca-Fib) antibodies. All triple positive patients were part of the ABC register.
207
  anti-CarP-FCS   anti-CarP-Fib 
 n/total (%)  n/total (%)  
 All JIA in total 19/234 (8.1%) NS 31/234(13.2%) ** 
 Systemic onset JIA 2/35 (5.7%) NS 2/35(5.7%) NS 
 Polyarticular RF negative 3/90 (3.3%) NS 9/90(10%) * 
 Polyarticular RF positive 8/19 (42.1%) ** 11/19(57.9%) ** 
 Oligo articular extended 3/41 (7.3%) NS 4/41(9.8%) NS 
 Oligo articular persistent 2/18 (11.1%) NS 2/18(11.1%) NS 
 Juvenile Psoriatic Arthritis 1/24 (4.2%) NS 3/24(12.5%) NS 
 Enthesitis related Arthritis 0 NS 0 NS 
 Undifferentiated 0 NS 0 NS 
 Controls 5/107 (4.7%)   3/107 (2.8%)   
 
Hissink et al. Figure 1
A B
CC
Anti-CarP-FCS Anti-CarP-Fib
n/total (%) n/total (%)
All JIA in total 19/234 (8.1) NS 31/234 (13.2) **
Systemic onset JIA 2/35 (5.7) NS 2/35 (5.7) NS
Polyarticular RF negative 3/90 (3.3) NS 9/90 (10.0) *
Polyarticular RF positive 8/19 (42.1) ** 11/19 (57.9) **
Oligo articular extended 3/41 (7.3) NS 4/41 (9.8) NS
Oligo articular persistent 2/18 (11.1) NS 2/18 (11.1) NS
Juvenile Psoriatic Arthritis 1/24 (4.2) NS 3/24 (12.5) NS
Enthesitis Related Arthritis 0 NS 0 NS
Undifferentiated 0 NS 0 NS
Controls 5/107 (4.7) 3/107 (2.8)
 
Figure 1 IgG anticarbamylated protein (anti-CarP) antibodies are present in juvenile idiopathic arthritis (JIA) sera. A cut-off 
for positivity (horizontal line) was determined using the mean plus two times the SD of the healthy controls. Antibodies 
against Ca-FCS (A) and Ca-Fib (B) in the sera of JIA patients and healthy controls are depicted in aU/mL. (C) Results of 
anti-CarP antibodies: positivity above cut-off per JIA category in absolute number, percentage and significance (NS=not 
significant, *p<0.05, **p<0.01). FCS=fetal calf serum; RF=rheumatoid factor.
Disease duration at sample collection, anti-nuclear antibodies status or age was not 
associated with the presence of anti-CarP antibodies. In the second cohort,266 we did not 
find an association of anti-CarP positivity with disease activity measured by time-in-active-
disease at the time of sampling. Within the ABC register cohort, no association was found 
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between the presence of anti-CarP antibodies and ACR-Pedi 30 response44 or reaching 
inactive disease 123 at 15 months after starting anti-TNF treatment. The cross-sectional 
nature of these three cohorts did not allow a more in-depth analysis on the association with 
clinical outcome.
This is the first study showing the presence of anti-CarP antibodies in JIA stimulating future 
studies on the diagnostic and prognostic value of anti-CarP antibodies in JIA.
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Chapter 5. General discussion
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The management of JIA has developed greatly in the last few decades. The possibility 
of treatment with synthetic DMARDs early in the disease course and the introduction 
of biologic therapy significantly improved the prospects of children with JIA. The ABC 
register has provided a unique opportunity to study the effects of the introduction of 
biologic treatment in real life. Previous analyses from this register predominantly reported 
on the effectiveness of etanercept on the disease activity and functional and quality of life 
outcomes. Since the introduction of etanercept however, a wide range of biologic agents 
has become available which resulted in a transformation of the management of JIA. This 
thesis studied the effects of these changes in an observational study design. It investigated 
both the effectiveness of biologic agents as well as the changes in the prescription 
behaviour of physicians. It looked into the patient population to which biologic agents are 
prescribed and examined its effectiveness in patients to whom the drug was prescribed 
off-label. Additionally part of this thesis is dedicated to the study of new developments in 
monitoring tools including biomarkers, a patient-reported joint-count and a new method of 
evaluating bone age and bone density.
In the following chapter the main findings of this thesis are reviewed and discussed in light 
of current clinical practice. Methodological considerations of this thesis and the study of 
JIA in general are discussed. Finally, recommendations for future research are given.
THE CHANGING LANDSCAPE OF JIA TREATMENT –  
FINDINGS AND CLINICAL IMPLICATIONS
Trends in biologic treatment, effectiveness and long term outcome
The efficacy and effectiveness of etanercept were proven in an RCT and numerous 
observational studies. Because it was the first (and for a long time the only) biologic 
agent to be approved for the treatment of JIA, etanercept has been studied extensively 
both in and outside the ABC register.164 In this thesis, the effectiveness of etanercept was 
underlined in a long-term follow-up study in which the gain in quality of life after start 
of treatment appeared to be persistent and disability scores were low, even 8.5 years 
after treatment began (chapter 2.2). Interestingly, although overall quality of life showed 
sustained improvement, pain scores worsened since the last measurement. The levels 
of pain patients indicated did not fully correspond with the low disease activity observed 
in this study. Chronic pain without corresponding disease activity is a subject that is not 
clearly understood and deserves attention.267  
Although we saw that over the course of the study biologic treatment was prescribed earlier 
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in the disease course (chapter 3.1), half of the patients in the long term follow-up study 
still had radiological damage in the long run (chapter 2.2). In the majority of these patients, 
some form of radiological damage had been reported already before the start of etanercept. 
Patients in the long term follow-up study were mostly patients included in the earlier 
years of the ABC register. However, it may be worth reconsidering the timing of biologic 
treatment; some patients may benefit from a start of biologic treatment very early in the 
disease course, thereby preventing the development of radiological damage.
With the expansion of the biologic armament the experience of physicians with this class 
of drugs increased (chapter 3.2). Both the increased treatment options as well as the 
increased experience led to changes in prescription patterns; a wider range of biologic 
agents was prescribed to more and different kinds of patients. 
Between 1999 and 2012, etanercept continued to be the most prescribed biologic agent for 
non-systemic JIA (chapter 3.1). Although adalimumab had been approved in 2008 for non-
systemic JIA, it was still prescribed infrequently and to a specific subset of patients.  
Over the course of the study, anakinra became the most prescribed drug for systemic JIA 
as first biologic treatment (chapter 3.1). With regard to the second biologic treatment, after 
failure of etanercept, we observed that systemic JIA patients responded well to a switch to 
anakinra, much better than to a second TNF-inhibiting agent (chapter 3.4). These findings 
were expected, because of an increasing understanding of the underlying immunological 
and inflammatory pathways. While non-systemic JIA is regarded as an auto-immune 
disease with principal abnormalities in the adaptive immune system, systemic JIA is 
now regarded as an auto-inflammatory disease with principal abnormalities in the innate 
immune system. These abnormalities result in high circulating levels of, among other pro-
inflammatory cytokines, IL-1 and IL-6.84 85 268 
Because we now regard the inflammatory process underlying systemic JIA to be distinct 
from non-systemic JIA, with an important role for IL-1, and because it was for long the only 
IL-1 inhibitor available, anakinra is currently the first choice of biologic treatment for this JIA 
category in treatment recommendations.269 It is however not approved by FDA or EMA for 
this indication. Tocilizumab is approved for systemic JIA, however is at this point regarded 
as second line biologic treatment for this indication. Off-label use of canakinumab is also 
regarded as a possible second-line step.269 For patients with systemic features IL-1 and 
IL-6 seem the most logical targets. However, there seems to be a distinct group of patients 
in whom the autoinflammatory start of the disease advances into an autoimmune disease 
course. For these patients in whom the systemic features subside, but polyarthritis remains, 
TNF-blockade may be an effective option.29 151 270 271 
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Tocilizumab has now also been approved for the treatment of non-systemic JIA. Its 
approval was so recent that we could not comment in this thesis on the tocilizumab’s 
effectiveness as either first biologic agent or second-line biologic treatment. It may be 
worth trying to target IL-6 after the failure of etanercept, as the effectiveness of a second 
TNF-inhibitor is likely to be reduced, especially when the reason for switching was 
ineffectiveness of etanercept (chapter 3.4). 
During the course of the study, biologic agents were also prescribed to a different kind of 
patient (chapter 3.1). We observed that biologic agents were no longer only prescribed 
to patients for whom biologic treatment was originally reserved (polyarticular or systemic 
course of disease). Also in these oligoarticular persistent JIA patients, who were all 
refractory to MTX treatment and intra-articular corticosteroid injections, TNF-inhibitors were 
effective in decreasing disease activity (chapter 2.1). Apparently for some physicians, the 
number of affected joints was not the most important feature in the decision to treat with 
a biologic agent. This is in line with current treatment recommendations for JIA, in which 
other prognostic factors and disease activity indicators are also part of the decision making 
process.17 Although these guidelines are a step in the direction of a more personalized 
treat-to-target regimen, there is room for improvement to fully individualize JIA therapy. For 
every patient, whether it is a patient fulfilling eligibility criteria or not, the physician has to be 
aware of the harms and benefits of the treatment that is prescribed. Although it seems that 
biologic treatment, and particularly etanercept, is safe, very long term effects are still largely 
unknown. In addition, the medication is relatively expensive. Possible adverse events and 
costs should always be part of clinical decision making.
Decision making and comparative effectiveness
The decision making process regarding treatment was also subject of research in this 
thesis. Although new treatment options became available in rapid succession, physicians 
were still relatively slow in adapting to these new treatment options, especially when the 
new drug targeted the same cytokine as an older and more well known drug, as is the 
case with adalimumab and etanercept (chapter 3.1 and chapter 3.2). Physicians indicated 
that they kept to etanercept because they were less familiar with the (long term) adverse 
events of adalimumab. Furthermore most physicians prescribed this new drug only to 
specific patients. They thought adalimumab to be more effective for the JIA category the 
patient was diagnosed with or for the extra-articular symptoms that accompanied that JIA 
category, such as uveitis or gastro-intestinal problems (chapter 3.2). Although they base 
their decisions on ideas about differences in effectiveness, true comparative effectiveness 
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studies are scarce and guidelines (for instance for uveitis treatment) are largely based on 
expert opinion.272 To achieve a higher level of evidence, particularly in this fast changing 
landscape of biologic treatment, comparative effectiveness studies are urgently needed to 
support clinical decision making.273
Several attempts were made in this thesis to compare different treatments. In these 
comparisons various methodological challenges were faced. Firstly, switching to another 
biologic agent after the failure of etanercept proved to be effective in some patients, using 
drug persistence as a proxy for effectiveness (chapter 3.4). When prescribed as the second 
TNF-inhibiting treatment after the failure of etanercept, adalimumab and infliximab seemed 
to be equally effective. Because this was an analysis performed in a real-life database, it 
was influenced by the prescription behaviour that prevailed at the time, which was again 
inevitably shaped by the availability of biologic agents within the study period. The drug 
adherence may very well be affected by the fact that etanercept was the only available 
drug at the beginning of biologic treatment. The same is true for the second treatment, 
after which again no other agents may have been available. Correcting for this confounding 
is difficult, and it is therefore hard to draw any definite conclusions on the comparative 
effectiveness of the separate TNF-inhibitors after the failure of etanercept. 
Physicians have their reasons to treat a specific patient with a specific drug, and this 
reasoning may also affect the outcome of the patient. The treatment choices of physicians 
and the resulting confounding by indication resulted in difficulties in the comparison of 
adalimumab and etanercept as first biologic agent (chapter 3.5). Three types of analyses 
could not give a definite answer to the question of the comparative effectiveness of 
these two agents. This study thereby identified an important issue that both physicians 
interpreting comparative effectiveness studies and investigators from other registers and 
observational studies should be aware of.  
The third study on comparative effectiveness in this thesis explored the possibilities of 
comparing the results of the RCTs performed with biologic agents in JIA (chapter 3.3). 
Although no differences in efficacy were found, the differences between the trials and 
the included study populations were significant, making the conclusions on comparative 
efficacy less reliable. 
Biomarkers and monitoring tools
Unfortunately, the attempts to compare several treatments have not yet been conclusive on 
the question of comparative effectiveness of the available biologic treatments, especially 
when the biologic agents target the same cytokine. For an informed treatment decision 
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however, we would not only like to know what the differences in effectiveness are, but we 
would also like to have more insight into the effectiveness of a drug for specific patients. 
Ideally, there would be a distinctive feature of the patient or a test or biomarker we could 
perform that would perfectly guide treatment decisions.
In this thesis, the biomarker MRP8/14 was tested for its accuracy in the prediction of 
treatment response to TNF-inhibitors in non-systemic JIA and also for its accuracy in 
predicting a flare after withdrawal of etanercept treatment when remission was achieved 
(chapter 4.4). MRP8/14 serum levels proved to be associated with response to treatment 
with TNF-inhibitors and with relapse after discontinuation of etanercept. It seems to be wise 
to postpone etanercept discontinuation when MRP8/14 levels are high. These associations 
were present for both an experimental ELISA as well as a commercial ELISA, although the 
prognostic accuracy differed slightly (chapter 4.4). The availability of reliable commercial 
ELISA kits, plus the fact that MRP8/14 is a very stable protein even when serum is stored 
at room temperature, make it a suitable biomarker for clinical practice. On the other hand, 
the prediction of both events was not perfect, MRP8/14 serum levels explained only a small 
part of the variance in outcome when added to predictive clinical factors and MRP8/14 
serum levels have up till now only been tested for MTX and etanercept treatment. Other 
predictors/biomarkers need to be identified to improve the recognition of patients who 
will benefit from the start of selected treatments and patients who can safely stop this 
treatment again.
Additionally, in an exploring investigation, anti-CarP antibodies were detected in serum 
samples of JIA patients and also found in ACPA and IgM-RF-negative patients (chapter 
4.5). The diagnostic and prognostic value of these proteins still needs to be determined.
This thesis also explored new options for monitoring JIA. 
Bone mineral density evaluation of patients with JIA is part of an ongoing debate. Some 
physicians feel it should be closely monitored and treatment should be given based on 
this monitoring. Others are aware of the risk of low bone density, but feel monitoring is not 
necessary and the focus should be on prevention of decreased bone density by treating 
all high risk patients.274 Both approaches are defendable, especially in the light of the 
difficulties in the determination of bone mineral density. DXA is the most used method 
for evaluation of bone mineral density, however it is not the gold standard.201 240 That term 
is reserved for pQCT, which is unfortunately more expensive, less accessible and has a 
relatively high radiation exposure. The BoneXpert method for automated determination 
of bone age and bone mineral density based on hand radiographs proved feasible in JIA 
patients. It is very easy to use, relatively cheap, uses existing hand radiographs and is less 
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burdensome for the patient than the other methods. The bone mineral density measure 
derived from the BoneXpert however did not correlate well to the often used DXA method 
(chapter 4.2 and chapter 4.3). We therefore feel a comparison with the gold standard 
(pQCT) for bone mineral density evaluation is warranted if we want to determine the value 
of BoneXpert in the evaluation of bone mineral density in JIA patients. Caution is necessary 
when using the BoneXpert method for the determination of bone mineral density in this 
patient group, especially because the bone mineral density of the hand may be locally 
decreased.
We feel that training of patients in recognizing joints with arthritis should be further 
investigated to get patients to be more involved in their disease but also in the decision 
making process. Implementing a patient-reported joint count without training is not useful, 
as a patient reported joint-count had limited agreement with a joint-count performed by 
the treating physician (chapter 4.1). However, when patients report no active arthritis, 
the physician mostly agrees with them. These results were consistent with other studies 
investigating patient-reported joint counts in JIA and RA.179-181 Furthermore we should 
determine what purpose we want a patient-reported joint count to serve. Instead of 
monitoring arthritis, we could also use it as a measure for the patient’s wellbeing/pain due 
to the disease activity. 
To conclude, we can say that etanercept is now very well studied and that it is effective 
and has a favourable safety profile, also in the very long term. Unfortunately, we have not 
been able to answer the question whether there is a difference in effectiveness between 
the available TNF-inhibitors. Furthermore, no single feature or biomarker is yet available to 
perfectly predict response to TNF-inhibitors. Other biomarkers and monitoring tools are still 
under investigation. For clinical practice it is therefore essential that the treating physician 
fully realizes why he or she prescribes a certain treatment. Additionally, participation in 
observational research will be vital in answering the questions we still have, as clinical trials 
will most likely be unable to provide those answers. 
METHODOLOGICAL CONSIDERATIONS IN THE CURRENT AND FUTURE STUDIES
The ABC register
The ABC register was designed with the aim of studying the effectiveness and safety of 
etanercept (and later every biologic treatment) prescribed to children with JIA.32 It was 
a national study in which every centre in which JIA patients were treated with biologic 
agents was included. It was one of the first registers studying biologic treatment, and 
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as such, contributed significantly to the literature on etanercept for JIA patients.24 26-32 
83 165 275-277 Because every participating centre had a representative in the ABC working 
group, everyone involved stayed up-to-date on developments in the register. Since 
the Netherlands is a relatively small country and lines between the investigators and 
participating physicians were short, we could ensure a dataset of high quality. Especially at 
the start of the ABC register, biologic treatment was new and everyone involved was very 
committed to the data collection. For reimbursement of biologic treatment, patients were 
required to be assessed on the same disease activity variables and the same time points as 
in the ABC register. A key strength of the register is therefore its very detailed prospective 
data collection, particularly in the first years of the study. Over the years, more and more 
patients were treated with biologic agents and biologic treatment became a normal part of 
clinical practice. Because data collection was at that point more time consuming and the 
participating physicians were less focused on the novelty and the importance of the data 
collection, the amount of missing data increased slightly. In the data analyses missing data 
was handled with multiple imputation methods where possible. The variables that were 
most often missing were the variables that were not routinely collected in all centres, such 
as the CHAQ and the accompanying VAS’.  
While in the earlier years of the register we can be fairly certain to have included every JIA 
patient in the Netherlands starting biologic treatment, in later years it is possible that a 
few have been missed, for instance because less specialized clinics decided to treat the 
patient without consulting one of the participating centres. Patients enrolled in clinical trials 
had to be excluded because of competing interests. Still, because the large majority of JIA 
patients is treated by a specialized paediatric rheumatologists in one of the participating 
centres, we feel patient inclusion remained at a high and representative level. 
No comparator group was included in the ABC register and its starting point was the 
prescription of a biologic agent. This limits the generalizability and the interpretation of 
the findings on effectiveness and safety of biologic agents. Because the ABC register 
follows daily clinical practice and therefore the prescription patterns adopted by the 
treating physicians, it is difficult to design an observational drug study with an appropriate 
comparator. There are several examples of studies in RA and JIA in which a comparator 
group is included.153 278-281 Often these comparator cohorts consist of biologic-naïve 
patients with similar disease characteristics starting MTX treatment. Several statistical 
techniques are applied to correct for confounding in comparing the two groups. For this 
to be successful, all possible confounders have to be registered and there has to be some 
overlap between the groups that are compared.  
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The advantage of these studies is the possibility of comparing effectiveness and safety 
to comparable patients. This can be especially useful in comparing safety issues, as JIA 
itself may be associated with a change in risk for certain adverse events. By comparing 
two comparable groups treated in a different way, one can control for these background 
risks. As long as the groups are similar, at least to some extent, with regard to confounding 
factors, also the comparative effectiveness can be studied, thereby controlling for the 
natural course of the disease.  
The disadvantage of the inclusion of a comparator group is the presence of unmeasured 
confounders, which is unavoidable. Additionally, especially in JIA patients who are almost 
all treated according to the same step-up regimen, finding overlap between the study 
population and the comparator group will most probably be problematic. 
Subgroups could be studied separately, making use of the data of the ABC register. The 
small sample size in these studies limits the power of the analyses, and therefore the 
inferences that can be made based on the data. 
Most of the data in the studies resulting from the ABC register are prospectively collected, 
which is one of the strengths of the register. However, for some analyses such as the long 
term follow-up study, part of the information was retrospectively retrieved from the treating 
physician. This limits the reliability of these data. 
The observational study design 
The observational study design itself has several strengths and weaknesses. In contrast 
to an RCT which is designed to evaluate short-term efficacy and safety in a standardized 
setting, the observational design is used to observe and apprehend the real-life use 
of biologic treatment and to capture its long term safety. Its biggest flaw is the lack of 
randomization. This gives rise to its greatest concern: confounding by indication. An 
observational drug study is always subject to the current treatment paradigm and every 
treatment decision is made by the treating physician. This means that some variables may 
be related to both the reason of prescription of a drug and to the outcome under study. 
Because subjects are randomized in an RCT, any differences between two groups that are 
compared are pure chance. Therefore, the effects measured are almost certainly the result 
of the intervention studied. In a study where confounding by indication is present and not 
corrected for, a claim on causality is very hard to prove. 
Confounding by indication almost certainly plays a role in several analyses in this thesis. 
In trends analysis, but also in drug persistence analysis in switching biologic treatments, 
the changing treatment availability of the drugs studied most definitely influences the 
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analyses. The attitude of physicians towards biologic treatment changed together with the 
treatment availability. They timed biologic treatment earlier, and the patient characteristics 
of patients treated with biologic agents changed. Additionally, patients included in the start 
of the register had been waiting for a treatment option like biologic treatment for a long 
time, as their disease was refractory to other drugs. These are the changes we know of 
and we can try to correct for in analyses. It is however not unthinkable that unmeasured 
factors changed as well. This unmeasured confounding is a challenge for observational 
studies. Differences between two patient groups treated with different biologic agents were 
detected in two studies in this thesis. Attempts to adjust for these differences partly failed, 
thereby identifying an important issue for future observational studies into the comparative 
effectiveness and safety of biologic agents.
Drug studies in paediatric rheumatology
JIA is an uncommon disease that results in a small population available for drug studies. 
Moreover, biologic treatment is only prescribed to a subset of JIA patients, which limits 
the sample size of biologic drug studies even further. The increasing number of biologic 
agents available restricts the power of single drug studies in the small patient population in 
which they can be tested. Furthermore, the heterogeneity of the disease makes it even less 
possible to generalize the effectiveness of a drug to a particular patient. These limitations of 
drug studies in paediatric rheumatology cannot be influenced by investigators and have to 
be recognized and dealt with in the best possible way.
However, the design of studies and the outcome measures used can be influenced by 
researchers and regulators. In this thesis it was shown that two trial designs are often used 
in paediatric rheumatology: the classic RCT and the withdrawal trial. The outcome measure 
of the withdrawal trial is not the true efficacy of the drug, but the efficacy of the drug to 
suppress a flare. Particularly now that the patients who are treated with biologic agents are 
changing, the question rises whether the withdrawal design is really the most appropriate 
trial design. In future trials, less severely affected patients will be included, in whom a flare 
may be less likely, also when the drug is withdrawn. Additionally, patients will be continuing 
MTX treatment or other co-medication during trials, which may also suppress a flare when 
the experimental treatment is stopped. These changes will make it difficult to reach the 
primary endpoint in a withdrawal trial.  
In paediatric rheumatology, and also in this thesis, numerous outcome measures are being 
used to evaluate drug effectiveness. These different outcome measures are contributing 
to less comparable results between studies. Additionally, now that the aim of treatment 
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has shifted to complete silencing of the disease, we should reconsider the definition of 
treatment efficacy. The ACRpedi response measures are most often used in RCTs and were 
also used to evaluate treatment response in this thesis.44 In clinical trials, a patient who 
achieved an ACRpedi30 score is considered as responsive to treatment. In these times 
of changing treatment possibilities we will have to rethink our response measures. Do we 
accept an ACRpedi30 as an indication of effect of treatment, or should we aim higher? 
In addition, the patient population in which we consider biologic treatment is constantly 
changing, and now also includes patients with a lower number of joints involved. For these 
patients a proportional response measure may not capture the true response to treatment. 
In the cases series studying patients with persistent oligoarticular disease we therefore 
evaluated the separate disease activity variables to study effectiveness of etanercept. 
The continuous disease activity score JADAS-10 was also used to evaluate disease 
activity in this thesis.23 It is a composite sum score including four of the JIA disease activity 
variables, including ESR. It is a relatively new measure that is still being improved. Although 
definitions of high and minimal disease activity are now available, at the time of writing, 
no generally accepted definition of improvement on this continuous score was available, 
limiting the interpretation of a change in JADAS-10.282-285 It is however a measure that 
because of its continuous nature is more appropriate to use in longitudinal analyses, and 
internationally used cut-offs will surely be available soon. 
Drug persistence is a common way to evaluate effectiveness in observational studies. 
Being only a proxy for the true effectiveness, it can be influenced by several factors and 
is therefore less reliable as an effectiveness measure. As only etanercept was available for 
the treatment of JIA for a long time, the drug persistence for etanercept as first biologic 
treatment is likely to be influenced by the absence of other treatment options. Perhaps 
treatment with etanercept would have been stopped earlier had other possibilities been 
available. This may have resulted in an overestimation of the effect of etanercept. The same 
is true for the second course of biologic treatment. 
SETTING THE AGENDA FOR FUTURE RESEARCH ON TREATMENT IN PAEDIATRIC 
RHEUMATOLOGY
The increasing treatment options for JIA have resulted in a shift in the aims of JIA treatment 
from managing the disease to achieving inactive disease and preventing long term damage. 
Although this aim is achieved in a large part of patients, still some patients with JIA cannot 
successfully be treated.
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At this point, all available biologic agents are able to attenuate the signs and symptoms of 
the disease to some extent. The key, however, is to find the right treatment for an individual 
patient sufficiently early in the disease, so that damage can be prevented and the disease 
course can – possibly – be truly attenuated. To really go forward, advances are needed in 
several areas. Basic, translational and clinical research should work together to achieve 
these advances. Firstly, we need to improve our understanding of disease pathogenesis, 
so that we can better predict the disease course. Additionally, we need to improve our 
understanding of the working mechanism of medical therapies for JIA, both existing and 
new treatments. In that way we can better predict response to treatment and understand 
the chronicity of the disease in some patients, despite treatment. Finally, we need to 
combine basic research into pathogenesis and into targeting the inflammatory pathway 
with clinical research studying the comparative effectiveness and safety of the increasing 
therapeutic arsenal.
Pathogenesis, disease course and response to treatment
The development of new treatments goes hand in hand with an increasing understanding 
of the disease. Since the first development of TNF-inhibitors, these drugs and their 
effects have been extensively studied and other cytokines were targeted. This led to a 
shift in the perception of the inflammatory and immune response from a hierarchical and 
static pathway to an interconnected and dynamic network 286 287 Although we understand 
more of the cytokines involved, we cannot directly relate these to the disease course in 
an individual patient. To provide tailored treatment we need predictive factors that can 
truly predict the course of the disease and the response to treatment, starting with the 
classification of patients at diagnosis. The current diagnostic criteria formulated by ILAR are 
consensus based and classify JIA patients into different categories based on the number 
of joints involved, the antibody status and accompanying extra-articular symptoms.1 
Although the subdivision of JIA into these categories has resulted in a widely accepted 
and internationally applied classification, significant patient heterogeneity still remains with 
regard to the course and outcome of the disease.288 
Future analyses should focus on combining the increasing knowledge on genotypes, 
gene expression, protein expression, and cellular phenotypes and the knowledge we have 
acquired over the years on predictive clinical features. An example of this combination 
is an analysis performed in the REsearch in Arthritis in Canadian Children, Emphasizing 
OUTcomes (REACHOut) and Biologically Based Outcome Predictors in JIA (BBOP) 
consortia, in which machine learning methods developed for pattern recognition were 
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applied to a defined set of demographic, clinical, laboratory, and cytokine expression 
data.289 From this dataset, five patient clusters were identified, which were more clinically 
and biologically homogeneous than the ILAR categories and strongly predicted the disease 
course. Discriminating factors were the levels of circulating cytokines, profiles of cytokines 
specific to a certain immune response and established clinical variables (including ANA, 
which has also in other studies been suggested as a distinguishing feature). This is one of 
the first studies to apply new methodological techniques to a large database of new onset 
JIA patients to try and develop a new classification system, and hopefully more are to 
follow. 
In addition to predicting the natural course of the disease attention should also be given 
to the possible modulation of the immune response. In RA the concept of a window of 
opportunity is becoming more and more established. Both in basic research as well as 
in treatment-strategy trials, this window of opportunity should be investigated, and the 
investigation of a switch from a step-up approach of treatment to a hit-hard, step-down 
approach can be considered.77 78 286 Mirroring treatment strategies in RA, both combinations 
of a DMARD and a biologic agent and combination therapy consisting of multiple DMARDs 
could be subject of future investigations in JIA. A combination of approaches could work 
additively (or the addition of an extra treatment could be redundant), but a synergistic effect 
could also be possible.
The future of comparative effectiveness and safety
In the fast changing landscape of biologic treatment, comparative studies are necessary to 
investigate the effectiveness and safety of the different drugs. The JIA study population is 
too small to do this in RCTs, especially if there is a need to detect marginal differences in 
effects, as is the case if we want to base our choices of personalized treatment upon the 
evidence derived from such trials. Indirect comparisons or meta-analyses are possible only 
if RCTs are made more uniform. Another way of addressing the question of comparative is 
in an observational study. It is important that in the analyses of such observational studies, 
an appropriate adjustment is made for the confounding discussed earlier, whether biologic 
treatment is compared with biologic treatment or a non-biologic comparator. 
National registers such as the ABC register have contributed hugely to the observational 
literature on biologic treatment, particularly on etanercept. However due to the rarity of JIA 
and the increasing biologic treatment options other than etanercept, no individual national 
study on biologic treatment will be able to answer questions on the effectiveness of less 
commonly prescribed biologics or rare adverse events. To answer these questions, a large 
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sample size is required. International efforts have therefore been made to combine data on 
biologics use from several countries across Europe.290
For several reasons, this thesis is the last that will result from the ABC register. Dutch data 
on biologic use are now recorded in a European database. The question remains whether a 
national database like the ABC register could still be of value. The use of biologic therapies 
differs a great deal across Europe, because of differences in availability and reimbursement. 
Additionally, general management strategies for JIA vary between countries. These 
differences have been shown in RA, but there is no reason to belief these do not exist in 
JIA.291 There are population differences in the observed benefits of a treatment, but also 
in the observed number of adverse events, either because the local incidence rates are 
different, or because the quality of the data collection differs between countries. A national 
study on biologic treatment is very useful in informing treating physicians and national 
health policy on the prescribing behaviour and the resulting effects. The results of a national 
study can thereby assist in improving local practice. On the other hand, for a national 
register to fulfil such a role, it has to be embedded in a national health structure that makes 
use of all the data coming out of the register. To solely have a register to collect data is 
not useful, as the data collection and analysis should have direct implications for health 
policies. One could question if these prerequisites are present in the Netherlands, where no 
authority demands the collection of national data, and where only a very small number of 
patients will be treated with all different kinds of biologic agents. In addition, to truly inform 
national health policies it may also be more useful to have a different starting point for a 
register. Instead of the use of biologic agents, this could be the diagnosis of JIA. In that way 
we would be able to study all different treatments presently used for the treatment of JIA. 
For combined analyses from different countries to be successful, consideration must 
be given to various factors. Information on the generalizability of the national data, the 
way patients are enrolled and the national regulations on the prescription of biologic 
agents all need to be collected. Data collection and outcome assessment must be 
uniform. Methodologies used should take into account the differences between countries. 
Sometimes this may lead to the conclusion that data across studies simply cannot be 
pooled. To make data from separate studies in RA as uniform as possible, an initiative has 
been started for combining data from drug studies292 293. It would be wise to undertake a 
similar action for studying drugs in observational studies in JIA. Although the use of large 
international databases is increasingly common (not in the least because of requirements of 
FDA and EMA), one should keep questioning whether the research questions of interest are 
still valid and whether they can be answered using pooled or combined data.
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To conclude, classification at diagnosis, the use of biomarkers (including imaging) to 
predict response to therapy and true inactive disease, the timing and kind of therapy 
used, the use of combination or monotherapy and the clinical safety and effectiveness 
of different treatments should all be studied further. Putting all these pieces of the puzzle 
together could result in a tailored treatment approach by which we might be able to not 
only attenuate disease activity but also the disease course. All these different pieces 
of information could then help us re-evaluate and adapt treatment in every stage of the 
disease course to the current status of the patient. 
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Chapter 6. Summaries
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ENGLISH SUMMARY
The main aim of this thesis was the evaluation of advances in the management of JIA. It 
focused on developments in the biologic treatment of JIA, using data from the ABC register. 
Additionally, it explored new biomarkers and methods for monitoring the disease activity, 
bone age and bone health of patients with JIA.
Chapter 2 started where the previous theses resulting from the ABC register left off: with 
the effectiveness of the first available TNF-inhibitors.  
In chapter 2.1 the effectiveness of TNF-inhibitors was evaluated for oligoarticular persistent 
JIA, an indication for which TNF-inhibitors are prescribed off-label. A total of 16 patients 
with this JIA category were included in the ABC register, most of them treated with 
etanercept. The majority of these patients had previously been treated with intra-articular 
steroid injections and MTX. Compared to other non-systemic patients included in the ABC 
register, more patients were tested positive for ANA and more patients had (a history of) 
uveitis. Treatment with a TNF-inhibitor decreased disease activity on all variables and more 
than half of patients achieved inactive disease within three months. Anti-TNF treatment 
therefore seems to be a justifiable option, when treatment with MTX and intra-articular 
steroid injections has failed. 
For chapter 2.2 patients from a previous sub-analysis from the ABC register were re-
contacted. The previous analyses had evaluated HRQoL and functional outcome of these 
patients. The aim of this new study was to assess these subjects again, more than five 
years after etanercept was started. 43 of the originally included 53 patients participated. 
The HRQoL improvement shown after start of etanercept was sustained after a median of 
8.5 years. Disease activity and disability scores were generally low. On daily life aspects, 
such as education and employment, patients functioned comparably or better than their 
peers. Persistence and possible deterioration of radiologic damage stress the importance 
of early treatment. Patients reported higher pain levels than at their last follow-up in the 
previous analysis, indicating that perceived pain needs attention, even when the disease is 
inactive.
The expanding biologic treatment options were investigated in chapter 3. 
In chapter 3.1 the trends in prescription behaviour observed in the ABC register over the 
period 1999-2012 were evaluated. An increasing number of patients were treated with 
an increasing diversity of biologic agents. Over the years, the patient profile changed, 
the decision to treat with biologic agents was taken earlier in the disease course and for 
patients with lower disease activity and who were diagnosed with other JIA categories. 
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Together with these changes, disease outcomes improved. Because so many factors 
changed over the observation period, it is hard to say whether these better outcomes can 
be attributed only to a more effective biologic treatment strategy. During the course of the 
study, new biologic agents became available and incorporated in treatment algorithms. For 
systemic JIA, anakinra became the biologic agent of choice. Although adalimumab was 
available for 4 years of the observation period, etanercept remained first choice for non-
systemic patients. 
The motivations of the paediatric rheumatologist to choose either etanercept or 
adalimumab for non-systemic JIA patients were evaluated in chapter 3.2. The presence 
of (a history of) uveitis was the most important factor directing the choice towards 
adalimumab. Factors specific for the paediatric population—such as painful adalimumab 
injections—as well as the physician’s familiarity with the drug accounted for the preference 
for etanercept.  
In chapter 3.3 the comparative efficacy of the available biologic agents was the subject 
of interest. Because RCTs comparing biologic agents directly are lacking, an attempt was 
made to indirectly compare the results from the placebo-controlled trials in the literature. 
For this analysis, several trials had to be excluded, because there was a wide variation in 
trial design (withdrawal design vs. classical RCT) and patient characteristics (for example 
the disease duration and the JIA categories of the patients who were included). For both 
systemic and non-systemic JIA, three trials were found to be sufficiently comparable to 
include them in two comparison-networks. The short-term efficacy seemed similar across 
biologic agents (etanercept, adalimumab and abatacept) for polyarticular course JIA. For 
systemic JIA, anakinra, canakinumab, tocilizumab were found equally efficacious. As much 
dissimilarity remained, uniformity in trial design is hardly needed to be able to perform 
indirect comparisons in the future. For now, the paediatric rheumatologist has to rely on 
these indirect comparisons supplemented by observational data derived from cohort 
studies and safety, practical and financial arguments. 
Chapter 3.4 is one of these examples for an observational study evaluating effectiveness 
of several biologic agents. It deals with the effectiveness of a second biologic agent after 
failure of etanercept, measured as drug persistence. Around 20% of patients treated 
with etanercept switched to a second biologic agent. For patients with non-systemic JIA, 
adalimumab and infliximab (both TNF-inhibitors) were equally effective. For patients with 
systemic JIA switching from etanercept to a second agent, anakinra was superior to a 
second TNF-inhibitor. Overall, effectiveness of the second biologic agent was lower than 
that of the first, and seemed especially low when the first biologic agent was discontinued 
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because of primary ineffectiveness. Switching does seem to be safe, and since limited 
treatment options are available for these patients, justifiable after etanercept failure. 
In chapter 3.5 an attempt was made to compare the effectiveness of the first biologic 
agent, focusing on the comparison of the two TNF-inhibitors approved for non-systemic 
JIA: etanercept and adalimumab. In this chapter, three ways of analysis were applied to the 
same dataset. A linear regression was fitted for the change in JADAS-10, with treatment 
as one of the covariates. A cox regression was fitted, also using treatment as a covariate, 
again using drug persistence as a proxy for treatment effectiveness. Thirdly, an attempt 
was made to construct a propensity score for the allocation of treatment, and to apply this 
propensity score in a logistic regression method with minimal disease activity as outcome 
measure. In the first two methods, no significant differences were found in effectiveness 
of the two TNF-inhibitors. The third analysis could not be brought to a successful end, 
because of the lack of overlap in patient characteristics between the two treatment 
groups, which may have been expected, based on chapter 3.2. This lack of overlap in 
confounding factors was the most important finding in this chapter. Physicians interpreting 
comparative effectiveness and safety studies, but also investigators from other registers 
and observational studies should be aware of this problem.
In chapter 4 new monitoring tools for JIA were explored. 
To investigate whether the patient is able to give information on the number of active joints 
with arthritis, and whether this information corresponds to the assessment of the treating 
physician, a patient-reported joint count was evaluated in chapter 4.1. At the outpatient 
clinic of the Erasmus MC, 75 JIA patients aged 12-21 were asked to mark joints with active 
arthritis on a mannequin before two subsequent clinic visits. The physician then performed 
a joint count without having seen the patient’s assessment. In general patients had a low 
number of active joints (median 1 joint, indicated by the physician). Although the agreement 
on both the overall number of joints and on individual joints was moderate at the first clinic 
visit, it decreased at the second clinic visit. The sensitivity to change was only moderate 
for worsening patients. When a patient reported no arthritis, the physician agreed in 
almost all cases. However for active joints this agreement was lower as patients generally 
overestimated active arthritis. The reports on a patient-reported joint count may be more of 
a general indication of wellbeing for the patient. If we want to use it as a measure of arthritis 
in clinical practice, the possibility of training patients to recognize active disease should be 
investigated. 
Since JIA patients are at risk for abnormal bone maturation and decreased bone mineral 
density. In chapter 4.2 and chapter 4.3 a new method to automatically determine both 
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in hand radiographs was studied. In chapter 4.2 this new method, called BoneXpert, was 
found to be feasible and easy to use in 69 JIA patients included in the ABC register. To 
apply this method, radiographs have to be of reasonable quality and patients’ bone age 
has to lie within the age ranges of the program. The patients in this study had delayed bone 
maturation and lower bone mineral density compared with healthy children. Subsequently, 
in chapter 4.3 the estimates of bone mineral density derived from BoneXpert were 
compared with those derived from DXA. DXA, albeit not the gold standard for measuring 
bone mineral density in children, is the most frequently used method. The correlation 
between age and gender corrected scores from BoneXpert and DXA was low. The chapter 
concludes that for application of this new method in clinical practice, it has to be compared 
with the gold standard in measuring bone mineral density, which is (p)QCT.  
In chapter 4.4 the predictive value of MRP8/14 serum levels was investigated for the 
response to treatment in 88 non-systemic JIA patients starting TNF-inhibitors. Additionally 
the predictive value of this same marker was assessed for predicting a disease flare after 
the discontinuation of etanercept when remission on medication had been achieved. Both 
an experimental in-house ELISA and a commercially available ELISA kit were tested. A 
subgroup of JIA patients who responded well to anti-TNF treatment had high serum levels 
of MRP8/14. When remission was achieved and etanercept withdrawn, elevated MRP8/14 
levels were associated with a higher chance to flare. On prediction of both events, the 
accuracy was not perfect. The two ELISAs tested performed equally. 
Finally, in chapter 4.5 serum samples from 234 patients included in three different cohorts 
were tested for the presence of anti-CarP antibodies, a novel antibody that was found to 
be associated with worse disease outcome in RA patients. Anti-CarP antibodies were more 
often present in the serum of JIA patients compared with healthy controls. Approximately 
half of the anti-CarP positive patients were also positive for anti-citrullinated antibody and/
or IgM-RF. As this was an explorative analysis, the prognostic value of anti-CarP in JIA 
remains to be determined.
The last chapter of this thesis (chapter 5) comprises an overview of its findings, together 
with a discussion of the clinical implications and methodological considerations. It ends 
with a personal view of what the future of JIA research and drug studies in JIA should look 
like. 
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NEDERLANDSE SAMENVATTING
In dit proefschrift staan nieuwe ontwikkelingen in de behandeling van JIA centraal. Hierin 
worden twee aandachtsgebieden onderscheiden. Allereerst zijn gegevens van het ABC 
register gebruikt om de veranderde mogelijkheden in de behandeling met biologicals te 
bestuderen. Vervolgens zijn ook nieuwe biomarkers en methoden voor het monitoren van 
de ziekteactiviteit, de botleeftijd en de botgezondheid van JIA onderzocht.
Hoofdstuk 2 begint waar de onderzoekingen beschreven in eerdere proefschriften die 
voortkwamen uit het ABC register eindigden: bij de effectiviteit van de verschillende TNF-
alfa blokkers voor de behandeling van JIA. 
In hoofdstuk 2.1 wordt onderzoek naar de werkzaamheid van TNF-alfa blokkers 
beschreven, wanneer deze medicijnen worden voorgeschreven aan patiënten met 
persisterende oligoarticulaire JIA. Deze diagnose is officieel geen indicatie voor behandeling 
met TNF-alfa blokkers. Toch werden in het ABC register 16 patiënten met deze JIA 
categorie geïncludeerd; 14 patiënten werden behandeld met etanercept en twee patiënten 
met adalimumab. Het grootste deel van deze patiënten werd eerder behandeld met MTX en 
intra-articulaire steroid injecties. Behalve dat ze minder aangedane gewrichten hadden dan 
de andere patiënten die in Nederland behandeld werden met biologicals, verschilden deze 
patiënten ook op andere eigenschappen van de overige patiënten. Zij testten vaker positief 
voor ANA en meer patiënten hadden (een voorgeschiedenis van) uveitis. Nadat behandeling 
met TNF-alfa blokkers was ingesteld daalde de ziekteactiviteit. Meer dan de helft van de 
patiënten had geen actieve artritis meer binnen drie maanden na start van de behandeling. 
De conclusie van dit hoofdstuk is dan ook dat behandeling van TNF-alfa blokkers een 
effectieve behandeling zijn voor patiënten met deze JIA categorie. De beslissing om deze 
patiënten te behandelen met TNF-alfa blokkers is te rechtvaardigen wanneer behandeling 
met MTX en intra-articulaire injecties niet effectief is gebleken. 
Voor hoofdstuk 2.2 werd met patiënten die eerder deel uitmaakten van een eerdere sub-
analyse van het ABC register opnieuw contact opgenomen. Deze sub-analyse had laten 
zien dat de kwaliteit van leven gerelateerd aan de gezondheid (“health related quality of 
life” (HRQoL)) en het dagelijks functioneren van patiënten sterk vooruitgingen na de start 
van etanercept. Het doel van de nieuwe studie in hoofdstuk 2.2 is om HRQoL en het 
functioneren opnieuw te onderzoeken, meer dan vijf jaar na de start van etanercept. Van 
de oorspronkelijk 53 geïncludeerde patiënten namen 43 patiënten deel aan deze nieuwe 
studie. Zij gaven 8.5 jaar na het starten van etanercept aan een zelfde niveau van HRQoL 
te hebben als kort na de start. Een groot deel van de patiënten had geen artritis en voelde 
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zich weinig beperkt in het dagelijks leven. Opleidingsniveau en arbeidsparticipatie waren 
op hetzelfde niveau of zelfs hoger dan leeftijdsgenoten. Bij veel van deze patiënten was 
al een vorm van schade waarneembaar bij röntgenonderzoek bij de start van etanercept. 
Deze schade bleef aanwezig of was mogelijk soms zelfs verergerd op het moment van deze 
nieuwe studie. In onze ogen benadrukt dit de noodzaak van vroege behandeling. Opvallend 
is dat de patiënten meer pijn aangaven dan bij het laatste follow-up moment in de vorige 
studie. Pijn bij lage ziekteactiviteit is een grotendeels onbegrepen probleem, en verdient 
aandacht zowel in de spreekkamer als in verder wetenschappelijk onderzoek.
De toenemende behandelmogelijkheden met biologicals zijn onderzocht voor hoofdstuk 3. 
In hoofdstuk 3.1 worden de trends in het gebruik van biologicals in het ABC register 
in de periode van 1999 tot 2012 beschreven. Een toenemend aantal patiënten werd 
in deze periode behandeld met biologicals en er werden meer verschillende middelen 
voorgeschreven. Het profiel van de patiënten die behandeld werden met biologicals 
veranderde over de jaren. Zo startten patiënten sneller na de diagnose JIA met behandeling 
met biologicals, bij een lager niveau van ziekteactiviteit. Naast patiënten met polyarticulaire 
en systemische JIA werden in latere jaren ook patiënten met de andere JIA categorieën 
behandeld met biologicals. Tijdens de studieperiode verbeterden ook de uitkomsten van 
patiënten die geïncludeerd werden. Omdat zoveel veranderingen tegelijk plaatsvonden 
kunnen deze verbeterde uitkomsten niet één op één verbonden worden aan de behandeling 
met biologicals. 
De toename in biologicals betekende dat de kinderreumatoloog keuzes moest maken in 
de behandeling van de individuele patiënt. Voor patiënten met systemische JIA koos de 
kinderreumatoloog steeds vaker voor anakinra, zodat aan het einde van de studieperiode 
dit middel de eerste keus bleek voor deze JIA categorie. Ondanks dat adalimumab de 
laatste vier jaar officieel beschikbaar was voor non-systemische JIA bleef etanercept de 
meest voorgeschreven biological voor deze groep patiënten.  
De keuze van de kinderreumatoloog voor ofwel etanercept ofwel adalimumab is het 
onderwerp van hoofdstuk 3.2. De behandelaars gaven aan dat de aanwezigheid van (een 
voorgeschiedenis van) uveitis de belangrijkste factor was om te kiezen voor adalimumab. 
Factoren die specifiek zijn voor de kinderreumatologische populatie (zoals de pijnlijke 
adalimumab injecties), samen met de bekendheid van etanercept bij de behandelend arts, 
zorgden voor een uiteindelijke voorkeur voor etanercept.  
Vanaf hoofdstuk 3.3 worden studies naar het verschil in effectiviteit tussen de verschillende 
biologicals beschreven. Omdat er geen gerandomiseerde trials zijn uitgevoerd die de 
werkzaamheid van de verschillende biologicals direct onderzoeken word in dit hoofdstuk 
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een poging gedaan om de beschikbare trials indirect te vergelijken. Een aantal trials kon 
niet geïncludeerd worden in deze indirecte vergelijking, omdat er grote variabiliteit was 
in de opzet van de verschillende studies (“withdrawal” vs. klassieke gerandomiseerde 
trial) en in de eigenschappen van de patiënten die geïncludeerd waren in de verschillende 
studies (zoals de ziekteduur en de JIA categorieën van deze patiënten). Twee 
vergelijkingsnetwerken konden worden geconstrueerd, een voor systemische en een voor 
non-systemische JIA. Beide netwerken bevatten drie trials die voldoende vergelijkbaar 
werden geacht voor deze analyse. De werkzaamheid van de verschillende biologicals 
op de korte termijn leek vergelijkbaar voor etanercept, adalimumab en abatacept bij de 
behandeling van non-systemische JIA. Voor de behandeling van systemische JIA leken 
canakinumab, anakinra en tocilizumab in gelijke mate werkzaam te zijn. Er waren echter 
nog steeds veel verschillen tussen de studies die in de indirecte vergelijking werden 
meegenomen. Voor het bepalen van de verschillen in werkzaamheid van deze middelen 
zijn trials die biologicals direct vergelijken hard nodig. Het is echter onwaarschijnlijk dat 
deze op korte termijn zullen worden uitgevoerd. Op dit moment moet de kinderreumatoloog 
afgaan op de indirecte vergelijkingen zoals de studie in dit hoofdstuk, gecombineerd met 
de resultaten van observationele studies, aangevuld met de eigen ervaring, praktische en 
financiële argumenten.  
Hoofdstuk 3.4 is een voorbeeld van een dergelijke observationele studie. Hierin wordt 
de effectiviteit van verschillende biologicals vergeleken, wanneer deze voorgeschreven 
werden als tweede biological, nadat behandeling met etanercept niet voldoende effect 
bleek te hebben. Ongeveer 20% van de patiënten die behandeld werden met etanercept 
als eerste biological kregen een tweede biological voorgeschreven. Na onvoldoende 
respons op etanercept, bleken adalimumab en infliximab (beiden TNF-alfa blokkers) even 
effectief voor JIA patiënten non-systemische JIA. Voor patiënten met systemische JIA bleek 
anakinra beter werkzaam dan een tweede TNF-alfa blokker. De effectiviteit van een tweede 
biological was globaal genomen minder dan die van de eerste en leek vooral laag wanneer 
er primair geen respons was op de behandeling met het eerste biological. Het veranderen 
van biological lijkt wel veilig te zijn en, omdat maar weinig andere behandelmogelijkheden 
voorhanden zijn, te rechtvaardigen. 
In hoofdstuk 3.5 wordt het onderzoek naar de verschillen in werkzaamheid van de 
eerst-voorgeschreven biological besproken. In deze studie ligt de focus op de twee voor 
non-systemische JIA geïndiceerde TNF-alfa blokkers etanercept en adalimumab. Drie 
analysemethoden werden toegepast op dezelfde dataset. Als eerste werd een lineaire 
regressie toegepast, met als uitkomstmaat de verandering in JADAS-10. De behandeling 
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werd als covariaat meegenomen. Als tweede werd een Cox regressie uitgevoerd, opnieuw 
met de behandeling als covariaat, maar nu met de continuering van de behandeling als 
maat voor effectiviteit. Als laatste werd geprobeerd om een propensity score te construeren 
voor de toewijzing van behandeling met een bepaalde biological. Vervolgens zou deze 
propensity score in een logistisch regressiemodel worden meegenomen, met het bereiken 
van minimale ziekteactiviteit als uitkomstmaat. In de eerste twee methoden werden geen 
significante verschillen gevonden tussen werkzaamheid van de twee biologicals. De 
derde analyse kon niet volledig worden uitgevoerd, omdat er te weinig overlap was in 
de eigenschappen van patiënten die als confounders werden gezien. Dit was mogelijk 
te verwachten, gebaseerd op hoofdstuk 3.2. Het gebrek aan overlap in confounders is 
de belangrijkste bevinding in dit hoofdstuk. Artsen die onderzoek naar de verschillen in 
werkzaamheid van meerdere middelen interpreteren voor de klinische praktijk, maar ook 
onderzoekers van andere registers en observationele studies moeten zich bewust zijn van 
dit probleem.
In hoofdstuk 4 liggen nieuwe biomarkers en methoden voor het monitoren van JIA onder 
de loep. 
Hoofdstuk 4.1 beschrijft het onderzoek naar een door de patiënt gerapporteerde 
gewrichtsscore. Geprobeerd wordt de vraag te beantwoorden of de inschatting van de 
patiënt ten aanzien van het aantal gewrichten met actieve artritis overeenkomt met de 
beoordeling van de arts. Hiervoor werden op de jongerenpolikliniek van het Erasmus MC 
alle patiënten tijdens twee opeenvolgende polibezoeken gevraagd om actieve artritis aan 
te geven op een gewrichtspoppetje. De arts vulde vervolgens eenzelfde pop in, zonder 
die van de patiënt te hebben gezien. Over het geheel genomen werden weinig actieve 
gewrichten gescoord. De overeenkomst tussen arts en patiënt was redelijk tijdens het 
eerste invulmoment, echter deze was veel minder bij het tweede invulmoment. Als een 
patiënt aangaf dat er geen actieve artritis was, was de arts het hier bijna altijd mee eens. 
Wanneer de patiënt echter aangaf actieve artritis te hebben, was dit volgens de arts vaak 
een overschatting van de aanwezigheid van artritis. Mogelijk is de rapportage van de 
patiënt meer een reflectie van zijn algehele staat van welbevinden. Als we een dergelijke, 
door de patiënt ingevulde gewrichtspop voor de klinische praktijk willen gaan gebruiken, 
moeten we eerst onderzoeken of het mogelijk is de patiënt te trainen in het herkennen van 
actieve artritis. 
JIA patiënten lopen risico een afwijkende bot-maturatie en verminderde botdichtheid te 
ontwikkelen. Hoofdstuk 4.2 en hoofdstuk 4.3 beschrijven de studies waarin een nieuwe 
methode om automatisch de botleeftijd en botdichtheid te bepalen (BoneXpert) wordt 
235
geëvalueerd. Deze nieuwe methode meet de botleeftijd en botdichtheid gebaseerd op 
röntgenfoto’s van de hand. Voor de studie in hoofdstuk 4.2 werden handfoto’s van 69 
patiënten uit het ABC register onderzocht en geconcludeerd dat deze methode uitvoerbaar, 
snel en makkelijk bruikbaar is bij JIA patiënten. De handfoto’s moeten wel van voldoende 
kwaliteit zijn en de botleeftijd van de patiënten moet binnen de grenzen van het programma 
liggen.  
Voor de studie in hoofdstuk 4.3 werd vervolgens de botdichtheidsbepaling van de 
BoneXpert vergeleken met die van de vaak gebruikte DXA scan. De scores, gecorrigeerd 
voor leeftijd en geslacht, correleerden minimaal. Aangezien DXA niet de gouden standaard 
is voor het bepalen van botdichtheid bij kinderen (dit is de pQCT), werd geconcludeerd dat 
BoneXpert met pQCT vergeleken zou moeten worden om zekerheid te verschaffen over de 
waarde van deze methode in de klinische praktijk van JIA. 
In hoofdstuk 4.4 wordt onderzoek naar de waarde van MRP8/14 in het serum van 88 
non-systemische JIA patiënten voor het voorspellen van de respons op behandeling met 
TNF-alfa blokkers beschreven. Daarnaast is ook naar de waarde van deze marker gekeken 
voor het voorspellen van een opvlamming van de JIA wanneer etanercept gestaakt werd na 
het bereiken van remissie. De MRP8/14 bepaling werd gedaan met een door onderzoekers 
in Münster ontwikkelde ELISA en een commercieel verkrijgbare ELISA. Een hoog niveau 
van MRP8/14 in het serum bleek voorspellend voor zowel een goede respons op TNF-
alfa blokkers als voor het opvlammen van de ziekte na het staken van etanercept, echter 
de bepaling had weinig toegevoegde waarde in een predictiemodel met andere klinische 
predictoren. Dit resultaat was hetzelfde voor beide bepalingsmethoden. De nauwkeurigheid 
voor het voorspellen van beide uitkomsten was echter niet perfect. MRP8/14 is een stabiele 
marker die reproduceerbaar met verschillende methoden bepaald kan worden. Mogelijk is 
er een toekomst voor deze marker in het monitoren van ziekteactiviteit in klinische trials. 
Voor de kliniek is de toegevoegde waarde op dit moment beperkt. 
In hoofdstuk 4.5 wordt een explorerende studie beschreven, die onderzoekt of anti-CarP 
antistoffen aanwezig zijn in het serum van JIA patiënten. Deze nieuwe antistof is bij RA 
patiënten geassocieerd met een slechtere prognose. Voor deze studie werd het serum 
van 234 JIA patiënten, afkomstig uit drie verschillende cohorten onderzocht. Anti-CarP 
antistoffen werden vaker aangetoond in het serum van JIA patiënten dan in het serum van 
gezonde controles. Ongeveer de helft van de anti-CarP positieve patiënten werden ook 
positief getest voor ACPA en RF antistoffen. Deze studie was een explorerende analyse, de 
prognostische waarde van anti-CarP moet nog nader worden bepaald. 
Het laatste hoofdstuk van dit proefschrift (hoofdstuk 5) bevat een overzicht van alle 
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bevindingen van dit proefschrift. Deze bevindingen worden bediscussieerd in het licht van 
klinische implicaties en methodologische beperkingen. Het hoofdstuk eindigt met een blik 
op de toekomst van algemeen JIA onderzoek en onderzoek naar geneesmiddelen voor JIA.
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APPENDIX II – LIST OF ABBREVIATIONS
ABC Arthritis and Biologicals in Children
ACPA Anti-Citrullinated Protein Antibody
ACR American College of Rheumatology
ACRpedi ACR paediatric response score
Aba Abatacept
ADA Adalimumab 
AE Adverse Event
AIC Akaike Information Criterion
Ana Anakinra
ANA Anti Nuclear Antibody
BA Bone Age
BE general Behaviour perceptions domain
BHI Bone Health Index
BMAD Bone Mineral Apparent Density
BMD Bone Mineral Density
BMDLS BMD of the Lumbar Spine
BMDTB Total Body BMD
BMI Body Mass Index
BP Bodily Pain domain
CarP Carbamylated Protein
CH Change in Health domain
cBMD cortical BMD
CHAQ Childhood Health Assessment Questionnaire
CHQ Chilld Health Questionnaire
CI Confidence Interval
CS Corticosteroid
(s)DMARD (synthetic) Disease Modifying Anti-Rheumatic Drug
DXA Dual X-ray Absorptiometry
DXR Digital X-ray Radiogrammetry
EMA European Medicines Agency
ERA Enthesitis Related Arthritis
ESR Erythrocyte Sedimentation Rate
ETN Etanercept 
FA limitations on Family Activities domain
FC Family Cohesion domain
FCS Fetal Calf Serum
FDA Food and Drug Administration
FU Follow-up
GH General Health perceptions domain
HAQ Health Assessment Questionnaire
HR Hazard Ratio
HRQoL Health Related Quality of Life
HUI3 Health Utility Index Mark 3
IA Intra-articular
IBD Inflammatory Bowel Disease
ICC Intra-Class Correlation
IL Interleukin
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ILAR International League of Associations for Rheumatology
IM Intramuscular
Infl Infliximab
IQR Interquartile Range
ISCED International Standard Classification of Education
IV Intravenous
JADAS Juvenile Arthritis Disease Activity Score
JADI-E Juvenile Arthritis Damage Index for Extra-articular damage
JAK Janus Kinase
JC Joint Count
JIA Juvenile Idiopathic Arthritis
JRA Juvenile Rheumatoid Arthritis
LOCF Last Observation Carried Forward
mAb Monoclonal Antibody
MCS Mental Component Summary score
MDA Minimal Disease Activity
MH Mental Health domain
MRP Myeloid Related Protein
MTX Methotrexate
NSAID Non-Steroidal Anti-Inflammatory Drug
oJIA Oligoarticular JIA
OR Odds Ratio
PCS Physical Component Summary score
PE Emotional impact on the Parent domain
PF Physical Functioning domain
PGA Physician Global Assessment
pJIA Polyarticular course JIA
pQCT peripheral Quantitative Computed Tomography
psJIA Psoriatic JIA
PT impact on the Parent’s personal Time domain
RA Rheumatoid Arthritis
RCT Randomized Controlled Trial
RE Role functioning: Emotional limitations domain
RF Rheumatoid Factor
RP Role functioning: Physical limitations domain
RR Relative Risk
SAE Serious Adverse Event
SE Self Esteem domain
SF Social Functioning domain
SF-36 Short Form 36
SI Sacroiliac
sJIA Systemic JIA
SRM Standardized Response Mean
SSZ Sulfasalazine
TM Temporomandibular
TNF Tumour Necrosis Factor
VAS Visual Analogue Scale
VT Vitality domain
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APPENDIX IV – DANKWOORD
Hier ligt het dan, het eindproduct van bijna vier jaar verdieping in de kinderreumatologie. 
In die vier jaar werd echter steeds duidelijker dat het niet alleen om dat eindproduct 
ging, maar even zoveel, of zelfs meer, om de weg daarnaartoe. Die weg leek soms 
onbegaanbaar, met zijwegen die tot niets leiden, en kronkelpaden waarvan de bestemming 
lang onduidelijk bleef, maar met beloning aan het eind. Bovenal was het echter een grote 
ontdekkingstocht met onderweg onverwachte ervaringen en ontmoetingen die leidden tot 
nieuwe inzichten, zowel op professioneel als persoonlijk vlak. 
Voor zo’n tocht is een goede infrastructuur onontbeerlijk en gelukkig lag deze al voor 
mij klaar: de ABC-projecten liepen, opgezet door mijn gedreven voorgangsters. Door 
het hele land zorgden kinderreumatologen, fysiotherapeuten, reumaverpleegkundigen 
en doktersassistenten ervoor dat gegevens werden verzameld. Zonder hen waren mijn 
onderzoeken nooit van de grond gekomen.
Zonder een goede expeditieleider is een beginnend onderzoeker nergens. De eerste 
stappen op het pad van de kinderreumatologie zette ik aan de hand van Marion, met veel 
persoonlijke aandacht en gezellige pasta-avonden. Eenmaal via haar op het ABC spoor 
gebracht, was daar co-promotor Lisette, die optrad als kompas. Waar ik soms mijn doel 
niet meer duidelijk voor ogen had, stuurde zij bij. In de afgelopen jaren heb ik veel respect 
gekregen voor haar manier van begeleiden, hoe zij in iedere promovendus het beste naar 
boven haalt en eenieder op waarde schat. Lieve Lisette, dank voor alle adviezen en het 
vertrouwen dat ik heb gekregen om de dingen op mijn eigen manier te doen!
Geen expeditie redt het zonder begunstiger zoals Prof. dr. A.J. van der Heijden. Beste Bert, 
ik voel me vereerd jouw laatste promovendus te zijn, zoals je zei: we gaan er een feestje 
van maken! 
In de leescommissie en grote commissie nemen tot mijn groot plezier een aantal belangrijke 
wegwijzers plaats. Prof. dr. J.M.W. Hazes, beste Mieke, dank voor het warme bad dat de 
reumatologie de afgelopen twee jaar geweest is. Dear Kimme Hyrich, thank you for all your 
hospitality and advice, I hope we will keep in touch! Lieve Marinka, wat een eer om jou in 
mijn grote commissie te hebben, de cirkel is rond! 
Beste Prof. dr. E.E.S. Nieuwenhuis, dank voor het plaatsnemen in de leescommissie en 
tot ziens in Utrecht! Beste Prof. dr. E.W. Steyerberg, dank voor het plaatsnemen in de 
leescommissie. Verder wil ik ook de overige leden van de grote commissie bedanken voor 
hun aanwezigheid.
Wat is er beter dan in goed gezelschap op reis gaan, met voldoende proviand. Gelukkig 
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waren beiden er in overvloed op alle buitenlandse reizen! Allereerst waren daar de andere 
angels. Marinka, Femke en Marieke, de congressen werden leuker en inspirerender door 
jullie aanwezigheid, maar vooral enorm gezellig, en wat hebben we heerlijk gegeten! 
Lieve Nus, adoptie-angel, door jou bedenk ik nu een vraag bij elk praatje dat ik zie. Wat 
een energie en vrolijkheid breng jij met je mee, ik ben heel trots dat jij naast me staat 
als paranimf! Fleur, elke dag naar Rotterdam, ook een beetje buitenland, werd een stuk 
draaglijker door jouw gezelschap!
Maar ook tijdens de intellectuele reis werd ik vergezeld door top-medereizigers, die met 
humor en relativeringsvermogen en een kritisch oog zorgden dat ik met plezier bleef 
openstaan voor alle nieuwe dingen die op mijn pad kwamen! Dank voor alle gezelligheid 
Janske, Nienke, Thijs, Marieke, Evelien, Yvette, Ruud, Iris, Myrthe, Joany, Idse, Dorien en 
Eefje, Sp 4 evah, jeweettoch! Auk! Hoe gezellig hebben wij het als eerste Na-ers gehad! Ik 
ga je missen! Lieve onderzoekers van de reuma: ik heb me heel welkom gevoeld bij jullie, 
bedankt!
Niets is fijner dan bij mooie ervaringen of heimwee terug te kunnen vallen op een veilige 
thuishaven. Lieve Arno, ik vind het zo fijn dat jij nu na al die jaren nog steeds m’n beste 
maatje bent en nu zelfs naast me staat als paranimf! Samen met lieve Kim, Lin en Jole 
hebben we ons al door veel heen ge-GKKt. Laten we daar nooit mee stoppen! Saar en 
Thijs, dank voor alle avonden die ik op jullie vensterbank heb mogen doorbrengen, heel 
veel liefs voor jullie! Em, Loor en alle andere co-groepje 16-ers, who’s the man? Joost en 
Anne, dank voor een thuis in Rotterdam! Lieve Niki, Stijn en Khan, Mau en Thijs, dank voor 
alle knuffels! Leen en Suus bij jullie kan ik altijd heerlijk onbeschaamd nerden! Lieve Marlies, 
jouw illustratie is fantastisch, dankjewel!
Die thuishaven begint natuurlijk bij een fijne basis: pap, mam, Jas, Ruud, Astrid en Ayla 
dank voor de steun die ik altijd onvoorwaardelijk van jullie heb gehad, zonder jullie was ik 
nergens. 
Liefste Will, de afgelopen twee jaar was je er altijd, ook al snapte je soms misschien weinig 
van al het ge-MD, MSc, PhD. Jij, zonnende zonnestraal, zorgde bij elk dipje dat ik direct 
weer op mijn knopjes was. Bij jou heb ik in ieder geval één bestemming gevonden. Thank 
you for being you! 
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APPENDIX VI – PHD PORTFOLIO: SUMMARY OF PHD TRAINING AND TEACHING
Erasmus MC Department: Paediatrics - Paediatric Rheumatology
Research School: Molecular Medicine (MolMed)
PhD period: February 2011 – February 2015
Promotor: Prof. Dr. A.J. van der Heijden
Co-promotor: Dr. L.W.A. van Suijlekom-Smit
1. PhD training Year Workload
General academic skills 
BROK (‘Basiscursus Regelgeving Klinisch Onderzoek’) 2011 1.0
Biomedical English Writing and Communication 2012 4.0
Course Research Integrity 2012 2.0
PhD Curriculum TULIPS 2014-2015 4.0
Research skills 2011-2013 40
Master of Science Clinical Epidemiology
Core curriculum:
Study Design 2012 4.3
Biostatistical Methods 1 2011 5.7
Clinical Epidemiology 2011 5.7
Methodological Topics in Epidemiologic Research 2012 1.4
Biostatistical Methods 2 2011 4.3
In-depth courses
Courses for the Quantitative Researcher 2012 1.4
Missing Values in Clinical Research 2012 0.7
Quality of Life Measurements 2012 0.9
Repeated Measurements in Clinical Studies 2012 1.4
Advanced Topics in Decision Making 2012 1.9
Epidemiology of Infectious Diseases 2012 1.9
Summer programme
Principles of Research in Medicine 2011 0.7
Clinical Decision Analysis 2011 0.7
Methods of Public Health Research 2011 0.7
Markers and Prognostic Research 2011 0.7
The practice of Epidemiological Analysis 2011 0.7
Pharmaco-epidemiology 2011 0.7
Topics in Meta-analysis 2012 0.7
Case-control studies 2012 0.7
History of Epidemiologic Ideas 2012 0.7
Logistic Regression 2012 1.4
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Seminars and workshops
PhD-day, Sophia Children’s Hospital Rotterdam 2011-2014 1.2
Young Investigators Day, Paediatric Association of the Netherlands 2011-2014 1.2
Young Investigators Meeting of the Paediatric Rheumatology 
European Society (PReS)
2012-2014 0.9
Paediatric Rheumatology European Society (PReS) Research 
Course, Genova
2012 1.4
1st EULAR Registers and Observational Drug Studies (RODS) 
Meeting, Prague
2013 0.5
International Conferences
Combined European Congress of Rheumatology (EULAR) and 
Paediatric Rheumatology (PReS) Berlin
2012 1.0
American College of Rheumatology Annual Meeting, Washington 
D.C. [poster presentation]
2012 1.0
European Congress of Rheumatology (EULAR), Madrid [oral 
presentation]
2013 2.0
Congress of the Paediatric Rheumatology European Society (PReS), 
Ljubljana [poster presentations]
2013 1.0
American College of Rheumatology Annual Meeting, San Diego 
[poster presentations]
2013 1.0
European Congress of Rheumatology (EULAR), Paris [poster 
presentation]
2014 1.0
Congress of the Paediatric Rheumatology European Society (PReS), 
Belgrade [poster presentations]
2014 1.0
2. Teaching
Lecturing
Working group on Diagnostic tests in the Epidemiology course for 
4th year medical students
2014 1.0
Supervising Master’s theses
M. Dijkstra, medical student, Erasmus University 2013 3.0
M. Sarwar, medical student, Erasmus University 2014 3.0
Other
Peer review of articles for international scientific journals 2012-2014 2.0
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Janneke revels in the opportunity to investigate a subject in depth, which is why a research 
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Stellingen behorend bij het proefschrift
Advances in the Management of Juvenile Idiopathic Arthritis 
The coming of age of biologic treatment
De sterk verbeterde behandelingsresultaten sinds de introductie van biologicals maken het 
noodzakelijk als volgende stap de middelen onderling te vergelijken en de timing van de 
behandeling aan te scherpen om inactieve ziekte te bereiken voordat schade is ontstaan.  
(Dit proefschrift)
De verbetering van kwaliteit van leven, bereikt door behandeling met etanercept bij patiënten met 
eerder refractaire JIA, blijft op lange termijn behouden. (Dit proefschrift)
Chronische pijn blijkt ook als er geen actieve artritis is, de kwaliteit van leven van JIA patiënten te 
beïnvloeden, dit is een complex probleem wat opheldering behoeft. (Dit proefschrift)
De keuze tussen de diverse biologicals wordt noodzakelijkerwijs ingegeven door resultaten 
uit onderzoek met weinig bewijskracht en persoonlijke ervaring van de kinderreumatoloog; 
deze “confounding by indication” bemoeilijkt de onderlinge vergelijking van biologicals in 
observationele studies. (Dit proefschrift)
Alle instanties betrokken bij de ontwikkeling en goedkeuring van nieuwe middelen voor de 
behandeling van JIA moeten zorg dragen voor meer uniformiteit in uitkomstmaten en design van 
klinische trials; meta-analyses worden dan mogelijk en de beschikbare gegevens van de kleine 
onderzoekspopulatie worden zo optimaal gebruikt. (Dit proefschrift)
Parents and children seek, and deserve, the assurance that comes from using medications 
rigorously studied in children rather than relying on a leap of faith based on adult trials.  
(DeWitt et al, 2008 Arthritis and Rheumatology)
Authors have the duty to make all their research publicly available, the positive as well as the 
negative or inconclusive results. This duty should extend to editors and reviewers of scientific 
journals. (Adapted from the declaration of Helsinki)
By considering RCTs and observational study designs complimentary, it might be possible to 
address questions faster, cheaper, and perhaps even better than either approach alone.  
(Merkow et al, 2013 JAMA)
Real shared decision making involves finding out what matters to the patient, to what extent 
they want to be empowered, and introducing scientific evidence in a way that informs a dialogue 
about what best to do, how and why. (Greenhalgh, 2014 BMJ)
It is important to give every doctor an interest in educating the public scientifically.  
(George Bernard Shaw, 1909)
A little nonsense now and then is relished by the wisest men. (Charlie and the Chocolate Factory, 
Roald Dahl, 1964)
